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Neurodegenerative diseases like Alzheimer’s Disease and Parkinson’s Disease are one of 
the biggest issues in healthcare that society is facing worldwide. Aging is a major risk 
factor for many neurodegenerative diseases and is thought to play a large role in their 
pathology. It is thought that the brain’s resident immune cells microglia can change with 
age to obtain a detrimental phenotype that disrupts tissue homeostasis and promotes 
conditions for neurodegenerative disease to develop. Therefore, understanding and 
implementing microglial aging into the study of neurodegeneration could be important to 
further advances in the area.  
A model of aging microglia is presented in this thesis. One of the marked characteristics of 
aging microglia is their accumulation of iron. Supplementing microglia with excess iron 
caused them to take it up and change into an iron-fed phenotype that resembles aged 
microglia. This was demonstrated by disrupted proteostasis and an altered secretory 
phenotype including the release of inflammatory cytokines and reactive oxygen species. 
This model was applied to the study of Alzheimer’s disease and it was found that the 
molecules secreted by iron-fed microglia degraded β-amyloid secreted by a neuronal cell 
line at a lower rate. The reduced degradation was due to the iron-fed microglia releasing 
lower levels of the protease insulin-degrading enzyme (IDE).  Further study showed this 
decreased release of IDE was a result of disrupted autophagic flux caused by increased 
endoplasmic reticulum stress.  
It was also shown that the aged microglia model can be applied to the study of 
Parkinson’s disease. Increased levels of tumour necrosis factor-α secreted by iron-fed 
microglia was found to induce an increase in α-synuclein expression. Increased α-
synuclein expression was found to sensitise neuronal cells to the toxicity of α-synuclein 
oligomers. It was found that this effect was conferred through an increase in Forkhead box 
O 3a expression that was caused by elevated iron levels due to the increased 
ferrireductase activity of α-synuclein.  
The findings of these studies show that changes that occur in microglial aging are capable 
of increasing the deposition of proteins thought to be central to the pathology of the most 
common neurodegenerative diseases. These results suggest that iron-fed microglia are a 
promising model of microglial aging and have great potential utility to be applied to the 
study of both neurodegenerative disease and aging itself. 
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1. Introduction
1.1 General introduction 
Neurodegeneration is most commonly represented by diseases such as Alzheimer’s 
Disease and Parkinson’s Disease. Such diseases are becoming an increasingly common 
and pressing issue worldwide. After many decades of research, some progress has been 
made in understanding these deadly conditions, but we are still far from completely 
unravelling the complex processes involved in their molecular pathology. As of now, most 
neurodegenerative diseases are incurable, and it’s not known how to prevent them. 
Accumulation of aggregated proteins has been shown to play a central role in the 
pathology of Alzheimer’s disease (β-amyloid) and Parkinson’s disease (α-synuclein).  
Aging leads to a multitude of changes in the brain that in many ways are similar to those 
of neurodegeneration. In fact, the biggest risk factor for neurodegenerative diseases is 
aging and it is thus imperative to understand in what way it affects their pathogenesis. 
However, aging is rarely incorporated into the study of neurodegeneration, partly due to 
the fact that it is not a process that is completely understood, but also due to the 
heterogenous changes that occur in a multitude of molecular pathways.  
Microglia are now thought to be central to the neuroinflammation seen in aging and age-
related neurodegenerative disease. Release of inflammatory molecules and toxic 
substances by microglia is thought to be a major driver of neuronal death but what causes 
this increase in inflammation has not been agreed upon. 
It has been shown that microglia change with age, but microglial aging is still poorly 
understood. It is linked both with increased release of inflammatory signaling factors such 
as cytokines and ROS but also reduced phagocytosis and motility.  Modelling aging 
microglia in the brain would be helpful in not only understanding how neurodegenerative 
diseases occur to begin with, but also in gaining a better idea of what specific molecular 
environment in the brain triggers neuronal death in those diseases.  
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1.2 Neurodegenerative Diseases 
Neurodegeneration is the progressive loss of function and death of neurons in the central 
nervous system (CNS) or the peripheral nervous system (PNS). It can be the result of 
hypoxia, trauma, stroke, poison, infections, cancer, diabetes but also due to chronic 
diseases that directly affect neurons known as neurodegenerative diseases (ND) 
(Przedborski et al. 2003). Depending on where and how the loss of neurons can occur, a 
variety ND has been identified. ND are incurable and typically result in years of 
progressively decreasing brain function and death. As ND are the most common reason 
for dementia, they result in an enormous physical, psychological, social and economic 
impact on society. Current numbers from the World Health Organisation (WHO) show that 
right now around 50 million people around the world live with dementia, with almost 10 
million new cases being diagnosed every year (WHO 2017). 
A myriad of ND has been identified with a few conditions being the most common. 
Alzheimer’s Disease (AD) is by far the most common neurodegenerative condition with an 
incidence of 5-8% over the age of 65 years, climbing to 25-50% over the age of 85. 
(Duthey 2013; Przedborski et al. 2003). The second most common ND is Parkinson’s 
Disease (PD) with an age-adjusted incidence of 9.7 to 13.8 per 100,000 population per 
year worldwide and up to almost 3% over the age of 80 (Hirsch et al. 2016; de Lau and 
Breteler 2006; WHO 2014). Less common but still important forms of neurodegeneration 
include Huntington’s disease (HD), Amyotrophic Lateral Sclerosis (ALS), prion protein 
diseases and many others. ND can be the result of genetic disorders (AD, PD, HD, ALS), 
environmental exposure to toxic agents (possibly PD) or can be ‘sporadic' with no clear 
cause (AD, PD, ALS).  
1.2.1 Risk factors for developing neurodegenerative disease 
The biggest risk factor for many major ND is age. With the increase in longevity worldwide 
seen in the last century the likelihood of an individual developing a ND in their lifetime has 
increased. Apart from age, other risk factors for developing sporadic neurodegeneration 
have been identified. Gender affects the incidence of the most common ND, where 
women are more likely to develop AD, but men have an increased risk of PD. Common 
health conditions such as obesity, diabetes and hypertension seem to increase the risk of 
developing cognitive impairment (Duthey 2013). There is also evidence that traumatic 
brain injury increases the risk of developing AD, PD and ALS (Louw et al. 2011). Lifestyle 
factors seem to also play a role in some ND symptoms. Some studies have linked an 
unhealthy diet, tobacco and alcohol use with increased risk of cognitive impairment 
(Mayeux and Stern 2012). Modifiable risk factors for dementia include depression, social 
isolation and cognitive inactivity (WHO 2017). Being aware of the risk factors for 
developing ND has not led to major advances in prevention or treatment, possibly due to 
significant gaps in understanding the underlying molecular cause of these conditions, with 
any treatments available being largely symptomatic. 
The pathophysiology of ND is generally characterised by a central loss of neurons 
accompanied by reactive gliosis (Pekny and Pekna 2016). Another common link for many 
ND is the abnormal accumulation of misfolded, oligomerised or aggregated proteins in 
neurons and in the extracellular space and an increase in oxidative stress (Zhao and Zhao 
2013; Kim et al. 2015). Aggregated proteins are thought to be central to disease pathology 
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and thus AD, PD, HD, prion diseases and others are termed proteopathies (Walker and 
LeVine 2000).  
Death of neurons in ND could be caused by the triggering of endogenous programmed 
cell death pathways. Cell death in AD and PD is thought to occur through apoptosis, 
necrosis and necroptosis, but identifying the dominating mechanism has proven to be 
difficult (Jellinger 2001; Caccamo et al. 2017; Zhang et al. 2017). Apoptosis is generally 
defined as cell death that comprises of cellular shrinkage, nuclear fragmentation and 
chromatin condensation that culminate in membrane fragmentation with unaffected 
organelle integrity. Many signals can trigger apoptosis in neurons. Absence of 
neurotrophic factors, excess of glutamate, oxidative stress and environmental toxins are 
all factors that can cause neuronal death (Kermer et al. 2004). Proteins thought to initiate 
the apoptotic process in neurons include caspases, Bcl-2-associated X protein (BAX), Bcl-
2 associated death promoter (BAD), glutamate receptors, Fas cell surface death receptor 
(FAS), prostate apoptosis response protein 4 (PAR-4) and tumour protein 53 (p53) 
(Mattson 2000). Mitochondria are thought to be central to initiation of the cell death 
process through the production of reactive oxygen species. The presence of misfolded 
proteins such as those in AD and PD and reactive oxygen species can cause apoptosis in 
neurons through impairing mitochondrial activity and causing endoplasmic reticulum 
stress (Bredesen et al. 2006). Endoplasmic reticulum stress- induced apoptosis has been 
documented in neurodegenerative disease. Stress sensors that are activated by ER 
stress lead to increased activity of the transcription factor C/EBP homologous protein 
(CHOP) that upregulates pro-apoptotic pathways. The activation of proteins such as bcl-2 
interacting mediator of cell death (BIM) or p53 upregulated modulator of apoptosis 
(PUMA) is required for this type of apoptosis. CHOP is thought to interact with Forkhead 
Box O3a (FOXO3a), a member the FOXO transcription factor family in order to activate 
these proteins and trigger apoptosis in neurons (Ghosh et al. 2012; Essafi et al. 2005; 
Sanphui and Biswas 2013; Puthalakath et al. 2007).  A newly identified form of 
programmed cell death – necroptosis has been shown to be implicated in AD and PD 
(Caccamo et al. 2017; Iannielli et al. 2018). It is thought to be initiated by receptor-
interactive protein kinases (RIP) 1 and 3 and mediated by mixed lineage kinase domain-
like (MLKL) protein. It is thought to be initiated as a response to tumour necrosis factor α 
(TNFα), TNF-related apoptosis-inducing ligand (TRAIL) and interferons (IFN) among 
others (Zhang et al. 2017). Investigations into the role of necroptosis in ND are suggesting 
that it could be a powerful therapeutic target but they are still in their early stages. 
 
1.2.2 The role of FOXO3a in apoptosis and neurodegenerative disease 
Forkhead Box O3 (FOXO3a) is a transcription factor that activates many pathways that 
impact cellular viability. FOXO3a is evolutionarily conserved from simple species such as 
nematodes or the hydra, through Drosophila, to mice and humans, indicating that the 
pathways controlled by FOXO3a and its homologues are essential to survival (Martins et 
al. 2016; Anton-erxleben et al. 2013). The first forkhead box transcription factor found to 
have an effect on lifespan was the gene daf-16 expressed in C.elegans (Kenyon et al. 
1993; Dorman et al. 1995). It was also the first to be linked to the insulin/IGF-like 
signalling pathway, suggesting that nutrient sensing mechanisms have an effect on 
lifespan (Partridge and Brüning 2008). The Drosophila ortholog of daf-16 - dFOXO has 
also been linked with lifespan extension mediated by altered nutrient sensing (Hwangbo et 
al. 2004; Giannakou et al. 2004). These findings have increased the interest in forkhead 
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box genes in mammalian aging research. While more primitive organisms have only one 
FOXO protein, mammals have 4 which are expressed in almost all tissues. FOXO3a is 
quite ubiquitous and is highly expressed in the brain and is therefore to particular interest 
to the study of age-related neurodegenerative disorders (Klionsky et al. 2009). The 
structure of FOXO3a is similar to that of other forkhead box proteins (Figure 1.1). It has a 
DNA binding domain (DBD or the forkhead box) followed by a nuclear localization signal, 
a nuclear export sequence and a transactivation domain (TAD) (Calnan and Brunet 2008).  
Variants of FOXO3a have been found to be linked to longevity in humans. Studies of very 
old individuals in various populations (Germans, Danish, Han Chinese, Americans, 
Italians) have linked single nucleotide polymorphisms (SNPs) in FOXO3a with increased 
lifespan (Zeng et al. 2010; Martins et al. 2016). These findings have resulted in substantial 
interest in the mechanism through which FOXO3a could confer these beneficial effects. 
The SNPs identified were intronic so did not belong to the coding regions of the gene. 
Therefore, it is possible that they affected the amounts of FOXO3a protein in the patient’s 
tissues instead.  
FOXO3a activity can be stimulated by oxidative stress or caloric restriction. The IGF-1 
signalling pathway is the best studied mechanism of FOXO3a regulation (Figure 1.1) 
(Brunet and Webb 2015). It is also a widely evolutionarily conserved mechanism that 
affects rates of aging. Insulin or IGF-1 binds to an insulin or IGF receptor which eventually 
results in the activation of AKT kinase. AKT phosphorylates FOXO3a and that results in its 
nuclear export and therefore its inhibition. Loss of function mutations in this pathway have 
been linked to increased human longevity. FOXO3a has been found to interact with 
different proteins apart from AKT kinase. FOXO3a has also been found to be 
phosphorylated by SGK, IKKβ, and ERK among others (Calnan and Brunet 2008). 
FOXO3a activity can also be modulated by acetylation and de-acetylation (Daitoku et al. 
2011). Acetylation occurs by enzymes such as p300 and is a modification that can have 
an activating or inhibitory effect.  
Another protein implicated in aging (SIRT1) has been found to de-acetylate FOXO3a 
(Wang et al. 2012; Giannakou and Partridge 2004; Hori et al. 2013). The effect of SIRT1 
deacetylation seemed to promote the cell-cycle arrest and oxidative stress alleviation 
activities of FOXO3a but inhibit the pro-apoptotic action of the protein and possibly target 
it for degradation by ubiquitination. On the other hand, AMP-activated protein kinase 
(AMPK) has been found to increase FOXO3a activation and promote its proapoptotic 
activity (Li et al. 2017).  It seems that the role of the many post-translational modifications 
FOXO3a undergoes is not just overall modulation of activity, but also promotion of 
particular FOXO target pathways that can have various consequences on viability and 
longevity. 
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 Figure 1.1 Simplified FOXO3a pathway and FOXO3a structure. This figure displays 
the IGF/Insulin pathway that results in the inactivation and trafficking of FOXO3a from the 
nucleus through AKT or SGK phosphorylation. The structure of FOXO3a schematic 
includes the main domains of the FOXO3a protein and the phosphorylation sites for 
AKT/SGK, ERK and IKKβ.  
FOXO3a activity could play a role in longevity in multiple ways. Firstly, it works to 
stimulate autophagy. This could occur through the direct upregulation of autophagy 
through the expression of inducers such as BCL2/adenovirus E1B 19-kDa interacting 
protein 3 (BNIP3) (Mammucari et al. 2007). Additionally it has been shown to promote 
autophagy through a FOXO1 dependent mechanism where FOXO3a activity results in 
increased FOXO1 phosphorylation which can bind Autophagy-related protein 7 (Atg7) and 
promote autophagy (Zhao et al. 2010; Zhou et al. 2012). Loss of protein homeostasis is a 
hallmark of age-related decline in organisms and is implicated in a myriad of 
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neurodegenerative disease as previously mentioned. FOXO3a activity is also linked to 
increased proteasomal degradation of cytosolic proteins through increased expression of 
ubiquitin ligases and proteasome components, another mechanism that is impaired in the 
aging organism. FOXO3a is also implicated in resistance to oxidative stress. Some of its 
main targets are MnSOD, catalase and GADD45, enzymes which neutralise ROS. 
Appropriate balance in the levels of ROS in the cell is very important for viability since 
they are used as signalling molecules but can damage cellular structures if in excess. 
ROS damage and elevated oxidative stress has been heavily implicated in 
neurodegenerative disease, to the point where antioxidant therapies have been trialled for 
treatment of AD and PD (Kim et al. 2015). Additionally, FOXO3a deletion has been found 
to disrupt the function of stem cells, which are integral to the regeneration of aging 
organisms. FOXO3a is also considered to be a type of tumour suppressor protein as it 
can trigger genes such as BIM, TRAIL and PUMA that code for pro-apoptotic proteins. 
Conversely, excessive and ill-timed FOXO3a activation can lead to the inappropriate 
growth arrest and apoptosis of healthy tissues. In fact FOXO3a inhibition has been shown 
to be neuroprotective against oxidative stress (Chong et al. 2004)  
As FOXO3a is implicated in so many mechanisms related to cell viability it’s not surprising 
that it also plays a role in neurodegenerative disease. Levels of FOXO3a have been found 
to positively correlate with cognitive impairment and β-amyloid load in AD (Sahin et al. 
2013). High levels of FOXO3a have been measured in the cortical neurons of aged and 
AD brains (Sahin et al. 2013). β-amyloid levels were also found to correlate with FOXO3a 
levels in mouse neurons (Qin et al. 2009). In a recent study it was found that the 
increased FOXO3a levels are a response to APP processing by γ-secretase, likely 
through action of the APP intracellular domain reducing phosphorylation of AKT (Law et 
al. 2017).  Pink1 is a pro-survival gene, loss of function of which is implicated in the 
pathology of PD. It is also a target for FOXO3a, which induces its transcription resulting in 
cellular survival (Mei et al. 2009). Interestingly, FOXO3a has been found to be ectopically 
expressed in Lewy bodies. FOXO3a has also been found to be induced by increases in α-
synuclein, probably due to its effect on autophagy. A low-level increase in FOXO3a 
activity can be neuroprotective by initiating the degradation of the α-synuclein aggregates. 
However, constitutive activation of FOXO3a resulted in the death of dopaminergic 
neurons (Pino et al. 2014; Law et al. 2017).   
It is evident that FOXO3a is a protein implicated in many cellular processes and its 
regulation is multifaceted and intricate. The timing and type of activation of FOXO3a can 
contribute to either neuroprotection and increased longevity or neuronal apoptosis and 
aging (Maiese 2017).  
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1.3 Alzheimer’s Disease 
Alois Alzheimer’s investigation published in 1907 described and named the main 
hallmarks of the AD brain (Hippius and Neundörfer 2003). AD accounts for the majority of 
cases of dementia in the world (Masters et al. 2015). More than 95% of patients suffer 
from the sporadic form of AD that is characterised by a late onset at 80-90 years of age 
(Masters et al. 2015). Less than 1% of patients suffer from a heritable form of AD with a 
mean age of onset of 45 years. Those cases of AD are directly caused by mutations in 
genes that code for proteins that contribute to the formation of amyloid plaques (APP, 
PSEN1, PSEN2). However, the genetic component of the vast majority of cases acts as a 
risk factor. The most significant example of this is the ε4 isoform of apolipoprotein E 
(APOE4) which is expressed in more than half of caucasian AD patients and can increase 
risk of developing AD up to 12-fold (Michaelson 2014). APOE has been found to interact 
with β-amyloid and the isoform APOE4 is thought to contribute to the formation of plaques 
by chronically decreasing β-amyloid clearance (Kim et al. 2009). Variants of the protein 
triggering receptor expressed on myeloid cells 2 (TREM2) have also been linked to higher 
risks of developing AD. Partial loss of function mutations in TREM2 which is expressed on 
the cell membranes of microglia reduce their ability to react to and clear β-amyloid 
(Carmona et al. 2018). 
AD is characterised by the loss of synapses and death of neurons in many brain regions 
including the hippocampus and the cerebral cortex. That results in progressive memory 
loss, changes in personality, loss of independence and eventually loss of basic body 
function, resulting in death. Symptoms of mild AD include forgetfulness, confusion, poor 
judgement, mood and personality changes which intensify as the disease progresses and 
problems with speech, language, disturbed sleep among others also arise. In the final 
stages of AD, the aforementioned symptoms become more severe with significant 
problems with short and long term memory continuing and symptoms such as dysphagia, 
incontinence, and loss of muscle tone developing as well (NHS 2018). AD is the most 
common cause of dementia worldwide, being the culprit for 60-70% of cases (WHO 
2017). AD is a chronic disease with the clinical stage lasting about a decade, but currently 
it is thought to be preceded by a pre-clinical stage of around two decades. The neuronal 
death that occurs affects both cholinergic and dopaminergic neurons. However, synaptic 
dysfunction seems to precede neuronal death and is enough to result in cognitive 
impairment. Normally the pathology is first detected in the frontal and temporal lobe and 
spreads at varying rates to other cortical areas (Masters et al. 2015). AD is characterised 
as a proteopathy because one of its major hallmarks is the accumulation of proteins in 
amyloid plaques and neurofibrillary tangles which have been implicated in neuronal death 
(Walker and LeVine 2000).  
Protein aggregation is a central event in AD. Amyloid plaques have been described as an 
accumulation of insoluble forms of the peptide β-amyloid. They are found in the 
extracellular space, but also in blood vessel walls. Plaque deposition has been found to 
precede the appearance of neurofibrillary tangles and to occur in the front and temporal 
lobes, hippocampus and the limbic system and to spread to other areas. Neurofibrillary 
tangles are aggregates of the hyperphosphorylated microtubule protein tau and are found 
in neurons. Tangles are initially found in the medial temporal lobes and hippocampus with 
the pathology spreading to other cortical areas with disease progression. The cause of 
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formation of tangles is unclear but β-amyloid is thought to play a role in increasing tau 
cleavage and hyperphosphorylation (Selkoe and Hardy 2016). A protease upregulated 
during aging called asparagine endopeptidase has been recently shown to cleave tau and 
enhance its aggregation (Zhang et al. 2014). The deposition of β-amyloid in AD is 
considered the disease-triggering event, however the mechanisms that result in this 
deposition and the exact role risk factors such as age play in it have not been fully 
unravelled (Allsop and Mayes 2014; Hardy and Allsop 1991). Protein aggregation in AD 
starts in the pre-clinical stages in the disease and thus those stages are of particular 
interest in terms of detection and treatment. 
Clinical trials for AD treatments have as of now yielded limited results in terms of both 
prevention and neuronal rejuvenation. Current available medications only manage 
disease symptoms by modulating the signalling of neurotransmitters such as acetylcholine 
and glutamate. Cholinesterase inhibitors such as donepezil and galantamine enhance 
acetylcholine signalling by increasing the time it is present in the synapse. Cholinesterase 
inhibitors are commonly applied in mild AD. N-methyl-d-aspartate A (NMDA) receptor 
antagonists such as memantine normalise glutamate signalling. Memantine has been 
found to have benefits in moderate AD with mild improvements in cognitive ability. 
Combination therapy with both kinds of agents only results in a short delay in progression 
of symptoms of 6-9 months (Masters et al. 2015). A big issue in treating AD effectively is 
that neuronal death is irreversible so treating patients who are already showing symptoms 
may be too late. Advances have been made in AD detection, with methods to measure β-
amyloid accumulation in pre-symptomatic patients improving (Roe et al. 2017). In-vivo 
positron emission tomography (PET) imaging of β-amyloid and tau accumulation in the 
brain by using dyes that specifically bind these proteins can now be achieved with great 
sensitivity (Masters et al. 2015). This has made the identification of patients in pre-
symptomatic stages of AD possible. Additionally, it is now feasible to measure changes in 
cerebrospinal fluid (CSF) metabolites that can predict familial AD at least a decade before 
symptoms develop (Fagan et al. 2014). Reducing β-amyloid levels in patients via 
monoclonal antibodies or pharmacological inhibitors have recently been pursued with 
limited success (Gold 2017; Yanagisawa 2018). Preventing protein aggregation in the 
preclinical stages is probably the key to stopping Alzheimer’s disease progression (van 
Dyck 2018; Masters et al. 2015).  
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1.4 Parkinson’s Disease 
Parkinson’s disease is a neurodegenerative disease caused by the loss of dopaminergic 
neurons in the substantia nigra pars compacta located in the midbrain. The neuronal 
degeneration and death results in a reduction in dopaminergic neurotransmission in the 
striatum. This results in loss of inhibitory signalling pathways altered activity of both the 
striatum and motor cortex. Symptoms arising from these changes include bradykinesia, 
tremors, gait changes and loss in muscle control. PD is a chronic disease that causes 
significant disability, reduced quality of life and life expectancy. It was first described by 
James Parkinson in 1817 in his work “An Essay on the Shaking Palsy”. Non-motor 
symptoms are also very common in PD, one of the earliest being constipation and with 
most patients eventually developing dementia, hallucinosis, incontinence and postural 
hypotension.  
PD can arise sporadically which covers the majority of cases with the underlying causes 
for the disease thought to be a combination between environmental factors and genetic 
predispositions. Hereditary PD occurs in a much smaller proportion of cases. Mutations in 
certain genes carry a significant risk for developing PD. Hereditary PD can be classified in 
three subsets (Poewe et al. 2017). Autosomal dominant PD can be caused by mutations 
in α-synuclein, leucine-rich repeat kinase (LRRK) and vacuolar protein sorting-associated 
protein 35 (VSP35). Early-onset PD can be caused by mutations in protein deglycase DJ-
1, parkin, PTEN-induced kinase 1 (PINK-1), and DnaJ heat shock protein family (Hsp40) 
member C6 (DNAJC6). Complex genetic inheritance in PD can be caused by mutations in 
Cation-transporting ATPase 13A2 (ATP13A2), (gene product: phospholipase A2 group 6 
(PLAG2G6), gene product F-box protein 7 (FBXO7), DNAJC6 and synaptojanin 1 
(SYNJ1). Many other genes have been linked to PD but their direct relationship to the 
disease has not been identified. Inherited mutations in α-synuclein are of particular 
interest in PD because of the protein’s central role in the pathology. Missense mutations in 
the α-synuclein gene have been shown to cause the classic PD phenotype while gene 
duplication or triplication cause early-onset PD with symptoms of dementia. 
Neurodegeneration and especially PD have been linked to environmental exposure to 
toxins (Cannon and Greenamyre 2011). A well-known example of this is 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), a chemical that, when ingested, can cause the 
death of dopaminergic neurons in the substantia nigra, producing symptoms very much 
like those of PD. Exposure to other chemicals has been linked to increased risk of 
developing PD as well. The pesticides paraquat and rotenone in particular have been 
linked to PD by epidemiological studies and in animal models produce loss of 
dopaminergic neurons. Chronic exposure to paraquat has been shown to induce cellular 
oxidative stress. This in turn can trigger the mitochondrial intrinsic proapoptotic pathway 
mediated through the release of cytochrome C and the activation of caspase 9 (Franco et 
al. 2010). Paraquat has also been shown to induce ER stress and to cause DNA damage, 
both alternative pathways through which apoptosis could be triggered (Yang et al. 2009). 
Rotenone’s mechanism of neurotoxicity is similar to that of paraquat and is driven by 
increased mitochondrial ROS that trigger cytochrome C and caspase-dependent 
apoptosis, but also by the induction of ER stress (Franco et al. 2010). Exposure to 
solvents has also been linked to increased risk of PD. Chronic trichloroethylene inhalation 
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has been shown to cause loss of dopaminergic neurons in rats and has been correlated 
with severity of PD symptoms.  
Additionally, metal exposure has been of particular interest in the study of AD and PD. 
Exposure to aluminium, zinc, copper and lead has been linked to AD and aluminium and 
lead exposure in animal models has recapitulated some features of AD. In PD, iron and 
manganese exposure have been studied with manganese poisoning causing a syndrome 
similar in symptoms to PD. In ALS exposure to mercury and lead have been identified as 
risk factors. Increased iron levels in the substantia nigra have also been linked to younger 
age of onset of PD in men (Bartzokis et al. 2004).  
Exposure to all these toxins is thought to cause oxidative stress and thus lead to neuronal 
loss. Environmental exposures have not been conclusively proven to be the underlying 
reason for all but a small minority of cases of neurodegeneration and the symptoms 
caused by these toxins only replicate a part of the pathology of common ND. However, 
what these risk factors illustrate is the sensitivity of the brain to oxidative stress caused by 
either chemical exposure or metal dyshomeostasis. 
Diagnosis of PD still largely relies on the presence of motor symptoms. Currently available 
PD treatments only address management of symptoms by pharmacologically substituting 
the depleted dopamine with its’ precursor L-DOPA. Dopamine replacement therapy has 
major motor side-effects and many non-motor symptoms are not affected by it. Deep brain 
stimulation of the subthalamic nucleus has also had some success in PD symptom 
management but has the same drawbacks as L-DOPA with the addition of requiring 
surgical placement of an electrode, making the treatment much riskier. No curative or 
preventative treatments have been identified yet and major strides need to be made with 
identifying robust biomarkers that allow for early pre-symptomatic diagnosis.  
The second most defining characteristic of PD besides neuronal death is the accumulation 
of α-synuclein. Lewy bodies, the first identified protein aggregate in PD, are intracellular 
neuronal inclusions and are mainly formed of α-synuclein but also other proteins 
complexed with iron (Castellani et al. 2000; Spillantini et al. 1997). They begin to form in 
pre-motor symptomatic stages of the disease in the olfactory bulb, medulla oblongata and 
the dorsal pons. As PD progresses to motor symptom stages, Lewy bodies also appear in 
areas of neuronal death. The loss of neurons normally starts in the ventrolateral 
substantia nigra and later on spreads to dopaminergic neurons of other brain areas such 
as the midbrain, the basal forebrain and the neocortex. The molecular mechanisms 
behind neuronal loss in PD are thought to involve many factors such as α-synuclein 
toxicity, neuroinflammation, oxidative stress, mitochondrial dysfunction and perturbed 
autophagy; all of which interplay.  
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1.5 Proteins that play a role in neurodegeneration 
Proteopathies are a class of diseases where one or more proteins develop structural 
abnormalities and become toxic to cells and tissues. The toxicity can be due to altered 
function, loss of function or aggregation (Walker and LeVine 2000). A common thread that 
links many of the ND is that they involve the accumulation and aggregation of proteins 
that can be toxic (Ross and Poirier 2004). As mentioned above, α-synuclein, β-amyloid 
and tau have been linked to the most common neurodegenerative diseases AD and PD, 
but also Dementia with Lewy Bodies, Frontotemporal Dementia, and Down Syndrome. 
Interestingly, other ND are also characterised by protein aggregation. A misfolded form of 
the prion protein (PrP) termed PrPSc is commonly found to aggregate in prion diseases. 
PrPSc accumulates extracellularly in a variety of forms that include plaques which can be 
seen in diseases such as Creutzfeldt–Jakob Disease (CJD), Kuru, Fatal Familial 
Insomnia, and Gerstmann–Straussler–Scheinker disease in humans and most famously in 
Bovine Spongiform Encephalopathy and scrapie in animals (Hughes and Halliday 2017). 
In Huntington’s disease mutant huntingtin and ubiquitin aggregate in striatal neurons 
(Bates et al. 2015). In amyotrophic lateral sclerosis multiple ubiquitinated proteins 
aggregate in motor neurons (Hardiman et al. 2017). TDP-43 is another protein found in 
inclusions in a number of ND including AD and dementia with Lewy bodies (Davidson et 
al. 2011; Cook et al. 2008). What unites many of the aggregates found in ND is that they 
commonly share a β-sheet structure and that in their sporadic forms they are the result of 
a complex network of events that results in changes in the environment of the brain of 
which we have a limited understanding. Elucidating the underlying reasons for protein 
aggregation and toxicity in neurons is central to understanding these diseases. 
Considering that aging is a risk factor to the main neurodegenerative diseases, changes in 
the brain that occur with aging may contribute to the eventual loss of neurons in these 
disorders. 
 
1.5.1 Amyloid precursor protein and β-amyloid in neurodegeneration 
1.5.1.1 Structure of APP 
 
Amyloid precursor protein (APP) is a highly expressed protein in many tissues including 
not only the brain but also muscle, adipose tissue, the intestine and the skin (Puig and 
Combs 2013). The mammalian gene that codes for APP contains 18 exons and has 
multiple alternative splicing forms consisting of  695, 639, 714, 751 and 770 residues in 
length (Golde et al. 1990; Nalivaeva and Turner 2013; Tang et al. 2003). Of those 
alternative splicing forms, the 695AA one is most common in the nervous system (van der 
Kant and Goldstein 2015). APP is a member of a family of similar proteins like the amyloid 
precursor-like proteins (APLP1 and APLP2). APP, similarly to APLP1 and APLP2, is a 
transmembrane protein with a small N-terminal intracellular domain and a large C-terminal 
extracellular domain (Figure 1.2). Unlike APLP1 and 2 it also contains the β-amyloid 
domain. The extracellular domain of APP includes the E1 and E2 domains and part of the 
β-amyloid sequence that is also partially located in the cytoplasm. A Kunitz-type protease 
inhibitor domain can be found between the E1 and E2 domains, but it is not present in the 
695AA form of APP. The E1 domain contains a heparin-binding/growth factor-like domain 
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(HBD/GFLD), and copper- and zinc- binding domains. The E2 domain includes another 




Figure 1.2 Hypothetical 3-dimensional structure of APP. Shown here is the proposed 
structure for APP which includes an E1 domain, Kunitz protease inhibitor (KPI) domain, 
E2 domain, transmembrane domain (TMD) and intracellular domain (C-terminal domain). 
The proposed lipid-binding site in the transmembrane domain is depicted with a 
cholesterol molecule bound to it. This structure includes the KPI domain which is not 





1.5.1.2 Function of APP 
 
The function of APP in the cell is still under dispute (Dawkins and Small 2014). It has been 
suggested to be heavily involved in the development of the nervous system, with possible 
roles in neuronal migration and synaptic formation and maintenance (van der Kant and 
Goldstein 2015). Putative functions of APP also include vesicle transport, maintenance of 
metal homeostasis, and regulation of intracellular calcium (Rogers et al. 2016; Müller and 
Zheng 2012). An emerging function of APP of some interest is the regulation of iron in the 
cell. Reductions in cellular iron inhibit APP translation through Iron-regulatory protein 
(IRP) binding an Iron Responsive element (IRE) found upstream of the coding region for 
APP (Cahill et al. 2009; Cho et al. 2010; Rogers et al. 2008). On the other hand, increases 
in iron also increase the levels of APP (Rogers et al. 2008). APP may play a role in iron 
efflux from the cells through the binding and stabilization of ferroportin (Wong et al. 2014). 
APP has been shown to be able to form dimers in the cell, a process that possibly occurs 
through its E2 domain (Lee et al. 2011). The dimerization process has been proposed to 
occur either between two APP molecules on the same cell membrane, intracellularly, or 
between APP molecules on two separate cells, suggesting a possible function of APP as 
a cell adhesion protein (Hoefgen et al. 2014; Soba et al. 2005). The E1 and E2 domains 
have also been shown to contain copper and zinc binding sites, with a possible iron 
binding site in E2 but this has been disputed (Wild et al. 2017; Honarmand Ebrahimi et al. 
2013; Barnham et al. 2003). Interaction of APP with copper could affect both dimerization 
and rate of proteolytic degradation, possibly decreasing production of β-amyloid (Spoerri 
et al. 2012).  APP is produced in the endoplasmic reticulum and transferred to the Trans-
Golgi network. From there it is trafficked to the cell surface or an endosomal compartment 
via clathrin-associated vesicles where it undergoes proteolytic processing (O’Brien and 
Wong 2011). As APP is proteolytically processed into many peptides, it is possible that 
they are the ones that fulfil APP’s function and indeed putative functions have been found 
for many of them (van der Kant and Goldstein 2015).  
 
1.5.1.3 Proteolytic digestion of APP  
 
APP can be cleaved by proteins called secretases, and one of those pathways generates 
β-amyloid (Figure 1.3). The enzymatic processing of APP can take two routes. The non-
amyloidogenic pathway starts in the cell membrane where APP is cleaved by an α-
secretase and then endocytosed and cleaved by a γ-secretase possibly in the trans Golgi 
network or in the late endosome. This process produces APP fragments that are not toxic, 
namely soluble APP α (sAPPα), C83, P3 and the APP intracellular domain (AICD). The 
amyloidogenic pathway occurs in endosomes where APP is cleaved by β-secretase and 
then γ-secretase enzymes. This generates the toxic β-amyloid fragment, but also sAPPβ, 
C99 and the AICD. The most likely candidate for α-secretase is considered to be the 
enzyme a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and 
for β-secretase - beta-site APP cleaving enzyme 1 (BACE1). γ-secretase is a protein 
complex that consists of four proteins: presenilin-1 or 2 (PSEN1,2), nicastrin, anterior 
pharynx-defective 1 (APH-1), and presenilin enhancer 2 (PEN-2). The soluble APP 
fragments sAPPα and sAPPβ seem to act as signalling molecules that increase neuronal 
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growth. sAPPα could also potentially act to protect neurons from excitotoxic stress. One 
suggested function of APP is a cell surface receptor similar to Notch. Netrin-1 and F-
spondin have been identified as potential ligands for APP and their binding is thought to 
induce complex-forming with the protein FE65. Post-FE65 binding the APP intracellular 
domain AICD is thought to be translocated to the nucleus where it can act as a 
transcription factor to upregulate genes related to endoplasmic reticulum stress, β-amyloid 
degradation, and growth suppressor genes among others (Multhaup et al. 2015).  
 
Figure 1.3 APP processing. This figure depicts the two main processing pathways for 
APP. The fragments APP is cleaved into by α, β and γ-secretase and the main candidates 
for those enzymes are also shown. 
 
1.5.1.4 β-amyloid production and degradation 
 
The peptide β-amyloid is the main component of amyloid plaques found in AD, which are 
a major pathological hallmark of the disease. It is thought that β-amyloid is a major 
contributing factor to neurodegeneration in AD (Hardy and Allsop 1991). This is not only 
due to the presence of amyloid plaques; but also due to the fact that some of the most 
common mutations linked to familial AD in the proteins PSEN1 and PSEN2 lead to an 
increase in the β-amyloid 40/ β-amyloid 42 ratio. Additionally, APP gene duplication in 
Down’s syndrome leads to early β-amyloid deposition and onset of AD (Bird 1993).  
Whether β-amyloid is just a by-product of APP processing or if it has a cellular function is 
currently unknown. It is possible that it can act as a signalling molecule. What is certain is 
that levels of β-amyloid in the brain are strictly regulated. In the healthy CNS β-amyloid 
has a short half-life of about 9 hours. The β-amyloid generated in neuronal late 
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endosomes can be degraded intracellularly or exported to the extracellular space. There it 
could also be degraded by proteases such as insulin degrading enzyme (IDE), neprilysin, 
matrix metalloproteases (MMPs) and others (Hernandez-Guillamon et al. 2015; Saido and 
Leissring 2012). β-amyloid can also be transported through the blood-brain barrier; and in 
fact, detection of β-amyloid in CSF and by positron emission tomography (PET) has 
become a commonly used biomarker for AD (Masters et al. 2015).  
In the healthy CNS, β-amyloid is degraded intracellularly by the neurons themselves and 
extracellularly by glial cells, such as astrocytes and microglia, by the secretion of the β-
amyloid degrading proteases mentioned above (Saido and Leissring 2012). Microglia and 
astrocytes have also been found to readily phagocytose β-amyloid both in vitro and in vivo 
(Lee and Landreth 2010). The accumulation of β-amyloid in AD brains can be explained 
not only by an increase in β-amyloid production but also a dysfunction in clearance 
especially as in the vast majority of AD cases there is no genetic component that leads to 
increased β-amyloid production. In fact, the biggest sporadic genetic risk factor for 
developing AD, APOE4 reduces the clearance of β-amyloid in the brain (Michaelson 
2014). Additionally, studies have found that even in early stages of the disease there’s 
evidence of reduced β-amyloid degradation with no detectable difference in production 
(Mawuenyega et al. 2010; Caccamo et al. 2005).   
 
1.5.1.5 β-amyloid toxicity 
 
Originally, it was thought that amyloid plaques were the cause of neurotoxicity in AD. That 
idea has come into question after many studies failed to correlate amyloid plaques with 
severity of dementia; as they are found a lot earlier than disease manifestation and their 
presence has been identified in post-mortem samples of many healthy individuals. 
Currently it is thought that soluble oligomeric forms of β-amyloid are the ones that confer 
the neurotoxic effect (Tabner et al. 2011). The sizes of β-amyloid produced in the brain 
vary, but the most common ones are the 1-40 and 1-42 amino acid isoforms. There is 
evidence that β-amyloid 1-42 is the more toxic of those two as it is more prone to 
oligomerisation and aggregation (Bitan et al. 2003; Qiu et al. 2015; Murphy and Levine 
2010). Increases in the ratio of β-amyloid 1-42/1-40 have been shown to stabilise toxic 
oligomeric species and to correlate with levels of neurodegeneration in AD while 
increases in β-amyloid 1-40 have been suggested to prevent amyloid deposition (Qiu et 
al. 2015). The neurotoxic effect of β-amyloid could be conferred through the generation of 
reactive oxygen species or the triggering of apoptosis through the activation of caspases 
as both have been observed in vitro (Troy et al. 2000; Cheignon et al. 2018). β-amyloid 
oligomers have been shown to damage synapse structure and function in vitro and have 
also been shown to impair memory function in rats. Additionally, higher levels of β-amyloid 
oligomers, as opposed to plaques, have been correlated with clinical AD (Selkoe and 




1.5.2 α-synuclein in neurodegeneration  
α-synuclein is a small cytosolic protein widely expressed in the brain, in particular in the 
regions of the substantia nigra, the hippocampus and the neocortex. It is coded for by the 
gene SNCA (Stefanis 2012). It is part of the synuclein family of proteins that share a 
similar sequence that in humans include β-synuclein and γ-synuclein (George 2002).  α-
synuclein was first identified as part of the non-amyloid component (NAC) of amyloid 
plaques in Alzheimer’s disease. A variety of disease have been shown to have 
accumulated, intracellular aggregates of the protein. These diseases include, AD, PD, 
dementia with Lewy bodies, diffuse Lewy body disease and multiple system atrophy. The 
inclusions found in the cells of diseased patients are termed Lewy bodies (Wakabayashi 




The structure of α-synuclein has been of considerable interest as it can inform on the 
protein’s function (Figure 1.4). It is a 14 kDa protein made up of 140 amino acids (Lashuel 
et al. 2013). Its N-terminus is lysine-rich and possesses an amphipathic nature, while its 
acidic C-terminus is disordered. Its middle region, also termed the NAC region is highly 
hydrophobic. 
Even though the association of α-synuclein with neurodegeneration has been extensively 
studied, neither its physiological function nor its functional conformation have been agreed 
upon. Traditionally α-synuclein has been viewed as a monomer. The monomeric form of 
α-synuclein is thought to exist in a disordered state which has high conformational 
flexibility (Breydo et al. 2012). α-synuclein is largely considered to be a cytosolic protein. 
However, its N-terminus has been shown to readily bind to lipid membranes and make the 
protein adopt a more helical conformation, enhancing its tendency to form multimers 
(Dikiy and Eliezer 2012). Membrane binding has been observed in up to a third of α-
synuclein in the cell (Visanji et al. 2011). α-synuclein binds lipids with acidic headgroups 
and favours smaller in size vesicles (Davidson et al. 1998). It has been found to localise to 
presynaptic vesicles, mitochondrial membranes, and sites of ER-mitochondria contact 
(Snead and Eliezer 2014; Guardia-Laguarta et al. 2015). 
A newer proposition about the native form of α-synuclein has been that it may form 
tetramers. 58kDa helically folded α-synuclein tetramers have been detected in human 
brain samples when analysed under non-denaturing conditions or cross-linked (Bartels et 
al. 2011). Tetramers have been reported to be abundant in freshly biopsied brain samples 
and are assumed to be non-toxic (Dettmer et al. 2015). Other studies have disputed these 
findings and reported a primarily monomeric form of α-synuclein in brain tissue and cell 
lines and explained that the reported tetramers were most likely due to the tendency of α-
synuclein to form extended conformations (Fauvet et al. 2012; Lashuel et al. 2013; Burré 
et al. 2013). The native form of α-synuclein could be a monomer or a tetramer with 
evidence supporting both theories, but neither of which being widely accepted. Some data 
suggest that there exists an equilibrium between monomers and tetramers (Dettmer et al. 
2016). It is possible that α-synuclein exists in multiple conformational and oligomeric forms 
that change depending on the cellular environment (Mor et al. 2016).  
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α-synuclein has been shown to bind metals such as copper, manganese and iron in vitro 
(Brown 2009). Different studies have identified different numbers of copper binding sites 
(Ranjan et al. 2017; Xiaoyan Wang et al. 2010; Davies et al. 2011). They have been found 
at the N-terminus, at H50, and with the C-terminus possibly coordinating copper as well 
but with lower affinity (Rasia et al. 2005; Brown 2009; McDowall and Brown 2016). The N-
terminus copper binding site has been found to disappear upon α-synuclein N-terminal 
acetylation which is thought to occur in vivo with the protein still being able to bind copper 
at H50 (Mason et al. 2016).  
Iron has also been shown to interact with the C-terminus of α-synuclein in two binding 
sites, with a particular affinity for the ferric form (Fe3+) (McDowall and Brown 2016). The 
affinity of α-synuclein for iron and other metals can be altered through phosphorylation, 
where Fe2+ but not Fe3+ binds much more readily after phosphorylation at Y125 and S129, 
(Lu et al. 2011; Duce et al. 2017). Phosphorylation at S129 is thought to occur in DLB 
(Anderson et al. 2006). The interaction of α-synuclein with iron and copper has been 
suggested to play a role in α-synuclein oligomerisation (Lu et al. 2011; Carboni and Lingor 
2015; McDowall and Brown 2016). Metal interactions are thought to play a major role in α-
synuclein biology while at the same time α-synuclein is thought to play a major part in iron 
homeostasis (Lingor et al. 2017; McDowall and Brown 2016).  
 
Figure 1.4 Structure of α-synuclein. Shown here is a schematic of the structure of α-
synuclein including its’ three main domains: The N-terminus amphipathic region, the 
middle NAC domain and the C-terminus acidic tail. The NAC domain is the one implicated 
in the aggregation of α-synuclein while all the common disease related mutations of α-




Theories about α-synuclein function include it acting as a dopamine release mediator and 
it being a ferrireductase. As it is present in presynaptic terminals it was suggested that it is 
involved in synaptic function (Sidhu et al. 2004). α-synuclein may act as a chaperone in 
soluble N-ethylmaleimide–sensitive factor attachment protein receptor (SNARE) complex 
assembly by directly binding synaptobrevin-2, facilitating the release of dopamine from the 
synapse (Burré et al. 2011). These observations were based on the monomeric form of α-
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synuclein, but there is data suggesting that a multimeric form that is bound to lipid 
membranes is necessary to fulfil this function (Burré et al. 2014). On the other hand, α-
synuclein oligomers have also been linked to preventing SNARE-mediated vesicle 
docking (Choi et al. 2013).  
Another theory for α-synuclein function is that it is an enzyme (Davies et al. 2011).  It has 
been found to reduce iron both in vitro and in vivo and that its active form is actually a 
tetramer (Bartels et al. 2011; McDowall et al. 2017). α-synuclein interacting with copper 
has been shown to be essential to ferrireductase activity, thus presenting a theory that 
incorporates a physiological function for copper binding. Increased ferrireductase activity 
has been detected in rat brains overexpressing α-synuclein. It is possible that 
ferrireductase activity in dopaminergic neurons can be neurotoxic as it was shown to 
increase cells’ sensitivity to DOPAL (McDowall et al. 2017). Moreover increased 
ferrireductase activity of α-synuclein has been linked to increased production of β-amyloid 
in α-synuclein overexpressing cells, possibly as a result of increased oxidative stress 
(Roberts et al. 2017).  
The apparent multifunctionality of α-synuclein could be linked to its conformational 
flexibility. It does seem like α-synuclein’s role in the cell is more of a supportive rather than 
essential molecule, as knockout organisms are viable possibly due to some functional 
redundancy with the other synucleins. α-synuclein null mouse models are also resistant to 
the neurotoxic effects of MPTP and LPS. Conversely, both excessive and overly reduced 
levels of α-synuclein result in impaired neuronal function (Stefanis 2012).  α-synuclein’s 
properties may be more related to long-term neuronal viability and become more visible 
under conditions of stress. Perturbations in α-synuclein localization, production and 
clearance can prevent it from fulfilling its neuroprotective function and instead form toxic 




α-synuclein is clearly a central molecule to the pathology of PD and other 
synucleinopathies. It most famously aggregates to form the main component of Lewy 
bodies and the non-amyloid component in AD amyloid plaques in the brain. The brain is 
not the only location α-synuclein has been found to aggregate with recent studies 
proposing that α-synuclein aggregation is initiated in the gut (Liddle 2018; Klingelhoefer 
and Reichmann 2015). α-synuclein has been shown to be expressed by enteroendocrine 
cells that connect to enteric nerves which allow α-synuclein aggregation to travel up the 
vagus nerve to the brain (Chandra et al. 2017). The types of aggregate found in Lewy 
bodies are mostly fibrils (Spillantini et al. 1997). Apart from these best-known types of 
aggregates α-synuclein can form protofibrils and a multitude of oligomers including small 
dimers, trimers and tetramers and bigger spheres, chains or rings. α-synuclein is thought 
to be constantly cycling between monomeric and oligomeric forms and for oligomers to 
assemble into fibrils through a nucleated polymerization mechanism. α-synuclein 
aggregation can be enhanced by the interaction with lipids such as those in membranes in 
the cell, but it has been shown to occur in both the cytosol and in association with lipid 
membranes (Lashuel et al. 2013; Galvagnion et al. 2015).  The N-terminus region is the 
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part of α-synuclein that interacts with lipid membranes, while the NAC region is central to 
aggregation (Bisaglia et al. 2006). In fact, in vitro studies have shown that deleting that 
region greatly diminished α-synuclein’s ability to oligomerize and form fibrils (Lashuel et al. 
2013). β and γ-synuclein differ from α-synuclein in this region and have not been 
observed to aggregate in disease. In contrast, the C-terminal section of α-synuclein is 
thought to have a stabilising function and deleting it results in molecules with a greater 
inclination to aggregate (Serpell et al. 2000). C-truncated species of α-synuclein that can 
be produced by proteases also show increased aggregation (Sevlever et al. 2008). In a 
mouse model of α-synuclein aggregation passive immunization against the C-truncated 
species prevented aggregation and ameliorated motor symptoms (Games et al. 2014). 
Another argument for the central role of α-synuclein aggregates in disease is that 
mutations in SNCA have been identified to cause rare familial forms of PD. The most 
common polymorphisms A30P, E46K, A53T and G51D are connected to early onset of 
the disease and H50Q is linked to a later presentation of symptoms. All of these mutations 
have a destabilising effect on the N-terminus and are thought to increase the formation of 
α-synuclein aggregates (Flagmeier et al. 2016; Brucale et al. 2009).  
Metal interaction has been shown to induce α-synuclein aggregation, where both the 
presence of copper and iron can result in the increased formation of α-synuclein 
aggregates (Uversky et al. 2001). In fact, in copper-free environments α-synuclein is 




The mechanism of toxicity of α-synuclein has been the subject of a lot of research and 
some progress has been made. Lewy bodies, the pathological feature of PD and DLB 
were originally thought to confer the toxic effect but in fact high levels of Lewy bodies have 
been found in a large proportion of aged non-demented individuals, thus suggesting that 
Lewy body accumulation may be a factor of age (Schulz-Schaeffer 2015). Additionally, 
Lewy bodies in PD have been found to appear after the onset of pathology and neuronal 
death. Moreover, the presence of Lewy bodies inside neurons didn’t correlate with 
neuronal cell death in the substantia nigra (Tompkins and Hill 1997).  
The potential native tetrameric form of α-synuclein is resistant to aggregation (Bartels et 
al. 2011).  It is possible that processes related to ageing or environmental exposure, as 
well as mutations destabilise the α-synuclein tetramers and can lead to the formation of 
toxic oligomeric species or aggregates. The PD causing mutations A53T and E46K have 
also been shown to destabilise tetramers by increasing the energy barrier to 
tetramerization (Dettmer et al. 2015; L. Xu et al. 2018).  α-synuclein has been shown to be 
able to oligomerise in laboratory conditions by the modulation of a myriad of factors 
including stirring, shaking and also adding ethanol, iron, copper or dopamine. The nature 
of the species of α-synuclein oligomers that are neurotoxic is evasive, but it is generally 
agreed that they exhibit an increased prevalence of a β-sheet secondary structure (Wong 
and Krainc 2017). A cell culture model of α-synuclein aggregation showed that copper is 
required for the neurotoxicity of α-synuclein and the type of oligomer that conferred the 
toxicity was stellate in shape with a β-sheet structure (Wright et al. 2009).  
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Elevated levels of soluble α-synuclein oligomers have been found in the brains of 
sufferers of DLB (Paleologou et al. 2008). In animal models, genetic variants of α-
synuclein that are prone to forming oligomers are more neurotoxic than ones prone to 
aggregating (Winner et al. 2011). Large α-synuclein oligomers have been shown in vitro to 
decrease the assembly of the SNARE complex, a proposed function of α-synuclein and 
thus acting to inhibit dopamine release at the synapse (Choi et al. 2013). α-synuclein 
oligomers have been shown to cause increased glial activation and neuroinflammation 
through TLR4 receptor activation (Fellner et al. 2013). The pore-like structure that α-
synuclein oligomers can assume can result in their incorporation into the membrane 
causing disrupted Ca2+ in neurons. Additionally, soluble oligomers can cause 
mitochondrial dysfunction, increase in ROS, impaired cytoskeletal formation, endoplasmic 
reticulum stress and impaired protein degradation (Roberts and Brown 2015). This way 
they can not only directly confer neurotoxic effects but also perpetuate decreased α-
synuclein clearance.  
How α-synuclein comes to accumulate in sporadic synucleinopathies is a question of 
significant importance. α-synuclein gene duplication and triplication has been shown to be 
the cause of rare familial PD thus pointing to the fact that increased levels of the protein 
are a disease-driving mechanism (Devine et al. 2011).  Studies have found no increase in 
α-synuclein mRNA in sporadic PD or in DLB compared to controls, therefore it’s possible 
that the accumulation of α-synuclein in those cases is due to impaired clearance 
mechanisms (Quinn et al. 2012; Su et al. 2017).  Major protein clearance mechanisms 
such as the ubiquitin-proteasome system and autophagy that have been shown to 
degrade α-synuclein are dysregulated in sporadic and hereditary synucleinopathies 
(Cuervo et al. 2004; Ghavami et al. 2014). In DLB α-synuclein accumulation has been 
linked to reduced expression of α-synuclein degrading proteases neurosin (kallikrein-6) 
(extracellular) and calpain-1 (intracellular) (Miners et al. 2014; Iwata et al. 2003). 
Cathepsin-D is another protease known to process α-synuclein that acts in the lysosome, 
with partial proteolysis resulting in the formation of C-terminal truncated species more 
prone to aggregation, but its deficiency is has also been shown to result in increased 
aggregation (Crabtree et al. 2014; Cullen et al. 2009; Sevlever et al. 2008). 
Glucocerebrosidase is another lysosomal enzyme implicated in α-synuclein aggregation, 
where loss of function results in an accumulation of its substrate which in turn facilitates α-
synuclein aggregation (Mazzulli et al. 2011). MMP-3 processes α-synuclein in the 
extracellular space, is secreted by microglia in stress conditions and also results in C-
terminal truncated species (Choi et al. 2011; Sung et al. 2005). Modulating the levels of 
these enzymes is considered a potential avenue for preventing neurotoxicity in PD and 
DLB (Wong and Krainc 2017; Park and Kim 2013).      
What all the current knowledge points to is that α-synuclein is the toxic molecule behind 
synucleinopathies and that understanding all the factors that lead to the formation of toxic 
oligomers in the brain will be crucial to both the prevention and the treatment of these 
diseases.  
For both α-synuclein and β-amyloid, ineffective clearance mechanisms seem to be central 
to accumulation and further disease development. Investigating the underlying reason for 
this ineffective clearance could be key to preventing sporadic age-related 
neurodegenerative disease. As the world population ages, it is becoming increasingly 
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imperative to not only manage the symptoms of these neurodegenerative conditions as 
and when they appear, but also to find ways to prevent them and reverse them. In order to 
achieve that it is important to recognise that aging plays a central role in the development 
of neurodegeneration.  
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1.6 Aging 
Aging is a process that occurs in living organisms. It is characterized by changes on the 
physiological, cellular and molecular level that result in the impairment of many functions 
of the organism. Death rates in many organisms including humans increase as a function 
of age. Additionally, humans are one of the few animals whose lifespan extends far 
beyond their fertile years. In humans, aging is a risk factor for many diseases that include: 
heart disease, pulmonary disease, cancer, and neurodegenerative diseases.  
Unlike humans some organisms such as some turtle species or naked mole rats do not 
exhibit a decline in fitness with age, a phenomenon called negligible senescence (Kogan 
et al. 2015). Others examples such as the hydra display indefinite stem cell division 
possibly due to the transcription factor FOXO activity (Boehm et al. 2012). Research also 
suggests that lobsters’ continuous expression of the enzyme telomerase protects them 
from accumulating DNA damage and prevents them from suffering any age-related 
changes in fitness (Klapper et al. 1998).  
 
1.6.1 Theories on the cause of aging 
The underlying reasons to the aging process have not been fully elucidated and many 
competing theories have been proposed over the years.  
Firstly, it is possible that life-spans are evolutionarily pre-programmed. Some have argued 
that ageing is evolutionarily beneficial while others believe it is a side-effect of sexual 
selection. The mutation accumulation theory proposes that random germline mutations 
accumulated over time that only affect an organism later in life do not get selected out of 
the gene pool as most animals in nature don’t survive long enough to reach old age 
(Kirkwood and Austad 2000). However, this theory does not account for differential gene 
expression in different tissues and different time points. The disposable soma theory 
states that organisms focus more energy and resources on growth and reproduction in 
early life due to evolutionary pressure and neglect cellular repair and maintenance which 
results in aging (Kirkwood 1977). This theory however doesn’t explain the extended 
lifespans of many organisms as a result of caloric restriction. The antagonistic pleiotropy 
hypothesis suggests that a gene can have an effect on multiple traits some of which are 
beneficial and some detrimental (Williams 1957). It is possible that genes that favoured an 
individual’s fitness in early life were selected during the evolutionary process. This comes 
as a trade-off with later age impairment after the individual has procreated. Aging would 
be caused when the benefits of those genes are shown early in life and the costs later. 
However, from the genes that have been identified to control aging and are conserved in 
different species not many have been identified to bring early-life benefits to fitness or 
reproductive ability. The effectiveness of the molecular mechanisms that regulate tissue 
maintenance and repair correlates with the overall lifespan of a species and more 
precisely with the time it takes for them to reach maturity. These mechanisms are complex 
and involve a multitude of interacting molecules. It is possible that they are controlled by a 
master switch capable of sensing outside conditions and thus modulating lifespan. The 
eventual failure of these systems to maintain cellular viability over a longer lifespan could 
therefore be passed on to the germline as it would not prevent the individual from 
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reaching adulthood and procreating (Kirkwood and Austad 2000). An argument against 
the pre-programmed lifespan theory is that in twin studies the genetic factor in heritability 
of human lifespans has been found to be only about 20-30% and to increase with age 
(Wyss-Coray 2016). This means that the majority of factors that determine the length of 
the human life are external such as their lifestyle, surroundings and exposure to toxins.  
External factors can impact an organism’s lifespan by inducing changes in their genome. 
Epigenetic changes in DNA occur over an organism’s lifespan which can lead to 
differential expression in many genes related to viability, cell division and dealing with 
cellular damage (López-Otín et al. 2013). Dysregulation of these processes is considered 
a hallmark of aging and could explain the differences in the transcriptome between young 
and aged cells (Horvath and Raj 2018). However, linking DNA methylation changes to 
actual changes in expression has proved challenging due to the dynamic nature of RNA 
expression (Sen et al. 2016). Additionally, it has not been determined how these changes 
come about and whether they are the cause of or an effect of aging. 
Natural accumulation of DNA and other macromolecular damage that results in the failure 
of many biological systems is another theory commonly used to explain aging (Gensler 
and Bernstein 1981). Indeed, a correlation between DNA damage and age has been 
shown a meta-analysis of human aging studies (Soares et al. 2014). The types of DNA 
damage that can accumulate include: point mutations, translocations, gene disruption and 
chromosomal abnormalities. They can be caused by oxidative stress, telomere shortening 
or just random chance errors that escape DNA proofreading and repair mechanisms 
(Maynard et al. 2015). Telomeres are structures in the ends of chromosomes that stabilize 
them and protect the integrity of DNA during cell division. Telomere shortening occurs 
every cell division and leads to chromosome instability and cellular senescence (Jiang et 
al. 2007). However, a mouse model of loss of telomerase activity doesn’t replicate all 
symptoms of aging (Rudolph et al. 1999). While on one hand telomerase deficiency has 
been linked to the premature development of diseases, telomere length in human blood 
cells has been found to be heterogenous with a possible telomere maintenance 
mechanism being at play in individuals with shorter telomeres (Nordfjäll et al. 2009; 
Svenson et al. 2011). It has been suggested that this pre-programmed limit on cellular 
division has evolved to suppress cancer (Cerella et al. 2016). 
DNA replication and translation into proteins is a process that occurs countless times over 
an organism’s lifetime and seems to be affected by ageing, with an accumulation of 
aberrant DNA polymerases and an increase in the mis-incorporation of nucleotides and 
amino acids (Milholland et al. 2017). It is thought that this results in an increase in protein 
errors and thus fundamental disruption in metabolic processes, leading to more damage 
and death (Rattan 2006). Organismal longevity clearly requires translational fidelity and 
accuracy of translation has been found to correlate with lifespan in rodents (Ke et al. 
2017). The evidence of an age-related increase in protein errors has been largely 
unconvincing but error accumulation at a steady pre-determined rate could result in the 
same detrimental effects. Additionally it has been proposed that age-related accumulation 
in somatic mutations in gene regulatory regions of DNA rather than protein encoding ones 
can have the same results on the organism but that accumulation is yet to be proven 
experimentally (Milholland et al. 2017).    
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The free radical theory of aging postulates that cells accumulate free radical damage over 
an organism’s life span (Harman 1956). Reactive oxygen species (ROS) which include 
free radicals are thought to act in biological systems to cause damage. ROS include 
oxygen radicals such as superoxide, and hydroxyl and nonradical oxidizing agents such 
as hydrogen peroxide among others (Bayr 2005). One of the main effects if increased 
levels of ROS during aging is thought to be oxidative damage (Liochev 2013). Oxidative 
damage can be induced by various environmental sources such as UV light, ionising 
radiation and toxins such as metals; and can cause not only DNA damage but damage to 
other cellular structures as well (Birben et al. 2012). ROS are also produced by 
mitochondria, the endoplasmic reticulum, peroxisomes and the cell membrane and play 
roles in normal cell metabolism (Phaniendra et al. 2015). Levels of ROS are constantly 
managed by enzymes such as superoxide dismutase and catalase but dysfunction in 
these processes can result in impairment of their protective functions (Lund et al. 2009; 
Selvaratnam and Robaire 2016). ROS can react with DNA and RNA where mitochondrial 
DNA is particularly vulnerable (Brunk and Terman 2002). ROS can also cause lipid 
peroxidation in membranes and react with amino acids in proteins. Moreover, ROS have 
been implicated in endoplasmic reticulum stress. Accumulation of ROS damage is thought 
to lead to apoptosis. On the other hand the role of ROS as important cell signaling 
molecules has been emerging and casts doubt on the free radical theory of aging (Ray et 
al. 2012; Hancock et al. 2001). Additionally, studies have shown that caloric restriction, 
which results in elevated oxidative stress can have a positive effect on lifespans (Fontana 
et al. 2010). It is possible that it is not the overall increase in intracellular ROS that initiates 
the negative effects of aging but the cells’ declining ability to maintain them at an 
appropriate level (Finkel and Holbrook 2000).  
 
1.6.2 The molecular signature of aging 
Understandably, great interest has been shown in the molecular causes of aging, with the 
idea that identifying which cellular processes are disrupted in an aged organism can lead 
to the amelioration or reversal of aging in humans. Aging proceeds in a similar manner in 
many organisms. The hallmarks of aging include genomic instability, telomere shortening, 
epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial 
dysfunction, cellular senescence, stem cell exhaustion and altered intercellular 
communication (López-Otín et al. 2013).  
An avenue for investigation of the molecular players in ageing is the study of longevity and 
what genetic variants confer a longer life in humans (Marques et al. 2010). Genome-wide 
association studies have had limited success in that field by reproducibly linking only 
APOE variants and FOXO3a variants with longevity (Broer et al. 2015; Nebel et al. 2011; 
Walter et al. 2011; Broer and van Duijn 2015). The difficulty in identifying single “longevity 
genes” through GWAS is due to the complexity of traits such as longevity and aging. 
Pinpointing which common variants with small individual effects interact together to 
produce a larger effect on longevity is a possible step forward. Another possible avenue in 
the study of longevity is identifying ways to measure changes in the larger pathways 
implicated in aging.  
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The hallmarks of aging manifest through the altered functioning of many molecular 
pathways in the cell. The idea that an aged organism can be identified by reproducible 
changes in gene expression has been investigated in a multitude of gene-expression 
studies (Kent et al. 2012; Van den Akker et al. 2014; Glass et al. 2013; Park and Prolla 
2005; Welle et al. 2003; Lee et al. 2000; Peters et al. 2015; Bryois et al. 2017; Ardlie et al. 
2015).  
A major analysis of changes in gene expression with age has uncovered large clusters of 
genes affected by age in a variety of tissues (Yang et al. 2015). The study highlighted that 
most tissues exhibited age-related mitochondrial dysfunction. They also commonly 
observed changes in DNA repair pathways, apoptosis, inflammation and the electron 
transport chain. Those findings corroborated many other studies that implicate these 
processes in aging in both humans and animal models. The aging signature of some 
tissues especially the nervous tissue and arteries correlated best with chronological age. 
In fact, pathways linked to age-related ND such as AD, PD and Huntington’s were 
significantly altered in multiple tissues. An additional finding was that genes implicated in 
tissue-specific diseases were over-represented in the same tissues, with pulmonary 
function markers downregulated in the lung, obesity associated genes elevated in adipose 
tissue and immune and inflammatory genes elevated in blood and arteries. 
Even though a lot of literature has been published on the topic it has proven difficult to 
identify universal genetic biomarkers for biological age. That is probably due to the great 
complexity through which the genotype and the environment interact to produce a 
phenotype. Measuring the levels of proteins and metabolites in the body is an alternative 
avenue through which biomarkers can be identified. Protein and metabolite levels have 
been found to change with age in both model and non-model organisms and in humans 
(Menni et al. 2015; Hoffman et al. 2017). Metabolic studies of aging have also moved 
more towards identifying pathways that are disrupted rather than individual molecules.  
One way to look at aging is through the study of disrupted cellular networks. In many 
biological pathways there are a small number of genes that have many interacting 
partners. Disruption in the activity of any of these genes results in disruption in the whole 
network. Some genetic pathways identified in high-throughput gene expression studies 
have been previously linked to aging through studies on life extension and longevity. A 
well-known life-extending factor in model organisms is caloric restriction which alters 
nutrient sensing pathways in the cell (Haigis and Yankner 2010). A small number of highly 
conserved pathways, namely the FOXO3a signalling pathway (mediated by insulin/IGF or 
AMPK), the target of rapamycin (TOR) pathway and sirtuin signalling are implicated in 
nutrient sensing, stress response, chromatin remodelling and DNA damage response. 
The proteins that control these pathways have a very large number of interacting partners 
and targets and can be manipulated to modulate survival and longevity. Therefore, they 
are thought to be key regulators of aging.
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 Protein Functions Aging changes 
FOXO3a Tumour suppressor, oxidative stress 




mTOR Inhibits autophagy, increases protein, 
nucleotide and lipid synthesis 
Increased signalling 
SIRT1 Histone deacetylation, DNA repair, anti-
inflammatory, pro-survival signalling 
Reduced signalling 
AMPK Sensor for nutrient scarcity, activates 
autophagy, connected to SIRT1 with a 
positive feedback loop 
Reduced signalling 
PGC-1α Activates mitochondriogenesis, improves 
antioxidant defences, stimulates fatty acid 
oxidation. Activated by SIRT1, acts with 
mTOR 
Reduced signalling 
ATM Major DNA repair regulator, works in 
conjunction with SIRT1, inhibited by 
mTOR 
Reduced signalling 
IGF-1 Nutrient sensor enables growth and 
survival, triggers FOXO inhibition and 
mTOR activation through AKT 
Reduced signalling 
Table 1.1 Proteins associated with aging. The proteins listed in this table alter their 
activity in the aging organism and interact with each other to cause the detrimental 
changes seen in the aging cell. The first column lists the protein or protein family 
implicated, the second one summarises their functions in the cell and how they have been 
found to interact with the others and the third summarises how their signalling changes 




Sirtuins are a family of proteins that possess a NAD-dependent deacetylase or a ADP-
rybosyltransferase function. They are linked to multiple hallmarks of aging, namely 
genomic instability, deregulated nutrient sensing and epigenetic alterations (López-Otín et 
al. 2013). Studies in budding yeast, C. elegans and Drosophila first demonstrated the 
potential importance of sirtuins to aging (Rogina and Helfand 2004; Tissenbaum and 
Guarente 2001; Kaeberlein et al. 1999). Overexpression of sirtuins in those organisms 
was found to increase lifespan. After some conflicting findings a more nuanced role for 
sirtuins in lifespan regulation has been emerging (Whitaker et al. 2013; Burnett et al. 
2011; López-Otín et al. 2013). Mammals possess 7 sirtuin proteins SIRT1-7 where SIRT1 
has been the best studied. SIRT1 expression has been found to decline with age in many 
tissues. Additionally, in mouse models of accelerated ageing, SIRT1 levels are found to 
decline with age as well (Gong et al. 2014).  
A major function of SIRT1 involves DNA repair as it can deacetylate DNA repair proteins 
and NBS1, a DNA double strand break sensor (Yuan et al. 2007; Fan and Luo 2010; 
Jeong et al. 2007). SIRT1 activity in DNA repair is thought to be ataxia telangiectasia 
mutated serine/threonine kinase (ATM) -dependent and ATM is found to be globally 
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reduced in aging (Dobbin et al. 2013). SIRT1 has also been implicated in epigenetic 
modification of chromatin through histone deacetylation (Zhang and Kraus 2010).  
SIRT1 is also plays a role in maintaining proteostasis. Targets of SIRT1 include 
autophagy related proteins, which are activated in starvation conditions. Autophagy is 
increased in times of nutrient deprivation as a way to create a source of energy and of 
free amino-acids to be used in protein synthesis. Maintaining autophagic flux is central 
process for cellular stress response and longevity. Thus, reduced levels of SIRT1 
signalling in aged organisms can result in inadequate protein turnover.  
SIRT1 activity can be reduced by a high-fat diet but stimulated by caloric restriction. 
SIRT1 deacetylates many proteins related to metabolism and stress response including 
nuclear factor kappa B (NFκB), p53, FOXO transcription factors and many others. An 
important target of SIRT1 is peroxisome proliferator-activated receptor gamma coactivator 
1-alpha (PGC-1α), an important stimulator of mitochondrial biogenesis and regulator of 
metabolism. In animal models SIRT1 deficiency results in impaired energy metabolism, 
damaged mitochondria and elevated ROS. Elevated SIRT1 expression results in 
improved metabolic parameters, but potential lifespan extension caused by SIRT1 may 
only be conferred in stress conditions (Bordone et al. 2007). 
Other sirtuins have also been implicated in lifespan extension. Mice deficient in SIRT6 
have a reduced lifespan and ones with elevated SIRT6 levels live longer than controls. 
Those effects are thought to be conferred by a reduction in IGF-1 signalling. SIRT3 has 




Mechanistic target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine 
kinase that is implicated in cellular senescence and age-related disease. The mTOR 
pathway inhibits autophagy and therefore has an essential role in protein homeostasis. Its 
activity can be attenuated by rapamycin but also in conditions of caloric restriction. 
Mammalian mTOR signalling has been found to be reduced in a mouse model of 
longevity. Additionally, inhibiting mTOR signalling can extend the lifespan of a variety of 
model organisms (Johnson et al. 2013). The targets of the mTOR pathway include not 
only autophagy but also cell growth, protein synthesis, ribosomal biogenesis and 
metabolism. In mammals the mTOR pathway is represented by two distinct protein 
complexes, mTORC1 (comprised of mTOR, RAPTOR, PRAS40 and MLST8) and 
mTORC2 (comprised of mTOR, RICTOR, MSIN1, PROTOR and MLST8). Downregulating 
the mTORC1 pathway in mice results in an extended lifespan. Key downstream targets of 
the mTORC1 include S6 kinase and eIF4E-binding protein 1 (Gingras et al. 1998; 
Magnuson et al. 2012). mTORC1 has also been found to interact with PGC-1α 
(Cunningham et al. 2007). Another interesting downstream effector of the mTOR pathway 
is the inhibition of ATM (Shen and Houghton 2013). Loss of ATM signalling in post-mitotic 
neurons in the genetic disorder ataxia telangiectasia results in neurodegeneration. 
Additionally, the mTOR pathway has also been found to control cell proliferation by 
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regulating the FoxO3a transcription factor via SGK1 kinase. Inhibiting mTORC1 signalling 
resulted in pro-survival and proliferation signalling by FOXO3a (Mori et al. 2014).  
Interestingly, alleles implicated in age-acceleration in the cerebellum localize near one of 
the mTOR complex subunits MLST8 (Lu et al. 2016). Autophagy is implicated in both 
aging and neurodegeneration where it is found to be beneficial for cellular survival and 
longevity (Menzies et al. 2015). Deficiency in autophagy related genes in mouse models 
results in protein aggregation and neurodegeneration. Blocking mTOR signalling 
increases lifespan possibly through increasing autophagy. 
The current level of knowledge suggests that aging is unlikely to be caused by a single 
mechanism. It seems to be a multifactorial process that is affected by changes in many 
different systems. Additionally, aging in mammals is thought to proceed in an organ-
specific manner (Yang et al. 2015). However, loss of protein homeostasis is a major 
hallmark of the aging organism. Proteostasis is constantly maintained at the cytosolic, 
organelle, cellular, intercellular and organ level. Defects in protein chaperones, the 
ubiquitin proteasome system and autophagy all contribute to the accumulation of 
misfolded and possibly toxic proteins with age. In a multitude of model organisms, 
interventions that stimulate these systems result in increased lifespans. The fact that the 
Sirtuin, FOXO3a and mTOR pathways have all been found to contribute to maintaining 
proteostasis and the fact that some of the most major age-related diseases have been 
linked to loss of proteostasis all point to a potential central role changes in these proteins 
play in age and disease (Morimoto and Cuervo 2014; Kaushik and Cuervo 2015).  
 
1.6.3 Cellular senescence and the senescence associated secretory 
phenotype 
Cellular senescence is a process that results in an arrest in cellular proliferation. It is 
thought to contribute to the process of aging and age-related disease. It was first identified 
in vitro where primary cells would divide a limited number of times known as the Hayflick 
limit (Hayflick and Moorhead 1961). The arrest in cell cycle is triggered by the shortening 
of telomeres and increased proteotoxicity which triggers the activation of the DNA damage 
response protein ATM which in turn activates tumour suppressor proteins such as p16 
(Childs et al. 2015). In vitro senescent cells are characterised by an increased size, 
resistance to apoptosis, increased senescence-associated β-galactosidase activity (SA-β-
GAL) and a senescence-associated secretory phenotype (SASP) (Dimri et al. 1995; 
Hampel et al. 2005; Ryu et al. 2007; Coppé et al. 2010). The SASP is characterised by 
increased transcription of inflammatory cytokines (IL-1α,IL-1β, IL-6, IL-8 among others) 
proteases (MMPs and serine proteases) and increased release of NO and ROS while on 
the other hand, anti-inflammatory cytokines and proliferation and differentiation factors 
remain unchanged or are reduced (Ghosh and Capell 2016; Coppé et al. 2010). SASP is 
largely caused by NFκB and p38 activation triggered by the response to genomic 
instability and mediated by mTOR increase and SIRT1 reduction in activity (Salminen et 
al. 2012; Ghosh and Capell 2016). The alteration in the secretory phenotype of senescent 
cells has been shown to alter the intercellular environment and to cause senescence in 
neighbouring cells in vitro (Nelson et al. 2012).  
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 Figure 1.5 Comparison of acute and chronic cellular senescence. Acute cellular 
senescence occurs in young organisms and maintain tissue homeostasis and are 
antitumorigenic by preventing cells that suffered genomic damage from proliferating. 
Chronic senescence occurs in older organisms and is the result of an accumulation of 
damage and can result in increased numbers of senescent cells due to inefficient 
clearance mechanisms. Those senescent cells can have multiple negative effects on 
tissue homeostasis. Adapted from López-Otín et al. 2013. 
In vitro cellular senescence can be induced though irradiation, RAS overexpression or 
chemotherapeutics (Childs et al. 2015). In vivo cellular senescence is commonly observed 
and can be separated into three categories: acute, embryonic and chronic (Figure 1.5). 
Acute and embryonic senescence have an important role in development and wound 
healing and seem to be programmed and beneficial to the organism. Chronic senescent 
cells are the type that presents in human aging and is linked to the development of age-
related disease as they can persist in tissues for a long time and potentially propagate 
through paracrine signalling (Nelson et al. 2012; van Deursen 2014). Chronic senescence 
can be caused by slow accumulation of damage to macromolecules such as protein 
aggregation, misfolding and DNA damage over time (Childs et al. 2015). The SASP of 
chronic senescent cells is thought to be more heterogeneous as it has been suggested 
that acquiring the senescent phenotype in aging is a gradual process (van Deursen 2014). 
Senescent cells in vivo can be identified by markers such as SA-β-GAL and p16 and have 
been shown to accumulate in aged tissues (Geng et al. 2010; Gruber et al. 2007; 
Krishnamurthy et al. 2004). Senescent cells have an important role in cancer with their 
secretory phenotype being both pro- and anti-tumorigenic but allowing them to be targeted 
for immune clearance (Kang et al. 2011; Cerella et al. 2016). Thus, the targeting of 
senescent cells for therapeutic elimination in ageing can be difficult because the same 
processes that trigger their senescence also work to protect from tumour development. It 
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is thought that cellular senescence is a protective mechanism that prevents cancers but in 
later age can be detrimental (Cerella et al. 2016). The processes that link cellular 
senescence and aging are SASP factors resulting in a diminished ability to repair damage 
to tissues and to losing stem cells that are needed for replenishing and renewing tissues 
to senescence (Childs et al. 2015) 
 
1.6.4 Aging in the nervous system 
In the human brain, aging shows some characteristics that are similar to the rest of the 
organism such as DNA damage, altered DNA methylation, increased inflammation, loss of 
protein homeostasis, metal dyshomeostasis and deregulated nutrient sensing (López-Otín 
et al. 2013; Wyss-Coray 2016).  
Accumulation of DNA damage is a major issue in the nervous system as neurons are 
post-mitotic cells (Chow and Herrup 2015). That means they are unable to carry out some 
routes of DNA repair that dividing cells are such as homologous recombination. The 
amount and patterns of DNA damage and repair in neurons are heterogeneous and are 
thought to start in development and are often the result of random external factors but 
also high transcription rates due to neuronal activity (Suberbielle et al. 2013). DNA 
methylation is another factor that is affected by aging in the brain, with the changes being 
consistent with the Horvath epigenetic clock, a generalised model that can predict the age 
of a tissue based on its methylation status with the exception of the cerebellum which is 
epigenetically “younger” than other brain tissues as it contained fewer age-related 
methylation markers than other brain areas (Horvath et al. 2015). In the aging brain genes 
that increase inflammation are preferentially activated in astrocytes and microglia and 
different communication molecules such as pro-inflammatory cytokines are secreted 
(Spittau 2017; Salminen et al. 2011). That could be due to epigenetic changes that 
change the secretory phenotype of the cells or due to the cells suffering protein 
homeostatic dysregulation for other reasons that switch them to a pro-inflammatory state. 
This pro-inflammatory state seems to contribute to the development of neurodegenerative 
disease.  
Proteins implicated in ageing such as SIRT1 and mTOR have also been linked to the 
ageing of the brain. Declining SIRT1 signalling in the brain results in impaired energy 
metabolism and circadian rhythms but also reductions in neuronal plasticity. They have 
also been implicated in increased neuroinflammation caused by activated microglia 
(Braidy et al. 2015; Satoh et al. 2017). Impaired mTOR signalling in the brain leads to 
disrupted energy metabolism, mitochondrial function and autophagy all of which are 
affected in the aged brain (Perluigi et al. 2015). Inhibiting mTOR signalling has the 
potential to rescue neurons from age-related degeneration. Increased autophagy induced 
by inhibition of mTOR signalling can ameliorate cognitive deficits in aged mice (Yang et al. 
2014).  
Loss of protein homeostasis is a major hallmark in aging brains. That includes 
accumulation of protein aggregates such as amyloid plaques, Lewy bodies, neurofibrillary 
tangles and lipofuscin in cognitively healthy aged brains. These are connected to 
lysosomal dysfunction and autophagy disruption. The accumulation of lysosomal proteins 
in the brain and the presentation of abnormal mitochondria, autophagosomes, endosomes 
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and lysosomes in both neurons and glia is another piece of evidence of the inefficient 
protein degradation pathways seen in aging (Menzies et al. 2015; Nixon et al. 2005; Nixon 
et al. 2000; Brunk and Terman 2002). Major changes in the levels of key metabolites have 
been found in the brains of aged mice. Those include declining levels of NAD and 
increases in AMP/ATP and abnormal nucleotide synthesis (Ivanisevic et al. 2016). This is 
another example of how cellular homeostasis is disrupted in the aging brain.  
Another hallmark of the aging brain is the accumulation of metals. Iron in particular has 
been reliably shown to accumulate in multiple brain regions. On top of that the 
dyshomeostasis of iron, copper and zinc have been implicated in ND. Even though metals 
are essential to cellular metabolism, in excess levels they can cause oxidative stress, ER 
stress, mitochondrial dysfunction, autophagy dysregulation and can activate apoptosis 
(Chen et al. 2016).  
Considering all the ways in which cellular health is compromised in the aging brain it is not 
surprising that brain aging has also been linked to neuronal death and general loss of 
brain volume, a phenomenon that could be due to loss of myelin, glia or fluid as well 
(Peters 2006). 
Research into the genomic signature of the aging brain is an important tool in 
understanding the age-related changes observed on the cellular level and to uncover what 
separates healthy brain aging and neurodegeneration. Many efforts have been made to 
document the ageing signature of the brain with findings generally pointing to the fact that 
it is heterogenous, with few gene expression studies having the same conclusions, 
possibly due to the heterogeneity of brain tissue itself. Genes involved in the aging of the 
brain are not necessarily affected in the aging of other systems. In one study only around 
1/5th of genes associated with age in the cortex or the cerebellum changed in the same 
direction as in whole blood (Peters et al. 2015) Gene expression studies in the human 
aged brain have found that pathways related to oxidative stress, immune activation and 
inflammation are upregulated in ageing while genes related to synaptic vesicle trafficking 
and calcium regulation were downregulated (Kumar et al. 2013). Network analysis has 
also shown that mitochondrial pathways are downregulated in aging in the human brain. 
Different regions of the brain have also been found to age differently. For example, 
lysosome metabolism and glucosaminoglycan degradation pathways have been 
implicated in the ageing of the cerebellum and the actin cytoskeleton, focal adhesion and 
tight junction pathways in the frontal cortex (Lu et al. 2004). The human pre-frontal cortex 
has also shown reductions in genes that play roles in mitochondrial function, vehicular 
transport and synaptic plasticity. On the other hand, genes related to inflammation, metal 
ion homeostasis and stress response were increased.  
Broadly, the changes reported in the aging brain replicate the changes seen in 
neurodegenerative disease but to a smaller scale. Therefore, understanding the role that 
aging plays in the pathology of neurodegeneration may be central to understanding it. 
 
1.6.5 Age as a risk factor for neurodegeneration 
It is a widely known fact that the vast majority of neurodegenerative diseases, including 
AD, PD and ALS, affect predominantly the aged population. The mean age on onset for 
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PD is 70, for AD – 85 and for ALS – 65 (Hardiman et al. 2017; Hindle 2010). Therefore, 
some factors that change with aging must increase the susceptibility of the nervous 
system to disease. As an organism ages, the accumulation of defects in the variety of 
mechanisms mentioned above that are considered normal aging can reach a tipping point 
and lead to neurodegeneration. It is possible that individuals who suffer from 
neurodegeneration are more susceptible to aging than others. Interestingly, epigenetic 
changes to DNA have been found to show more signs of aging in neurodegenerative 
conditions. In a comparison of DNA methylation patterns between aged cortices with and 
without AD it was found that the AD brains were affected by epigenetic signatures of 
accelerated aging that correlated with loss in cognitive ability and histological markers of 
AD (Levine et al. 2015). Markers of increased immune system aging have been also 
detected in blood samples of PD patients (Horvath and Ritz 2015). Selective neuronal 
vulnerability is a phenomenon seen in neurodegenerative diseases but also in normal 
ageing. The genetic changes seen in aged vulnerable neurons have also been found in 
AD vulnerable neurons (Xinkun Wang et al. 2010). Additionally, changes in autophagy 
seen in aging have been heavily implicated in neurodegenerative disease. Mutations in 
Presenillin-1, linked to hereditary AD have been shown to impair autophagic flux and 
result in ineffective clearance of proteins. PINK1 and parkin, proteins that are mutated in 
hereditary PD are thought to promote mitochondrial autophagy, impairment in which 
results in dysfunctional mitochondria, generating high levels of ROS thus increasing 
oxidative stress (Haigis and Yankner 2010). 
It is unclear which of the hallmarks of the aging brain actually control the process of aging 
and which are simply consequences thereof, but it is thought that by altering the levels of 
different communication molecules in the brain many of the deleterious age-related 
changes could be kept at bay. It is possible that the increased inflammation and impaired 
protein homeostasis that come with age create the right conditions for neurodegenerative 
disease to develop. Which one an individual eventually succumbs to in their lifetime then 
could be due to additional genetic or lifestyle risk factors. 
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1.7 Microglia  
Microglia are a type of glial cell that makes up about 10% of total brain tissue and during 
homeostasis maintain an even spread among all brain areas. They were first identified by 
Santiago Ramόn y Cajal in 1913 and described and named by Pío Del Río-Hortega 
(Pérez-Cerdá et al. 2015). Like all glial cells their role in the brain is supportive. Microglia 
are mononuclear phagocytic cells and are the brain parenchyma’s only resident 
macrophage (Li and Barres 2017; Prinz and Priller 2014). Initial bone marrow experiments 
in mice suggested that microglia had a bone marrow origin (Hickey and Kimura 1988). 
However, DNA labelling studies later on pointed to microglia being a stable and persistent 
population (Lawson et al. 1992). That notion was later challenged by a new set of studies 
on bone marrow chimera mice that showed continuous replacement of microglia by bone 
marrow derived precursors (Priller et al. 2001). It was later shown that the radiation used 
to generate mouse chimeras caused brain inflammation which was the cause for the 
migration of bone marrow precursors (Mildner et al. 2007). It is now accepted that 
microglia are derived from yolk-sac macrophage precursors and are genetically different 
from blood mononuclear cells (Prinz and Priller 2014). 
Microglia play an important role in development of the CNS and also CNS homeostasis in 
health and disease. It is unclear why microglia have a unique origin or why they reside 
only in the CNS. They are not the only immune cell in the brain; perivascular, meningeal 
and choroid plexus macrophages also reside at the CNS interface (Goldmann et al. 2016). 
Additionally, peripheral macrophages are capable of migrating through the blood-brain 
barrier.  However, unlike other macrophages microglia haven’t been found to be 
continuously renewed from myeloid progenitor blood cells and instead they increase in 
number through cell division (Askew et al. 2017).  As the microglial population is 
predefined early in development it is not surprising that they are vulnerable to 
physiological disturbances such as ageing that can contribute to the development of 
psychiatric and neurodegenerative diseases.  
Until recently microglia were viewed under the misconception that they were static 
bystanders and only acted in conditions of injury or disease. Now it has been shown that 
microglia constantly interact with different CNS components and have a central role in the 
maintenance of brain homeostasis. In development microglia migrate from the yolk sac to 
the CNS at approximately the same time neurons are formed. Thus, microglia participate 
in many important events in the developing CNS such as neurogenesis, apoptosis, 
synaptic pruning and modelling of neural networks (Pont-Lezica et al. 2014; Hoshiko et al. 
2012; Paolicelli et al. 2011; Prinz and Priller 2014). 
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 Figure 1.6 Microglia in the brain. Healthy microglial cells play a myriad of supportive 
roles in the brain including sensing, intercellular communication, promotion of 
inflammation, degradation and repair.  
In the adult organism microglia maintain that multifunctionality and are capable of quickly 
adapting to changing conditions to adopt a variety of states (Figure 1.6). In the healthy 
brain microglia maintain a quiescent “resting” phenotype which is maintained by soluble 
factors secreted by healthy neurons and increased levels of microRNA-124 (Conrad and 
Dittel 2011).  Resting microglia can be recognised by their ramified morphology. Ramified 
microglia constantly screen the brain with their highly motile processes for signs of 
damage-associated molecular pattern molecules (DAMPs) such as ATP or calcium 
release (Nimmerjahn et al. 2005). The most morphologically adaptable and motile cell in 
the brain, they have been reported to constantly extend and protract their processes and 
be able to contact the synapses of neurons and secrete communication molecules to 
regulate them (Panatier and Robitaille 2012; Hristovska and Pascual 2015).  
If signs of damage are detected the microglia migrate to the site of injury and convert to 
an activated or reactive state (Nimmerjahn et al. 2005). The morphology of microglia is an 
identifying characteristic of their activation state. Non-phagocytic reactive microglia display 
a thickening of their branches, upregulation of MHCI/II, secretion of proinflammatory 
cytokines and ROS (Colton 2009; Rock et al. 2004; Gehrmann et al. 1995). As they 
progress in their activation they can assume a phagocytic state which is characterised by 
a large ameboid shape and in addition to the aforementioned inflammatory signals they 
gain the ability to phagocytose material and display it for T-cells (Gehrmann et al. 1995; 
Rock et al. 2004; Aloisi 2001). 
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It is thought that depending on the signals they receive microglia can polarise to states 
similar to M1 and M2 in macrophages where M1 is pro-inflammatory and M2 is phagocytic 
and aids in tissue regeneration. However, the M1/M2 model fails to account for the 
complexity of the brain environment and the variety of signals microglia are exposed to by 
different cell types. Sequencing of microglial transcriptomes in resting and reactive states 
has found their reactive signature is diverse and difficult to characterise (Hirbec et al. 
2018; Wes et al. 2016). Some have argued that the M1/M2 distinction should be done 
away with altogether as it was developed through in vitro experiments in a simplified 
environment that cannot be replicated in vivo (Ransohoff 2016). In the human brain 
microglia are found to adopt intermediate activated phenotypes demonstrating the 
complex role these myeloid cells are expected to play in the brain. That has led to the 
agreement that describing activation states in macrophages including microglia is best 
done by referring to the stimulating molecule that produced the reactive state (Wes et al. 
2016). Just as it has been proven difficult to distinguish specific activation states in 
microglia on the molecular level, so it has been hard to identify the specific morphology of 
those cells in live tissue. Historically, most observations of microglia have focused on 
diseased states and on fixed tissue. As mentioned above microglia are highly reactive 
cells that can change both their morphology and their molecular signature with changing 
conditions. With the emergence of more accurate techniques to image live tissue such as 
two-photon laser scanning microscopy (2P-LSM) we are beginning to get a better 
understanding of microglial motility and morphological spectrum in physiological 
conditions (Stopper et al. 2018; Hristovska and Pascual 2015).  
Microglial priming is a process driven by changes in the molecular environment including 
exposure to molecules that drive proliferation (Perry and Holmes 2014). It consists of the 
increased reactivity of microglial cells upon stimulation. It has been reported in aged mice 
upon stimulation with IL-1β and IL-12 (Lee et al. 2013). Two types of priming have been 
reported, classic which has been linked to exposure to IFN-γ and is neurotoxic and 
alternative – linked to exposure to IL-4 and IL-13 suggested to be neuroprotective 
(Hickman et al. 2013). Toll-like receptors 2,3 and 4 have been shown to be essential for 
the classical priming process (Facci et al. 2015). The transcriptional signature of microglial 
priming seems to be dependent on the High mobility group box 1 (HMGB1) and inhibiting 
it prevents microglia from entering a primed state (Holtman et al. 2015; Fonken et al. 
2016). 
 
1.7.1 Microglial aging 
Evidence of microglial aging was first identified in the brains of aged individuals by 
immunohistochemistry. They were found to be widespread and were characterised by a 
dystrophic morphology that included process deramification, shortening, gnarling and 
beading, the formation of spheroids and cytoplasmic fragmentation. It was this type of 
dystrophic microglia that were also found to store iron through elevated levels of ferritin 
(Lopes et al. 2008). The accumulation of iron in microglia with age is an interesting 
phenomenon as microglia are not the main iron-storing cell type in the brain and iron may 
play a major role in the age-related microglial dystrophy.  
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 Figure 1.7 Characteristics of microglial aging. When microglia age they lose process 
ramification, develop process abnormalities and exhibit cytoplasmic fragmentation. They 
show increased iron storage and ferritin expression. Their increased release of neurotoxic 
substances and reduced ability to phagocytose debris and toxic protein aggregates leaves 
neurons vulnerable. 
Aging microglia have also been found to have an altered resting phenotype with less 
dendritic branching and reduced process motility (Figure 1.7). When confronted with injury 
they exhibit lower migration rates and have a more sustained inflammatory response in 
reaction to damage (Damani et al. 2011). This characteristic increase in low-grade 
inflammation is typical of the aging brain with higher levels of pro-inflammatory cytokines 
and lower levels of anti-inflammatory cytokines detected in aged brains. Microglia have 
been found to be very long-lived cells in a study that monitored them over the mouse 
lifespan (Weinberg 2008). This puts microglia as ideal candidates for chronic senescence 
and explains how microglial senescence can potentially have a major effect in ND. As 
microglia are the main immune cells in the brain the way they affect inflammation in the 
brain has been studied extensively. Aged microglia have been found to not only change 
their cytokine signature to a pro-inflammatory one but also exhibit reduced phagocytosis 
and increased ROS production. These changes result in microglia not only failing to 
maintain neuronal health but also impairing it thus contributing to the possible 
development of neurodegenerative diseases. The senescence associated secretory 
phenotype (SASP) is a newer method of characterising aged microglia (Streit et al. 2014).  
The criteria for SASP differ from cell type to cell type, but microglia have been found to 
undergo SASP-congruent increases in TNFα, IL1β, IL-6 and IL-8 (Sierra et al. 2007). 
Interestingly, one of the criteria for developing SASP in a cell type is DNA damage (Coppé 
et al. 2010). DNA damage has been found to increase in aged microglia, particularly in 
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mitochondria (von Bernhardi et al. 2015; Hayashi et al. 2008). Telomere shortening is also 
found in human and rat aged microglia, especially in association with dystrophy (Flanary 
and Streit 2004). It is likely that a SASP signature will be established for aging microglia in 
the near future.  
The genomic signature of aged microglia has been of great interest since the advent of 
next generation sequencing technologies. Unfortunately attempts to characterise them 
have yielded varied and often conflicting results with no clear and consistent specific 
genetic or protein markers for aged microglia emerging (Crotti and Ransohoff 2016; 
Spittau 2017; Olah et al. 2018; Wes et al. 2016). The aged microglia in the mouse retina 
exhibited significant changes in genes controlling inflammation including the NFkB 
signalling pathway and upregulated complement genes C3 and complement factor B (Cfb) 
(Ma et al. 2013). A study on the microglial sensome of aged mice reported a shift in 
microglia to a more neuroprotective phenotype with age with a particular decrease in 
genes related to sensing endogenous ligands but not phagocytosis or exogenous sensing 
(Hickman et al. 2013). Those two studies suggested that microglial aging is associated 
with neuroprotection. In contrast, another study on aged mouse microglia gene expression 
reported decreased expression in cytoskeletal reorganization suggesting aged microglia 
are less motile. They also observed increased expression of cytokine genes suggesting 
that microglia have a reduced ability to migrate to sites in injury and stimulate 
inflammation, suggesting they play a less neuroprotective role (Orre et al. 2014). A recent 
gene expression meta-analysis reported that aged microglia display a different expression 
signature from LPS or IL-4 stimulated microglia, suggesting they don’t exhibit a classic 
activation state but do overlap with primed microglia which are also neurotoxic (Holtman 
et al. 2015). The few datasets currently published on human microglia aging transcriptome 
point in the direction that mouse and human microglia may age differently (Galatro et al. 
2017; Olah et al. 2018). Olah et. al. (2018) detected significant changes in more than 
2000 genes in aged microglia. The pathways that were upregulated were involved in 
amyloid fibril formation while the TGF-β signalling pathway was downregulated thus 
suggesting a more pro-inflammatory phenotype for aged microglia. Other upregulated 
genes were linked to SASP, cytokine signalling, DNA methylation and maintenance 
among others. That study also validated their expression data with proteomic data as well, 
finding that many proteins from the amyloid fibril formation gene set were still upregulated 
in aged microglia. The changes detected in the Galatro et al. (2017) study involved 
reduced expression of genes related to the actin cytoskeleton and cell surface sensor 
receptors and alterations in immune response genes. Comparison of this dataset with an 
existing mouse dataset found very limited overlap in gene expression changes between 
the two organisms. It is possible that this is due to isolation methods of the cells that may 
alter their gene expression, but it could also be due to microglia exhibiting different aging 
signatures in different parts of the brain (Grabert et al. 2016). The differences detected 
between human and mouse datasets could potentially be explained by the vast disparity 
in the lifespans of the organisms and of the microglia themselves as a consequence but 
also by the environments that humans are exposed to that laboratory mice never would. It 
seems that gene expression studies can reproducibly detect changes in larger networks in 
aged microglia such as inflammatory response, cytoskeletal remodelling, and ligand 
sensing; but it’s difficult to identify specific biomarkers for identifying aged microglia just 
from expression data (Holtman et al. 2015). Some proteins related to microglial aging 
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have been identified in a number of studies that directly investigate the pathways affected 
by aging. 
SIRT1 is a protein related to aging (see above) that has been the object of some interest 
as its levels decline in many senescent cells. SIRT1 levels were also found to decline in 
aging microglia both in aged human brain samples and in mouse models (Olah et al. 
2018; Cho et al. 2015). Decline in SIRT1 is thought to contribute to age-related 
neurodegeneration by stimulating inflammatory pathways in microglia through the 
activation of IL-1β, thus contributing to the SASP phenotype (Cho et al. 2015)  
KV1.3 is a potassium channel found in microglia also thought to control inflammatory 
response (Moussaud et al. 2009). KV1.3 is involved in the secretion of cytokines that are 
part of the SASP signature of aging microglia (Charolidi et al. 2015). Increased levels of 
KV1.3 have been detected in aging microglia and recently KV1.3 has been identified as a 
major controller for pro-inflammatory genes in disease associated microglia in AD models 
where KV1.3 has also been found to be upregulated (Rangaraju et al. 2018). Additionally, 
KV1.3 inhibition has recently been suggested as a potential therapy targeting microglia in 
AD (Maezawa et al. 2018).  
The triggering receptor expressed on myeloid cells 2 (TREM2) signalling pathway is 
another interesting example. TREM2 is a central microglial cell surface receptor that is 
thought to regulate microglial survival, inflammatory signalling, migration and 
phagocytosis. Changes in TREM2 expression and signalling in aging can lead to 
increased inflammation and reduced phagocytosis (Forabosco et al. 2013). The release of 
a soluble form of TREM2 (sTREM2) further complicates the role for this receptor in aging. 
The understanding of the function of TREM2 in the healthy brain and in 
neurodegeneration is still limited (Mecca et al. 2018). It is important to identify the reason 
why all these signalling pathways change and play a role in microglial aging.  
 
1.7.2 Models of aged microglia 
The study of aging microglia is important not only in terms of understanding their 
phenotype and gene expression, but also in understanding what their role is in both the 
aging of the CNS and in ND. Thus, having models of aging microglia that can be used to 
study their effect on neurons is extremely important. Obviously, aging microglia can be 
found in aged animals and some studies have utilised them in the study of senescence. 
(Sierra et al. 2007; Griffin et al. 2006; Letiembre et al. 2007; Stichel and Luebbert 2007; 
Perry et al. 1993; Godbout et al. 2005)  Unfortunately, using aged animals for experiments 
can be exceedingly expensive and time consuming, thus making them very impractical. 
Additionally, despite some reported methods  isolating and maintaining aged microglia in 
culture has by and large proven to be very difficult (Von Bernhardi et al. 2011).  Some 
have made the case for the importance of studying age-related diseases in aged models 
being important enough to be worth the extra costs. However, currently it is just as difficult 
to obtain aged animals as ever (Johnson 2015). Transgenic models of accelerated aging 
are another potential avenue for observing microglial aging. The Ercc1(-/Δ) transgenic 
mouse model displays accelerated aging through DNA-repair deficiency (Schermer et al. 
2013). This model has shown age-related changes in microglia(Raj et al. 2014). Another 
model of accelerated aging is the mTerc−/− mouse that exhibits telomere shortening whose 
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microglia exhibit some signs of senescence and priming (Raj et al. 2015). An alternative to 
a full animal model can be cell culture models of aged microglia. One study has reported 
that microglia isolated from neonatal mice start resembling aged microglia with time in 
culture, including reduced phagocytic ability, reduced motility, reduced autophagy, and 
changes in microRNAs and SA-β-galactosidase activity (Caldeira et al. 2014). However, 
these cells didn’t exhibit the SASP expected from aging microglia. Additionally, at 16 days 
this model is very short lived, thus again making it impractical for the study of 
neurodegeneration. Another method to induce age-like changes in microglia has recently 
been presented by Park et al. (2018). By treating primary rat microglial cultures with the 
drug dexamethasone (a corticosteroid) they simulate chronic stress inflicted by steroid 
hormones that microglia experience over time with aging. This model exhibited increased 
SA-β-galactosidase activity, increased expression of tumour suppressor genes and 
dysfunctional phagocytosis similarly to senescent cells. However, they also showed 
increased autophagy, decreased expression of inflammatory genes and decreased 
cytokine release which is unlike aged microglia.  
The utility of an easily replicable model of microglial aging is clear as it would enable a 
major risk factor of neurodegeneration to be included in the study of these diseases 
(Koellhoffer et al. 2017).  
 
1.7.3 Aged microglia and neurodegeneration 
Healthy microglial cells are essential to neuronal survival as they maintain brain 
homeostasis and fight off infection through a complex signalling system driven by 
secreted factors. Activated microglia were thought to be the cause of inflammation seen in 
neurodegenerative disease. However, senescent microglia present both the impaired 
neuroprotective ability and the low but sustained secretion of molecules that drive 
inflammation seen in neurodegeneration (Koellhoffer et al. 2017). Dystrophic microglia 
have been identified in both aged brains and the brains of patients with neurodegenerative 
disease. They have been found near sites of tau pathology and amyloid plaques of AD 
brains and near Lewy bodies in dementia with Lewy bodies brains (Lopes et al. 2008; 
Streit et al. 2004; Streit et al. 2009; Streit and Xue 2016). In neurodegenerative disease 
microglia seem to adopt an intermediate phenotype where they present both markers of 
M1 and M2 activation. Chronically activated microglia have been found in the brains of 
patients with a multitude of neurodegenerative diseases such as AD, PD, ALS and prion 
disease. It isn’t known why microglia adopt this phenotype. A comparison of microglial 
markers between individuals with AD and high-pathology but cognitively normal controls 
showed that microglial activation is increased in AD, suggesting that microglial activation 
is not simply a reaction to AD pathology such as β-amyloid deposition (Hopperton et al. 
2018). It is possible microglia are pushed towards a more proinflammatory phenotype 
through age-related changes.  
Mutations in genes related to microglial function have been linked to neurodegenerative 
disease risk. For example, a rare variant of the TREM2 gene leads to an increase in the 
risk for developing AD 3-4 times and more severe pathology. In the context of both aging 
and neurodegeneration TREM2 is thought to interact with APOE activate pathways linked 
to microglial activation, survival and phagocytosis (Krasemann et al. 2017). Loss of 
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function mutations in TREM2 also cause a rare deadly disease (Nasu-Hakola Disease) 
that presents with neurodegenerative symptoms and bone cysts (Yeh et al. 2017).  The 
expression of soluble TREM2 by aged microglia of a mouse AD model was also found to 
rise with both amyloid load and markers of microglial activation over time, suggesting that 
sTREM2 also plays a role in the neurodegenerative process (Brendel et al. 2017). Leucine 
rich repeat kinase 2 (LRRK2) is a protein expressed highly in microglia that is implicated 
in both microglial activation and lysosomal degradation. Mutations in LRRK2 are the most 
common in both familial and sporadic PD. They are thought result in increased 
proinflammatory signalling and possibly preventing microglial cells from degrading protein 
aggregates (Schapansky et al. 2015; Gillardon et al. 2012). CSF1R is a cell surface 
receptor for the cytokine CSF1 and in the brain it is expressed predominantly in microglia 
and is a mediator for microglial proliferation and differentiation. CSF1R loss of function 
mutations have been shown to cause hereditary diffuse leukoencephalopathy with 
spheroids (HDLS), a neurodegenerative disease that has symptoms of dementia and 
parkinsonism among others (Rademakers et al. 2012). CD33 is another microglial cell 
surface receptor that has both found to be upregulated in AD and has a rare variant that 
confers increased risk of developing AD. CD33 acts to reduce microglial proliferation and 
phagocytosis and thus exacerbates AD pathology (Griciuc et al. 2013; Malik et al. 2013). 
These examples show that microglial function is essential to maintaining neuronal 
homeostasis and health and thus any disruption in microglial function can result in 
neurodegeneration. 
As immune cells, microglia have been found to react to the presence of misfolded proteins 
in both AD and PD. Microglia are well known to be activated by the presence of β-amyloid 
and to cluster around sites of amyloid plaques. As the main protein that aggregates in PD, 
α-synuclein can also interact with microglia. Microglia have been shown to react to 
aggregated α-synuclein but not to monomeric through TLR receptor activation (Béraud et 
al. 2013; Fellner et al. 2013). The TLR2 receptor has been shown to be activated by the 
most likely toxic form of α-synuclein aggregates – β-rich oligomers(Kim et al. 2013). 
Additionally, microglia can also become activated through the detection of neurons under 
stress. Activated microglia secrete IL1β and TNFα that have been found to contribute to 
neuronal demise through the recruitment of neutrophils and chemokines from blood. 
Through the secretion of proinflammatory signals and ROS activated microglia can lead to 
the retrograde apoptosis of neurons that are connected to the degenerating neurons thus 
spreading the pathology. Therefore, through inappropriate action microglia are capable of 
perpetuating neurodegeneration in a feedback loop of inflammatory signalling (Perry et al. 
2010).  
As phagocytes, one of the roles of microglia is to clear any cellular debris and protein 
aggregates that they encounter. Therefore, one of the functions of microglia is 
degradation of β-amyloid. However, aging microglia lose their ability to clear β-amyloid 
effectively from the extracellular space.  In mouse models aged microglia have been 
found to have reduced expression of β-amyloid degrading enzymes and reduced 
phagocytosis (S. E. Hickman et al. 2008). It is thought that in AD microglial function is 
impaired by the mere presence of β-amyloid aggregates, thus leading to a self-
perpetuating cycle of increased β-amyloid accumulation and further damage. A systematic 
review of microglial markers in AD found that most studies observed increases in markers 
related to microglial activation, but no significant difference in overall microglial markers. 
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They also found no difference in overall cell counts suggesting that microglial number 
does not increase in AD, but microglial levels of activation do (Hopperton et al. 2018). 
Inflammation and ineffective protein clearance are strongly linked in neurodegeneration. It 
has been shown that microglia play a major role in the pathology of Alzheimer’s disease 
and Parkinson’s disease by driving inflammation in the brain (Subramaniam and Federoff 
2017). In fact, in a mouse model, eliminating microglia didn’t affect amyloid deposition but 
prevented neuronal loss and degeneration and also resulted in improved cognition 
(Spangenberg et al. 2016; Dagher et al. 2015). Reducing inflammation by the use of 
NSAIDs is also linked to a lower risk of developing PD (Gagne and Power 2010). In an 
organotypic cell culture model of β-amyloid accumulation in the aged brain, old microglia’s 
ability to clear β-amyloid was rescued by the presence or the conditioned medium of 
young microglia, suggesting that the effects of microglial aging on amyloid deposition can 
be reversed (Daria et al. 2017).  
Microglia’s ability to clear aggregated proteins may be linked to their age or state of 
activation. Aged microglia in models of β-amyloid load that exhibited a lower phagocytic 
ability were also found to express the cytokines TNFα and IL-1β, unlike microglia that did 
phagocytose β-amyloid (Hickman et al. 2008). The expression of inflammatory cytokines 
is thought to also drive further microglial damage and perpetuate the AD pathology. 
Microglia have also been shown to be able to internalise and degrade extracellular α-
synuclein aggregates in a cell culture study, an activity that is apparently controlled by the 
activation state of the cells as it was reduced by activation with lipopolysaccharide (LPS) 
(Lee et al. 2008).  
The role of iron-rich microglia in neurodegenerative disease cannot be ignored. Ferritin-
positive dystrophic microglia have also been found associated with amyloid plaques and 
neurofibrillary tangles (Streit et al. 2014). Iron also accumulates in AD brains in the 
hippocampus and in particular in the amyloid plaques of AD patients (Raven et al. 2013; 
Smith et al. 1997). It is possible that iron together with other metal ions plays a role in the 
toxicity of β-amyloid oligomers (Tabner et al. 2011). Iron appears to also accumulate 
excessively in regions affected by Parkinson’s disease such as the substantia nigra and is 
associated with Lewy bodies where dystrophic ferritin positive microglia have been 
identified (H. Xu et al. 2018). Disruption in iron homeostasis has also been linked with a 
higher secretion of proinflammatory cytokines in microglia in vitro (Wang et al. 2013). 
Furthermore, short-term iron exposure has been found to induce rat primary microglia to 
potentiate neurotoxicity (Zhang et al. 2013). High lifetime exposure to iron has been linked 
to an increased risk of developing PD. Neuromelanin, a protein that stores iron in neurons 
can be phagocytosed by microglia attracted to degenerating neurons, thus increasing the 
iron load of those cells. Interestingly, it has been demonstrated that neuromelanin 
phagocytosis can induce increased release of proinflammatory cytokines and ROS, thus 
driving inflammatory processes that can contribute to neuronal degeneration further 
(Rathnasamy et al. 2013). It is possible that iron accumulation in microglia could be a 
protective mechanism from iron toxicity in the brain which then can proceed to damage 
the microglia themselves and induce the accelerated aging signature seen in 
neurodegeneration (Krabbe et al. 2013).  
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1.8 Hypothesis, Aims and Objectives 
1.8.1 Hypothesis  
The main hypothesis of this thesis is that microglia acquire a pathological phenotype with 
age that is linked to the accumulation of iron and that this phenotype plays a role in the 
processes that initiate neurodegenerative disease. It is further hypothesized that this 
phenotype can be modelled by forcing microglia to take up iron and can be used to 
incorporate an aging aspect into the study of neurodegenerative disease. 
1.8.2 Aims and objectives 
There is a clear gap in knowledge related to how aging in the brain affects the 
pathogenesis of neurodegenerative disease. This thesis aims to provide a link between 
factors affected in ageing in the brain and the processing and toxicity of proteins heavily 
implicated in neurodegeneration. Even though it is now known that microglia are linked to 
the pathology of AD and PD and that their phenotype changes with age, not many studies 
have incorporated microglial aging in the study of those diseases.  
1. The first objective is to investigate whether supplementing human and mouse 
microglial cell lines and primary mouse microglia with iron changes them to an aged 
phenotype and to characterise it for iron storage, expression of cytokines, proteins 
and other molecules linked to aged microglia. 
2. The second objective is to find out if a human iron-fed microglia cell line can be 
applied to the study of β-amyloid aggregation and to show whether the soluble factors 
released by these model aged microglia in their conditioned medium can change the 
detected levels of β-amyloid in a neuronal cell line. If it is found that β-amyloid levels 
are influenced by conditioned medium the mechanism will be determined. This will be 
pursued by analysing whether break down or release of β-amyloid is affected. The 
level of activity of secretases and changes in the levels of proteases secreted by 
microglia such as IDE or neprilysin will be analysed. 
3. The next objective is to determine whether conditioned medium from iron-fed mouse 
primary and cell line microglia can influence both α-synuclein expression in neuronal 
cells and the formation of toxic α-synuclein aggregates. If this is found to be the case 
the molecule present in conditioned medium that caused the changes will be 
identified. A likely candidate for this would be inflammatory cytokines. If a particular 
cytokine or combination of cytokines is found to elicit those changes, the pathway 
through which those act will be investigated through pharmacological inhibitors. 
4. The final objective will be to investigate the downstream effects of the aged microglial 
model on α-synuclein. Overexpressing α-synuclein but not β-synuclein was found to 
make a neuronal cell line more vulnerable to α-synuclein oligomer toxicity. This 
process could be mediated through increased FOXO3a expression in the α-synuclein 
overexpressing cell line. If that is the case, it will be tested if FOXO3a levels increase 
after treating the neuronal cell line with Fe2+ as a possible source of ROS. If iron 
treatment is found to elevate FOXO3a levels it will be tested if the overexpression of 
another known ferrireductase (STEAP3) and another synuclein protein (β-synuclein) 
can replicate the effect of α-synuclein on FOXO3a expression. Finally, the effect of β-
synuclein overexpression on iron and ROS levels in neuronal cells will be 
investigated as a potential explanation for its observed protective ability.
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2. Altered Processing of β-amyloid in SH-SY5Y cells 
induced by Model Senescent Microglia 
2.1  Introductory commentary 
As mentioned in the Introduction the lack of models of microglial aging is detrimental to 
the study of neurodegeneration. A good model of senescent microglia would ideally be 
easy to induce, replicate and would replicate the changes seen in microglial aging.  
 
Papers published by the Streit group show that the accumulation of iron is an interesting 
quality of aging microglia. (Streit et al. 2014; Lopes et al. 2008; Streit et al. 2004). This 
finding inspired us to investigate how the accumulation of iron by microglia alters their 
phenotype. We investigated this question in cell culture as it allows us to manipulate and 
measure the cellular environment and phenotype of microglia with more precision. 
Microglial cells in culture have been shown to have a high resistance to iron toxicity in the 
medium (Bishop et al. 2011). Preliminary data generated by our laboratory showed that 
simply incubating microglial cells with excess iron causes them to change morphology. 
This resulted in the hypothesis that culturing microglia with iron results in a change in the 
factors that they secrete to communicate with neurons.  
 
The work presented in the next chapter aims to characterise iron-fed microglia as a cell 
culture model of aged human microglia. A human microglia cell line was forced to adopt 
an aged phenotype by incubation with ferric ammonium citrate for two weeks. The second 
aim of the paper is to show that this model can be used in the study of neurodegenerative 
disease by investigating the effect of the microglial conditioned medium on β-amyloid 
released by SHSY5Y neuronal cells. The work focuses on find out to what extent this 
model matches the phenotype of aged microglia described in the literature and on 
understanding the mechanism behind the observed alteration in β-amyloid processing by 
measuring key proteins and pathways. The SV-40 microglial cell line chosen in this study 
was derived from human primary microglial cells and shown to express the microglial 
markers TREM2 and Iba1 (Patel et al. 2016). They were chosen due to the difficulty in 
obtaining primary human microglia but also because this cell line allowed the generation 
of sustainably large numbers of microglia that were necessary for generating the data.  
Conditioned medium from the microglia was used when assessing their effect on neuronal 
cells as this reduces the number of variables that need to be measured down to 
molecules secreted by the microglia.
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ABSTRACT: The single greatest risk factor for neuro-
degenerative diseases is aging. Aging of cells such as microglia
in the nervous system has an impact not only on the ability of
those cells to function but also on cells they interact with. We
have developed a model microglia system that recapitulates
the dystrophic/senescent phenotype, and we have combined
this with the study of β-amyloid processing. The model is
based on the observation that aged microglia have increased
iron content. By overloading a human microglial cell line with
iron, we were able to change the secretory proﬁle of the
microglia. When combining these senescent microglia with
SH-SY5Y cells, we noted an increase in extracellular β-
amyloid. The increased levels of β-amyloid were due to a
decrease in the release of insulin-degrading enzyme by the model senescent microglia. Further analysis revealed that the
senescent microglia showed both decreased autophagy and increased ER stress. These studies demonstrate the potential impact
of an aging microglial population in terms of β-amyloid produced by neurons, which could play a causal role in diseases like
Alzheimer’s disease. Our results also further develop the potential utility of an in vitro model of senescent microglia for the study
of brain aging and neurodegenerative disease.
KEYWORDS: β-amyloid, APP, microglia, ER stress, autophagy, insulin degrading enzyme
■ INTRODUCTION
There is overwhelming evidence for the importance of aging to
the etiology of neurodegenerative diseases.1 Conditions like
Alzheimer’s disease (AD) increase in frequency as we age.2
There are numerous diseases, including inherited forms of AD
and prion diseases, in which dominant inherited mutations
lead to neurodegeneration but only when the carrier passes a
certain age.3,4 Clearly understanding how the brain changes
with age and how such changes result in the development of
diseases involving neuronal dysfunction and loss is essential for
understanding neurodegeneration. Therefore, it is quite
surprising that very few studies incorporate any aspect of the
aging brain in their models. There is an inherent diﬃculty in
including an aspect of aging in the development of a model of
neurodegeneration because of the time requirement; for
example, animal models would have to utilize animals that
are toward the end of their life span.5 In vitro models have even
greater hurdles because such models are inherently short-
term.6,7 Therefore, a potential alternative is to develop a
method to induce a phenotypic change equivalent to that seen
in cells from an aged brain.
Microglia are important cells in the brain that maintain
neuronal well-being.8 There is a plethora of information
suggesting that microglia may participate in changes in the
brain associated with neurodegenerative diseases.9−15 These
changes mostly relate to an altered secretory proﬁle wherein
the molecules released either result in reduced protection of
neurons or an increase in proinﬂammatory or toxic molecules
such as cytokines or reactive oxygen species.16 Microglia
change phenotype in this way with age, and aged microglia are
frequently described as dystrophic.17 Microglia may develop a
senescent-associated secretory phenotype (SASP).18−20 While
SASP is mostly associated with a study of molecular changes in
cells, the dystrophic phenotype has largely been assigned on
the basis of morphological changes. While both phenotypes are
age associated, they have been rarely used in conjunction to
describe aged microglia. Understanding how microglia could
enter such a phenotypic state and the potential of microglia to
alter neuronal activity as a result is of considerable importance.
Phenotypically, dystrophic microglia express increased levels of
the iron storage protein ferritin,21,22 which is directly related to
the increased levels of iron stored by them.23 Increased iron
levels in the brain are associated with both aging and patients
with a variety of neurodegenerative diseases including AD and
Parkinson’s disease.24−27
Dystrophic/senescent microglia are present in the brains of
patients with AD.20,28 However, while their presence has been
shown, any causative role is unknown. AD is mostly associated
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with the deposition of protein aggregates, which include β-
amyloid in the form of plaques and tau in the form of paired-
helical ﬁlaments or tangles.29,30 Microglia secrete enzymes that
are able to degrade β-amyloid such as insulin-degrading
enzyme (IDE) and neprilysin.31,32 There have also been
reports suggesting neuronal loss in AD may come from
activation of microglia as a result of interaction with β-amyloid
deposits.33,34 While there is considerable interest in microglia
in terms of the pathology of AD, the impact of microglial
senescence on the etiology of the disease is unknown.
In this work, we examine a new model of senescent
microglia based on the observation that overloading microglia
Figure 1. Iron-fed microglia in culture. Photomicrographs of human immortalized microglia in culture. (A) Microglia grown in control conditions
showed many ﬁne process (arrows). (B) Microglia grown in 500 μM ferric ammonium citrate (iron-fed) for at least 2 weeks showed a loss of these
processes. Arrows indicated more amoeboid appearance. Scale bar = 100 μm.
Figure 2. Iron and ferritin in iron-fed microglia. Perl’s stain is a traditional stain for the detection of iron deposits in cells. Cultured microglia were
stained using Perl’s stain. Iron deposits appear blue following the procedure. (A) Control microglia show no obvious staining, while (B) iron-fed
microglia (grown in iron for at least 2 weeks) show extensive blue staining in almost all cells (arrows). (C) Western blotting was used to detect
ferritin in protein extracts from control and iron-fed microglia. GAPDH was used as loading control. (D) Densitometric analysis of ferritin
expression was normalized to GAPDH levels (relative value). Iron-fed microglia show signiﬁcantly higher levels of ferritin expression (p < 0.05)
when compared to controls. Shown are the mean and SE of four experiments. (E) The level of iron was detected in extracts from microglia using a
commercial kit. The iron-fed microglia showed very high and signiﬁcantly diﬀerent (p < 0.05) levels of iron when compared to controls. Shown are
the mean and SE of four experiments.
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with iron forces them into a senescent-like phenotype.
Combining these microglia with a neuronal cell line allowed
us to investigate how the change in phenotype alters the
generation of β-amyloid. Following treatment of SH-SY5Y cells
with conditioned medium from dystrophic microglia, there is
an increase in β-amyloid present in the medium due to a
decrease in the secretion of IDE. We have linked this change in
IDE release to increased ER stress in microglia induced by the
iron overload. The results cast light on the possible mechanism
by which brain aging causes increased deposition of β-amyloid,
which could lead to AD.
■ RESULTS
Phenotype of Iron-Fed Microglia. We used a human
microglia cell line as the basis of our investigation. This line
was chosen because it allowed the generation of suﬃcient cells
for experiments and also because it maintained the species
match for experiments involving β-amyloid generated by the
human SH-SY5Y neuroblastoma cell line. As aged dystrophic
microglia show high levels of stored iron, we hypothesized that
the dystrophic phenotype might be a consequence of high
retention of iron.22 Iron (particularly Fe(II)) causes damage to
macromolecules and increased storage could be suﬃcient to
induce changes seen in the dystrophic phenotype. For this
reason, we grew the human microglial cell line in 500 μM ferric
ammonium citrate for at least 2 weeks.
In microglial cells grown in medium with high iron (iron-
fed), we observed morphological changes similar to dystrophic
microglia.17 Under normal culture conditions (Figure 1A),
microglia cells showed a small cell body with multiple
projections and frequent branches. In contrast iron-fed
microglia (Figure 1B) showed no branches and little to no
projections. In many cases, the microglia became amoeboid.
We veriﬁed that iron storage had occurred by three methods.
First we used Perl’s stain to identify iron deposits in the cells.
As can be seen in Figure 2, control microglial cells (Figure 2A)
had little to no deposits while iron-fed microglia showed large
numbers of iron deposits in blue (Figure 2B). This
demonstrates that iron-fed microglia store considerably more
iron than the untreated control. Similarly, levels of ferritin are
considered to reﬂect the levels of stored iron in cells. We
measured the levels of ferritin in control and iron-fed microglia
by western blot and immune detection. The levels of ferritin in
iron-fed microglia were much higher than in controls (Figure
2C,D). Lastly, we directly measured the levels of total iron in
the microglia using a commercial kit. Iron-fed microglia
showed considerably higher levels of total iron (Figure 2E).
Treatment of the microglial cell line with high concen-
trations of iron may have adversely aﬀected their viability in
culture. To control for this, we measured their proliferation
when compared to controls using a BrdU incorportation assay.
Control and iron-fed human microglia were plated at a range
of densities, and the incorporation of BrdU was assessed using
an ELISA assay (Figure 3). Regardless of plating density, the
iron-fed microglia showed no signiﬁcant diﬀerence in BrdU
incorporation suggesting that the iron-fed microglia main-
tained the same proliferation rate as the untreated controls.
Alteration in the secretory proﬁle is an indication of a
potential senescent phenotype in cells.35 Microglia are known
to show increased pro-inﬂammatory cytokine secretion with
age.18 Therefore, we assessed a panel of cytokines associated
with pro-inﬂammatory responses. Conditioned medium from
control and iron-fed microglia were collected and normalized
in relation to the protein content of the microglia used to
conditioned the medium. The cytokines measured were IFN-γ,
IL-10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, and TNF-
α (Table 1). Some of the cytokines tested could not be
detected, while others showed no changes. However, a number
of the cytokines measured showed signiﬁcant elevation. These
included IL-1β, IL-6, and IL-8. The other measurable cytokines
showed no changes (IL-2, IL10, IL13, and TNFα). This
selective change in cytokines suggests a change in microglial
phenotype similar to that suggested for aged microglia.
We also assessed other reported markers for aged/senescent
microglia. It has been suggested that during the aging process
microglia show reduced secretion of glutamate.36 We used a
commercial glutamate assay kit to measure glutamate released
into culture by control and iron-fed microglia. Figure 4A shows
Figure 3. Proliferation of iron-fed microglia. The rate of proliferation
of human immortalized microglia was assessed using a BrdU based
ELISA kit. Both control and iron-fed microglia were plated onto a 96
well plate at a range of densities and grown overnight. BrdU was then
added for a further 16 h before the ELISA assay was used to assess
incorporation levels. The level of incorporation was assessed by a
colorimetric assay with a read out at 450 nm. Iron-fed microglia
showed no signiﬁcant diﬀerence in proliferation at all plating densities
(p > 0.05). Shown are the mean and SE of four separate experiments.
Table 1. Cytokines Released into Conditioned Mediuma
cytokine control iron-fed
IL-8 47211.41 ± 19621.34 120271.14 ± 22992.87b
IL-6 3393.33 ± 1501.62 14181.68 ± 2346.10b
IL-1b 35.95 ± 12.72 115.31 ± 23.87b
IL-13 1.05 ± 0.16 1.47 ± 0.29
IL-10 0.03 ± 0.00 0.05 ± 0.01
IL-2 0.05 ± 0.04 0.15 ± 0.02




aSerum-free conditioned medium was generated from cultured
microglia over 24 h, and the levels of cytokines were assessed with
the MSD ELISA system. Cytokine concentrations were determined by
comparison to a standard curve for each cytokine. Values were the
concentration in the medium (ng/mL) divided by the concentration
of the protein in the cells that were used to generate the conditioned
medium (mg/mL). Shown are the mean (ng/mg) and SE for four
experiments. bSigniﬁcant diﬀerence between control and iron-fed (p-
value <0.05). cNot detectible due to the levels detected being below
the level of lowest standard on the standard curve for that cytokine.
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that iron-fed microglia released signiﬁcantly less glutamate
than control microglia. In addition, we measured two known
markers for aged microglia. These included KV1.3, a microglial
potassium channel, and SIRT-1 (sirtuin-1), a deacetylase.
KV1.3 has been shown to be altered in aged mice and to play a
role in the release of cytokines.37,38 SIRT-1 has been shown to
be decreased in aged microglia, and this may contribute to
cognitive decline and neurodegeneration.39 We used western
blotting and speciﬁc antibodies to detect these proteins in
extracts from control and iron-fed microglia (Figure 4B−D).
Iron-fed microglia showed a signiﬁcant increase in the level of
expression of KV1.3 but a signiﬁcant decrease in expression of
SIRT-1. These results are consistent with the suggestion that
iron-fed microglia demonstrate a change in phenotype similar
to dystrophic or senescent microglia in vivo. We are therefore
conﬁdent that our iron-fed human microglia represent a robust
in vitro model of senescent microglia.
Eﬀect of Microglial Conditioned Medium on APP
Metabolism in SH-SY5Y Neuronal Cells. Alzheimer’s
disease is associated with the deposition of abnormal proteins
including β-amyloid. The rate of formation of β-amyloid
depends upon the metabolism of its precursor, APP, and the
relative activity of the two secretase pathways that degrade
APP to form either β-amyloid (β-secretase dependent) or P3
(α-secretase dependent). In either pathway, the end result is
the release of an APP fragment by the γ-secretase complex.
However, the rate of formation of these products could be
inﬂuenced by the level of expression of APP and the enzymes
ADAM10 (α-secretase) and BACE-1 (β-secretase). The model
we used to study the levels of these proteins was the human
neuroblastoma cell line, SH-SY5Y. Conditioned medium was
prepared from control and iron-fed microglia and applied to
SH-SY5Y cells for 24 h. After that time, the SH-SY5Y cells
were assessed for the expression of these proteins by western
blot and immunodetection with speciﬁc antibodies. As shown
in Figure 5, treatment of SH-SY5Y cells with microglial
conditioned medium had no signiﬁcant eﬀect on the
expression of either APP or BACE-1. In contrast, conditioned
medium from iron-fed microglia but not control microglia had
a signiﬁcant eﬀect reducing the levels of ADAM10 protein by
SH-SY5Y cells.
We investigated the consequences of altered ADAM10
expression through a variety of assays. First we used a dual
luciferase assay of APP cleavage to assess if there is any change
in the rate of formation of the AICD fragment of APP. In this
system, a GAL4 DNA binding tag is attached to the C-
terminus of the APP protein. The assay is dependent on the
cleavage of this tagged form of APP and the release of the tag,
Figure 4. Glutamate release and protein expression iron-fed microglia. (A) The release of glutamate by human immortalized microglia was assessed
with a commercial glutamate assay kit. Control and iron-fed microglia plated at equal density were grown in serum free medium for 48 h. The level
of glutamate was then determined after collecting the medium. The protein content of the conditioning cells was determined in parallel. Glutamate
concentration was assessed relative to the protein content of the cells to account for diﬀerences in cell number. Iron-fed microglia released
signiﬁcantly less glutamate than control microglia (p < 0.05). (B) Western blotting was used to assess the level of expression of KV1.3 in protein
extracts from control and iron-fed microglia. A speciﬁc antibody was used to detect KV1.3 and GAPDH. (C) Western blotting was used to assess
the level of expression of SIRT-1 in protein extracts from control and iron-fed microglia. A speciﬁc antibody was used to detect SIRT-1 and
GAPDH. (D) Densitometric analysis of KV1.3 and SIRT-1. Expression was normalized to GAPDH levels (relative value). Iron-fed microglia show
signiﬁcantly higher levels of KV1.3 expression (p < 0.05) and signiﬁcantly lower SIRT-1 expression (p < 0.05) when compared to controls. *
indicates signiﬁcant diﬀerence. Shown are the mean and SE of four experiments for all parts.
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which is then able to induce luciferase expression by binding to
the luciferase reporter. Our previous work has demonstrated
that in SH-SY5Y cells, the predominant cleavage of this tagged
APP is sequential via β-secretase and then γ-secretase to release
the tagged AICD fragment.40 SH-SY5Y cells were transiently
transfected with the APP expression plasmid, the luciferase
reporter plasmid, and a third Renilla luciferase construct that
controls for transfection eﬃciency and diﬀerences in cell
number. The transfected cells were then treated with
conditioned medium from control and iron-fed microglia for
24 h. Luciferase activity was then measured in extracts from the
cells and compared to transfected controls that were treated
only with serum free medium. The result showed that medium
from both control and iron-fed microglia had a signiﬁcant
eﬀect on the luciferase levels detected (Figure 6A). This
suggests that AICD fragment formation is greatly reduced by
microglia conditioned medium. However, there was no
signiﬁcant diﬀerence between control and iron fed conditioned
medium. This implies that the change in ADAM10 expression
induced by iron-fed microglia had no eﬀect on rates of APP
cleavage.
We then measured the activity of the ADAM10 promoter
using a reporter construct containing the promoter for human
ADAM10. The SH-SY5Y cells were similarly transiently
transfected with this construct and the Renilla control. The
transfected cells were then treated with conditioned medium
from control and iron-fed microglia for 24 h. The result
showed that neither medium from control nor iron-fed had any
signiﬁcant eﬀect on the luciferase levels detected (Figure 6B).
This implies that the change in ADAM10 protein expression
that we observed was not a consequence of altered tran-
scription of ADAM10 mRNA.
Following from this, we wished to conﬁrm whether altered
ADAM10 expression resulted in altered ADAM10 activity. We
therefore used a FRET-based assay to assess ADAM10 activity
in extracts of SH-SY5Y cells treated with conditioned medium
from control and iron-fed microglia. The assay measured the
cleavage of a tagged peptide substrate. After 24 h of treatment
Figure 5. Eﬀects of microglial conditioned medium on protein expression. Conditioned medium was prepared from control and iron-fed microglia.
The conditioned medium was applied to SH-SY5Y cells for 24 h. Extracts were prepared from the SH-SY5Y cells along with cells that had been
treated only with serum free medium (SFM). The extracts were applied to a PAGE gel, and the gel was blotted to a membrane. APP, ADAM10,
BACE-1, and tubulin (loading control) were detected on the resultant membrane with speciﬁc antibodies. Following detection, the intensity of the
bands was assessed using densitometry. (A, B) Analysis of APP expression in SH-SY5Ys showed there was no signiﬁcant (p > 0.05) eﬀect of either
control or iron-fed conditioned medium. The same result was seen whether the individual bands were quantiﬁed together or separately. (C, D) In
contrast, treatment of SH-SY5Y cells with conditioned medium from iron-fed microglia (but not control) reduced the protein expression of
ADAM10 signiﬁcantly (p < 0.05) when compared to SFM. (E, F) There was no signiﬁcant eﬀect of either microglial conditioned medium on the
expression of BACE-1 in SH-SY5Y cells. Shown are the mean and SE for four experiments each. * indicates a signiﬁcant diﬀerence when compared
to SFM.
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with conditioned medium, extracts from the treated SH-SY5Y
cells were applied to the assay, and the level of cleavage was
measured. The results showed that there was no signiﬁcant
diﬀerence in ADAM10 activity in SH-SY5Y cells treated with
conditioned medium from microglia (Figure 6C). The
implication of this is that, despite the change in ADAM10
protein expression, there is no consequence of this in terms of
measurable activity.
Lastly, as we have observed reduced protein expression of
ADAM10, we looked for an alternative explanation for the
change. It is known that ADAM10 translation can be down-
regulated through the activity of the translation suppressor
FMRP (fragile-X mental retardation protein).41 We assessed
the expression of FMRP in SH-SY5Y cells by western blot. SH-
SY5Y cells were treated with conditioned medium from control
and iron-fed microglia for 24 h. Protein extracts were then
prepared, and the western blot procedure was carried out. The
levels of FMRP were assessed using a speciﬁc antibody. The
results showed a signiﬁcant increase in FMRP in SH-SY5Y
cells treated with conditioned medium from iron-fed microglia
but not from control microglia (Figure 6D,E). What this points
to is that conditioned medium from iron-fed microglia
increases the expression of the translation inhibitor FMRP
known to regulate the translation of ADAM10.
The cleavage of APP causes release of β-amyloid from
neuronal cells such as SH-SY5Y cells. The released β-amyloid
can be detected in cell culture medium. We used a very
sensitive MSD immunoassay to measure β-amyloid released
into the serum free cell culture medium by SH-SY5Y cells.
Treatment of SH-SY5Y cells with conditioned medium from
Figure 6. Investigation of microglia induced changes in ADAM10. (A) The level of APP cleavage in SH-SY5Y cells was measured using a dual
luciferase reporter assay. The assay is based upon binding of a GAL-4 DNA binding domain to the DNA sequence in the luciferase reporter
construct. Binding is directly proportional to the release of the ACID domain from APP to which the GAL-4 domain is fused. SH-SY5Y cells
transfected with the reporter constructs were treated for 24 h with conditioned medium from control and iron-fed microglia or with serum free
medium (SFM). Activity measured from the ﬁreﬂy luciferase reporter construct reporting AICD release was divided by Renilla luciferase control
activity (pTK) to give relative luciferase activity for each treatment. Conditioned medium from both control and iron-fed microglia caused a
signiﬁcant reduction in the luciferase activity measured (p < 0.05) compared to SFM. However, there was no signiﬁcant diﬀerence when comparing
the eﬀect of control and iron-fed microglia conditioned medium to each other. (B) The level of ADAM10 promoter activity was assessed in SH-
SY5Y cells. The cells were transiently transfected with the luciferase reporter construct carrying the ADAM10 promoter and the control reporter
(pTK). The cells were treated with conditioned medium from control and iron-fed microglia for 24 h. The level of luciferase activity was then
assessed and compared to that measured in the SFM control. Neither control nor iron-fed microglial conditioned medium had a signiﬁcant (p >
0.05) eﬀect on luciferase activity. (C) The level of ADAM10 activity in SH-SY5Y cells was assessed with a commercial kit. The kit measured
ﬂuorescent activity following cleavage of an ADAM10 substrate by ADAM10 present in extracts from the cells. Extracts were prepared from SH-
SY5Y cells treated for 24 h with conditioned medium from control or iron-fed microglia or SFM. Fluorescence was measured at 520 nm in a plate
reader following application of extract to the assay. The values were adjusted to the protein concentration of the extracts. Treatment of SH-SY5Y
cells with microglia conditioned medium had no signiﬁcant eﬀect (p > 0.05) on measured ADAM10 activity. (D, E) FMRP is a translation inhibitor
known to inﬂuence protein expression of ADAM10. We measured FMRP expression in protein extracts from SH-SY5Y cells by western blot. SH-
SY5Y cells were treated with conditioned medium from control and iron-fed microglia or SFM. After 24 h, protein extracts were prepared from the
SH-SY5Y cells and applied to the western blot procedure. FMRP and tubulin (loading control) were detected with speciﬁc antibodies, and the band
intensity after chemiluminescence detection was assessed with densitometry. Conditioned medium from iron-fed microglia but not control
microglia had signiﬁcant eﬀect on FMRP detected in SH-SY5Y cells (p < 0.05), greatly increasing the level detected. Shown are the mean and SE
for four experiments in all cases. * indicates a signiﬁcant diﬀerence when compared to SFM.
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Figure 7. Microglia degradation of β-amyloid. We used an MSD Sector Imager to measure the levels of β-amyloid in culture medium. The
multiplex MSD assay measured both Aβ1−40 and Aβ1−42 simultaneously in the same experiments. (A, B) SH-SY5Y cells were treated with
conditioned medium from control and iron-fed microglia. The levels of β-amyloid released after 24 h were assessed and compared to that of SH-
SY5Y cells grown in serum free medium alone (SFM). The levels of both Aβ1−40 and Aβ1−42 were signiﬁcantly (p < 0.05) reduced after either
treatment. However, the levels of both peptides were signiﬁcantly higher when SH-SY5Y cells were treated with medium from iron-fed microglia
than when they were treated with medium from control microglia. (C, D) Synthetic Aβ1−40 and Aβ1−42 were treated with conditioned medium from
control and iron-fed microglia or SFM for 24 h. The conditioned medium was diluted with SFM. After this time, the levels of β-amyloid remaining
were assessed with the MSD assay. In the SFM controls, 904 ± 141 ng/mL Aβ1−40 and 157 ± 27 ng/mL Aβ1−42 were detected. The amount
remaining in the conditioned medium treated wells is shown as a percentage of these values. At both 50% and 25% conditioned medium, there was
signiﬁcantly more Aβ1−40 and Aβ1−42 remaining under iron-fed conditions than control (p < 0.05) implying that conditioned medium from iron-fed
microglia degraded both forms of β-amyloid less than control microglial conditioned medium. (E, F) The experiment with synthetic Aβ1−40 and
Aβ1−42 was repeated but with the addition of enzyme inhibitors. Aβ1−40 and Aβ1−42 were treated with conditioned medium from control and iron-
fed microglia with the addition of DMSO vehicle, IDE inhibitor, or neprylisin (NEP) inhibitor. After 24 h, the levels of Aβ1−40 and Aβ1−42
remaining were assessed with the MSD assay. In the SFM controls, 3715 ± 385 ng/mL Aβ1−40 and 246 ± 42 ng/mL Aβ1−42 were detected.
Compared to the DMSO control, the NEP inhibitor had no signiﬁcant eﬀect on the levels detected for either control or iron-fed conditioned, while
the IDE inhibitor signiﬁcantly reduced degradation of both Aβ1−40 and Aβ1−42 (p < 0.05). (G, H) The levels of IDE were measured in both control
and iron-fed microglia and also in the conditioned medium generated from these cells. The relative levels of IDE were measured using western
blotting and detection with a speciﬁc antibody. GAPDH was measured as a control for loading of the cell lysates. The conditioned media from the
microglia were concentrated 10-fold with a 30 kDa centrifugal ﬁlter (Sartorius) to increase chances of detection. After western blotting the detected
bands were densitometrically quantiﬁed. The levels of IDE in the cells were not signiﬁcantly diﬀerent between control and iron-fed microglia while
that released into the medium was signiﬁcantly (p < 0.05) reduced for iron-fed microglia. For all sections shown are the mean and SE for at least
four independent experiments. * indicates a signiﬁcant diﬀerent between treatment and control. † indicates a signiﬁcant diﬀerence between
treatments with conditioned medium from control and iron-fed microglia.
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control microglia for 24 h resulted in a large and signiﬁcant
reduction in β-amyloid (both Aβ1−40 and Aβ1−42) that could be
detected in the medium (Figure 7A). In comparison, SH-SY5Y
cells treated with conditioned medium from iron-fed microglia
had a signiﬁcantly reduced eﬀect on the levels of β-amyloid
(Figure 7A,B). The implication of this result is that control
microglia are more able to reduce the levels of β-amyloid
released by SH-SY5Y cells than iron-fed microglia. It should be
noted that treatment of SH-SY5Y cells with just iron had no
signiﬁcant eﬀect on β-amyloid levels (Supporting Figure 1).
The decreased levels of β-amyloid detected in medium of
SH-SY5Y cells following treatment with microglial conditioned
medium can either be a result of decreased release of β-
amyloid or increased breakdown of the peptide. While we have
shown that conditioned medium from microglia reduced APP
cleavage, there was no signiﬁcant diﬀerence between control
and iron-fed microglia. Therefore, the diﬀerence we noted in β-
amyloid present in the medium is more likely to be a result of
altered breakdown. We therefore used synthetic β-amyloid to
measure its breakdown by microglia conditioned medium.
Equal amounts of β-amyloid was placed in wells and treated
with either serum free medium, control microglia conditioned
medium, or iron-fed microglia conditioned medium for 24 h.
Following the assay, the levels of β-amyloid measured were
compared as a percentage to the levels detected in the serum
free medium control as a percentage. Three diﬀerent
concentrations of the conditioned medium were tested. β-
amyloid (both Aβ1−40 and Aβ1−42) was degraded by the
conditioned medium in direct relation to the amount of
conditioned medium added (Figure 7C,D). At 25% and 50%
concentrations, conditioned medium from iron-fed microglia
had a signiﬁcantly weaker eﬀect. The implication is that
microglia release factors in their conditioned medium that
degrade β-amyloid and iron-fed microglia release signiﬁcantly
less of these.
Microglia release a number of factors known to degrade β-
amyloid. Among these are insulin-degrading enzyme (IDE)42
and neprilysin.43 We tested speciﬁc inhibitors of these enzymes
to determine what part of the reduction in β-amyloid caused
by microglial conditioned medium was due to the presence of
these enzymes. We repeated the MSD assay for testing the
degradation of β-amyloid by conditioned medium but added
either 30 μM ML345 (IDE inhibitor)44 or 10 μM thiorphan
(neprilysin inhibitor)45 in parallel. The results show that the
IDE inhibitor but not the neprilysin inhibitor signiﬁcantly
reduced the degradation of β-amyloid (both Aβ1−40 and
Aβ1−42) by microglia conditioned medium (Figure 7E,F). This
implies that IDE is the likely candidate protein released from
microglia that degrades β-amyloid in our system.
We veriﬁed that IDE was released by control and iron-fed
microglia by collecting conditioned medium from microglia,
concentrating it, and testing for the presence of IDE by
western blot. IDE was detected at equivalent expression levels
in control and iron-fed microglia and was also present in the
medium collected from the cells (Figure 7G,H). The levels of
IDE in iron-fed microglial conditioned medium were
signiﬁcantly lower than for control. This supports the
suggestion that iron-fed microglia release signiﬁcantly less
IDE than control microglia.
Mechanism of Reduced IDE Release by Iron-Fed
Microglia. We observed no change in IDE expression in iron-
fed microglia. Therefore, another factor must be altering the
levels released. It has been reported that IDE released from
microglia is inﬂuenced by changes in autophagy.46 Therefore,
we assessed autophagic ﬂux in our model microglia. The
expression levels of the protein LC3-II are a reliable indicator
of the level of autophagosomes in cells.47 Inhibition of
autophagy with baﬁlomycin in conjunction would then give
an assessment of the turnover of LC3-II.48 Therefore, an
increase in LC3-II levels in microglia that remains unaltered by
baﬁlomycin treatment would be indicative of reduced
autophagy. Control and iron-fed microglia were grown in
serum free medium and treated either with 13 nM baﬁlomycin
or the equivalent volume of methanol vehicle (20 μL). After 16
h, protein extracts were prepared from the cells, and the levels
of LC3-I and LC3-II were determined by western blot (Figure
8). Iron-fed microglia grown in serum free medium showed
signiﬁcantly higher LC3-II levels than control microglia.
Baﬁlomycin signiﬁcantly increased the levels of LC3-II
detected in control microglia when compared to the methanol
control, but there was no such change for iron-fed microglia
with the same treatment. The results suggest that autophagy in
iron-fed microglia is inhibited in comparison to control
microglia.
Figure 8. Autophagy in iron-fed microglia. The levels of LC3-II were
determined in human microglia by western blot. Control and iron-fed
microglia were grown in serum free medium (SFM) and treated either
with 13 nM baﬁlomycin (Baﬁlo) or the equivalent volume of
methanol (20 μL, 0.67% of total volume). After 16 h, protein extracts
were prepared from the cells and applied to a 14% PAGE gel. After
transfer to a membrane, the presence of LC3-II and GAPDH (loading
control) was detected with speciﬁc antibodies. After chemilumines-
cent detection to visualize the bands (upper panel), the intensity of
the bands was assessed with densitometry. Iron-fed cells grown in
SFM showed signiﬁcantly higher levels of LC3-II than control
microglia (p < 0.05). Treatment with baﬁlomycin signiﬁcantly
increased the levels of LC3-II for control microglia but not for
iron-fed microglia. Shown are the mean and SE for seven experiments.
* indicates a signiﬁcant diﬀerence between treatment and methanol
control. † indicated a signiﬁcant diﬀerence between control and iron-
fed microglia.
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Changes in autophagy are often associated with changes in
endoplasmic reticulum (ER) stress. Mechanistically, this would
provide a potential start point for the changes observed as ER
stress can be induced by iron overload.49 We therefore
examined the expression of a range of proteins that either link
or are associated with ER stress and autophagy. These include
mTOR (mammalian target of rapamycin) associated with
down-regulation of autophagy when phosphorylated,50 EIF2a
(eukaryotic translation initiation factor 2a) associated with
increased ER stress,51 SCAMP5 (secretory carrier membrane
protein 5), which links increased ER stress to decreased
autophagy,52 FMRP, which decreases the expression of
proteins such as SIRT1 as a result of ER stress,53 and
acetylated NF-κB, which is associated with alteration in
released cytokines as a result of ER stress.54 Extracts were
prepared from control and iron-fed microglia and applied to
the western blot procedure. Speciﬁc antibodies were used to
detect bands associated with the proteins of interest (Figure
9), and the bands were quantiﬁed by densitometry (Table 2).
There was a signiﬁcant increase in the level of phosphorylated
mTOR, but the levels of total protein remained the same. This
change ﬁts with the suggestion that autophagy is down
regulated in iron-fed microglia. Similarly, levels of phosphory-
lated EIF2a were increased with no change in the total protein.
This ﬁts with the notion that ER stress is increased in iron-fed
microglia. Both FMRP and SCAMP5 were increased further
supporting these suggestions. Lastly, acetylated NF-κB (p65)
was increased with no change in total NF-κB levels. This
change is also associated with decreased autophagy through
decreased SIRT-1 activity.55
As we have evidence that both autophagy and ER stress are
altered in iron-fed microglia, we wished to determine if
inhibiting autophagy and inducing ER stress would cause a
change in IDE release from control microglia. We therefore
used baﬁlomycin to inhibit autophagy and both brefeldin A
and tunicamycin to induce ER stress. Conditioned medium
Figure 9. Expression of proteins related to autophagy and ER stress. Protein extracts were prepared from control and iron-fed microglia. western
blotting and immunodetection were used to assess the level of expression of a range of proteins. These proteins were (A) phosphorylated-mTOR
(p-mTOR) and total mTOR (T-mTOR), (B) phosphorylated-EIF2a (p-EIF2a) and total EIF2a (T-EIF2a), (C) FMRP, (D) SCAMP5, and (E)
acetyl-NF-κB and total NF-κB (T-NF-κB). In each case, GAPDH was also analyzed to ensure equal loading of the samples. Quantitation appears in
Table 2.
Table 2. Altered Expression of Protein in Iron-Fed
Microgliaa
protein control iron-fed
total mTOR 1.6 ± 0.2 1.8 ± 0.2
ratio p-mTOR/T-mTOR 1.0 ± 0.1 4.2 ± 0.7b
total eIF2a 1.1 ± 0.2 1.0 ± 0.1
ratio p-eIF2a/T-eIF2a 1.0 ± 0.3 2.3 ± 0.3b
FMRP 1.0 ± 0.2 2.3 ± 0.3b
SCAMP-5 1.0 ± 0.2 2.4 ± 0.4b
total NF-κB 1.1 ± 0.2 1.0 ± 0.2
ratio acetyl-NF-κB/T-NF-κB 1.0 ± 0.3 2.6 ± 0.7b
aDensitometric analysis of the bands on western blots shown in
Figure 10. Total levels of mTOR, eIF2a, and NF-κB were assessed as
well as the ratio of the modiﬁed (p or acetyl) form to the total form
(T). Shown are mean and SE for 4−8 experiments each. bSigniﬁcant
diﬀerence between control and iron-fed (p < 0.05).
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was collected from control microglia that had been treated
overnight with these compounds, and extracts were prepared
from the treated microglia to assess cellular levels of IDE. The
conditioned medium was concentrated, and the IDE levels
were assessed by western blot (Figure 10). All three
compounds signiﬁcantly reduced the levels of IDE that could
be detected in conditioned medium but had no eﬀect on the
cellular levels of IDE. These results support the notion that ER
stress and consequential reduced autophagy cause reduced
levels of IDE release by microglia.
Lastly, to verify that the eﬀect of autophagy inhibition and
ER stress diminishes the ability of microglia to degrade β-
amyloid, the conditioned medium from the microglia treated
with baﬁlomycin, brefeldin A, or tunicamycin was applied to
the MSD assay using synthetic β-amyloid. β-Amyloid was
treated with the conditioned medium from the microglia for 24
h, and the levels of β-amyloid remaining were assessed.
Treatment of the microglia with all three compounds
signiﬁcantly decreased the degradation of β-amyloid (both
Aβ1−40 and Aβ1−42), indicating that reduced IDE release
resulted in decreased β-amyloid degradation (Figure 11).
■ DISCUSSION
Nonfamilial AD is the most common neurodegenerative
disease, and incidence rapidly increases with age, making the
aging process the major risk factor.56 Therefore, understanding
how brain aging impacts the incidence of AD is a major
necessity for its possible treatment. While the exact cause of
AD remains unresolved, the deposition of aggregates of β-
amyloid is at the least a signiﬁcant marker for its progression
and at the most the causative agent.57 The true role of β-
amyloid in the pathogenesis probably lies somewhere between
these extremes. While the formation of β-amyloid is a normal
cellular consequence of the metabolic breakdown of APP,
increasing its levels either through alterations in the metabolic
fate of APP or increasing its extracellular survival through
reduced breakdown directly corresponds to increased
possibility of extracellular aggregates forming.58−60
There has been increasing discussion of the potential role of
microglial aging and dysfunction in AD.20,28,61−63 However,
the nature of patient tissues and even animal models make
assessment of molecular interactions diﬃcult, necessitating cell
models where real time interactions can be monitored and
changes assessed. Our model of dystrophic/senescent micro-
glia therefore provides an opportunity for which there is
Figure 10. Autophagy, ER stress, and IDE release. The levels of IDE
were measured in cell extracts from control microglia with and
without treatment with either with 13 nM baﬁlomycin, 0.1 μg/mL
brefeldin A, or 1.0 μg/mL tunicamycin. The treatments were for 16 h,
and after that time conditioned medium generated from these cells
was collected, and protein extracts were made from the cells. The
relative levels of IDE were measured using western blot and detection
with a speciﬁc antibody. GAPDH was measured as a control for
loading of the cell lysates. The conditioned media from the microglia
were concentrated 10-fold to increase chances of detection. After
western blot, the detected bands were densitometrically quantiﬁed.
None of the treatments increased IDE levels in the microglia, but all
treatments caused a signiﬁcant decrease (p < 0.05) in IDE detected in
the medium when compared to the control. Shown are the mean and
SE from seven independent experiments.
Figure 11. Autophagy, ER stress, and β-amyloid. Synthetic Aβ1−40 and
Aβ1−42 were treated with conditioned medium from control microglia
treated with 13 nM baﬁlomycin, 100 ng/mL brefeldin A, 1.0 μg/mL
tunicamycin, or SFM alone for 16 h. After this time, the levels of β-
amyloid remaining were assessed with the MSD assay. In the SFM
controls, 3326 ± 240 ng/mL Aβ1−40 and 231 ± 10 ng/mL Aβ1−42
were detected. All three treatments signiﬁcantly increased (p < 0.05)
the level of Aβ1−40 and Aβ1−42 detected when compared to control
microglia conditioned medium. Shown are the mean and SE for four
experiments.
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currently little alternative. Given the issues with rodent models
to reproduce an inherently human disease,64 we deliberately
chose human cell lines for our approach. While diﬀerent
microglia “states” such as activated and primed65 or
phenotypes such as ramiﬁed and phagocytic can be modeled,
there are no such models for senescent/dystrophic microglia.
The major criterion for determining the characteristics of
dystrophic microglia is based on morphological changes in
tissue, which inherently poorly translates to in vitro
models.18,35 Similarly, there is no universal marker that can
discriminate a dystrophic microglia from any other.18 Worse
still is that large scale proteomics/transcriptomics based
studies have failed to identify reproducible diﬀerences between
aged microglia and controls, with each study listing almost
incomparable data sets.66−71 The one exception to this is
ferritin expression. Microglia express more ferritin than most
cells of the brain, but this is further elevated in dystrophic
microglia and implicates that iron storage is also increased.22 A
more objective way to assess senescence in microglia is to use
the same criteria used for assessing general cellular senescence,
that is, the characterization of their secretory phenotype.72 The
induction of the senescence associated secretory phenotype
(SASP) is likely to become the standard approach to identify
senescent cells in the absence of a speciﬁc marker.73
We induced a senescent/dystrophic phenotype in microglia
by iron overload. This resulted in a change in expression of
ferritin and iron storage. While the high levels of iron used
were artiﬁcial and unlikely to be encountered in vivo, they were
employed as a means to an end and played no further role once
we had induced the phenotype, as the high iron environment
was removed from the culture system when analyzing changes
and producing conditioned medium. However, the levels of
stored iron and the increase in ferritin levels that we measured
are in line with previous suggested increases in both iron
concentrations and ferritin levels in speciﬁc brain regions that
have previously been measured.74 Of all the cell types in the
brain, microglia show the largest increase in iron storage with
age and are therefore likely to have much higher levels than the
average for any speciﬁc brain region.25
We veriﬁed the senescent/dystrophic phenotype by
measuring molecules released by the microglia (cytokines
and glutamate),36,75 as well as changes in protein expression
associated with an aged phenotype (KV1.3, SIRT-1).37,39
Interestingly age associated changes in both KV1.3 and SIRT-1
have been shown to inﬂuence increased cytokine release.38,39
Other changes observed later in the study also support the
SASP state of the iron-fed microglia. These include changes in
autophagy and ER stress.76,77
The multitude of changes we have measured in our model
microglia converge on a general phenotype that would be
expected in a senescent cell. Along with altered release of
molecules such as cytokines, these changes included reduced
ability to deal with stress and a failure in processes aimed at
clearing away damaged proteins such as autophagy.
The relation of microglia to AD has long been
considered.78−81 Similar to the study of many neurodegener-
ative diseases, the study of microglia in AD has principally
concerned the physical relation of microglia in patient brains
and transgenic mice to pathological hallmarks such as β-
amyloid deposition82 or neuronal loss.83 The potential role of
microglia has been suggested to be direct (causing neuronal
loss through activation in response to β-amyloid),84 indirect
(changing parameters such as plague load),85 or bystander
(attracted to plaques without altering the pathology). There
have been some suggestions that β-amyloid is not necessary to
the mechanism of neuronal loss and that eliminating microglia
in AD transgenic mice prevents neuronal loss without change
to β-amyloid plaque levels.86 However, the most convincing
evidence suggests that microglia inﬂuence clearance of β-
amyloid due to the production of enzymes able to degrade it or
by phagocytic uptake.32 Thus, regulation of β-amyloid
clearance is the most likely physiological role of microglia in
AD.
Our ﬁndings emphasize the importance of microglial
proteases to the removal of β-amyloid and how disruption of
the release of enzymes like IDE could compromise this role.
The human microglia cell line we used released IDE, which in
our system almost completely removed β-amyloid released by
SH-SY5Y cells over 24 h. IDE is released by primary microglia
but not all microglia cell lines (e.g., BV2), indicating that
caution must be used in the choice in cell lines to model age-
related microglia changes.87,88 The reduced release in IDE we
observed for iron-fed microglia was a result of reduced
autophagy, which has been previously observed,46,89 but is a
mechanism that has been poorly studied. It has been noted
that changes in this pathway involve changes in the level of
phosphorylated mTOR,89 which we also observed. Outside of
the possible association of reduced IDE release with the
dystrophic phenotype, we observed that both reduced
autophagy and increased ER stress had the same eﬀect. The
implication is that any process that alters microglia in a similar
way could also inﬂuence the levels of β-amyloid in the brain.
However, reduced autophagy and increased ER stress are
characteristics of senescence-associated secretory pheno-
type.76,77 It should also be noted that the change in IDE
release was not due to a general failure in IDE expression in the
cells as we did not observe any change in cellular expression.
There has been discussion of how important reduction in β-
amyloid degrading enzymes is to AD. There are some reports
that suggest that such a reduction would only contribute to late
stage changes.90 Of course, studies of patients do not take into
account preclinical changes that may play a role in disease
onset. The general consensus is that these enzymes are
extremely important and regardless of causality, regulating
their activity may have therapeutic value.91 An additional
consideration is the relative contributions of the diﬀerent
enzymes to β-amyloid degradation in the brain. Our study has
focused on IDE and not neprilysin because we found no
contribution from the latter in our system, but this may not
reﬂect the roles of these enzymes in AD. There has been
suggestion that neprilysin is the main enzyme aﬀected in AD,92
and others suggest it might be a diﬀerent enzyme altogether,
such as angiotensin-converting enzyme.93 However, IDE is
clearly important when considering β-amyloid degradation in
the brain. First, IDE is reduced with age in regions associated
with AD.94 Second, overexpression of IDE causes a signiﬁcant
reduction in plaque load.95 Third given these enzymes are both
released by microglia and as the principal change may be in the
SASP of microglia it may be a moot point exactly which
enzyme is most involved.
A ﬁnal additional factor is that enzymes generated by
neurons themselves and released extracellularly might also
contribute to APP degradation. Such enzymes include
endothelin-converting enzyme and membrane type metal-
lomatrix proteins (MMPs).96,97 These enzymes may also be
released by SH-SY5Ys. Factors from microglia may also
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inﬂuence levels of these proteins, which could have also
aﬀected levels of β-amyloid in our system.
We also examined other factors that could alter the
generation of β-amyloid by SH-SY5Y cells. In particular, we
noted that conditioned medium from microglia signiﬁcantly
reduced the formation of AICD, a C-terminal cleavage product
of APP, but this eﬀect was replicated when the conditioned
medium was generated from iron-fed microglia. While a
change in the processing of APP could result in reduced release
of β-amyloid by SH-SY5Y cells and consequently the level of β-
amyloid measured in the MSD assay, it has no bearing on the
assays with synthetic β-amyloid. Therefore, these results
support the potential role of microglia in regulating β-amyloid
levels released from cells. Destruction of microglia in mice has
been shown to increase plaque size.98
We also noted a signiﬁcant change in the levels of ADAM10
expression in SH-SY5Y cells treated with conditioned medium
from iron-fed microglia, but as there was no observed change
in the activity of ADAM10, the consequences of this altered
expression are likely to be insigniﬁcant to the processing of
APP and the subsequent levels of β-amyloid. These ﬁndings do
not rule out other potential changes to protein expression and
metabolism in SH-SY5Y cells, but these may or may not have
any bearing on APP metabolism speciﬁcally. While the study
on microglia−neuron interactions is hardly new, there has
been little study of the impact of microglia on APP processing
in neurons. This is surprising given there is signiﬁcant evidence
that APP processing is inﬂuenced by cytokines released by
microglia.99−101 However, we are conﬁdent that a system of
study such as ours will increase consideration of microglia in
the study of APP.
In summary, we have established a unique model of
senescent/dystrophic microglia and used this to examine the
role of dystrophic microglia in the turnover of β-amyloid, a
major player in AD. A comprehensive overview of our ﬁndings
is illustrated in Figure 12. Microglia induced to take up iron
show changes in molecular expression suggestive of changes in
ER stress and autophagy. The consequence of these changes is
the adoption of a senescence associated secretory phenotype
and changes in the release of a variety of proteins including
cytokines and enzymes like IDE. Decreased release of IDE
results in decreased breakdown of β-amyloid released by
neuronal cells. These ﬁndings provide a potential mechanistic
insight into how microglial aging can contribute to the
accumulation of β-amyloid and advance the pathology of AD.
■ METHODS
Unless otherwise stated reagents were purchased from Sigma-Aldrich.
Cell Culture. The microglia cell line used in this study was the
SV40 immortalized human microglia cell line (ABM). Cells were
cultured in DMEM with 4.5 g/L glucose (LONZA) supplemented
with 10% FBS (Labtec) and 1% pen/strep. Cells were maintained at
37 °C and 5% CO2 in a humidiﬁed incubator. The neuronal cell line
used in experiments was the SH-SY5Y human neuroblastoma. This
cell line was grown under the same conditions as the microglial cell
line. Images of microglia were produced using either a Nikon
Diaphot-TMD inverted microscope (live cells) or a Nikon Eclipse
E800 microscope (stained cells). Perl’s staining was performed using a
kit from Atom Scientiﬁc. Control and iron-fed microglial cells were
plated onto coverslips and left overnight. They were washed in PBS
and ﬁxed in ice-cold methanol for 5 min at −20 °C. The cells were
stained according to the manufacturer’s instructions and mounted
onto slides using glycerol jelly as mounting medium.
Microglia were cultured in high iron conditions to induce a
senescent phenotype. The iron stock solution used was 25 mM ferric
ammonium citrate (Acros Organics) prepared in deionized water and
ﬁltered through a 0.22 μm syringe ﬁlter (Millipore) Microglial cell
lines were grown in medium containing in 500 μM ferric ammonium
citrate for a minimum of 2 weeks. Cell lines were maintained under
these conditions until used for experiments. Conditioned medium was
produced from the microglia by washing them with serum free
medium (DMEM) to remove excess iron and then growing them for
48 h in DMEM supplemented with B27 without antioxidants (Gibco)
plus 1% penicillin and streptomycin. The conditioned medium was
collected from both control and iron-fed microglia, centrifuged to
remove debris, and ﬁltered through a 0.45 μm ﬁlter before use in
further experiments.
Drug treatments were for 16 or 24 h. Brefeldin A (10 mM),
baﬁlomycin (2 μM), and tunicamycin (1.2 mM) were prepared as
stock solutions in methanol. Concentrated stocks of the IDE inhibitor
ML345 (10.4 mM) and the neprilysin inhibitor thiorphan (1 mM)
were prepared in DMSO. Synthetic β-amyloid was from Meso Scale
Discovery.
Western Blot. Cells were lysed in PBS with 0.5% Igepal CA-630
and “complete” protease inhibitor cocktail (Roche), sonicated 5 s on
ice, incubated on ice for 20 min, and centrifuged 10 000g for 5 min to
remove insoluble membranes. Protein concentration was determined
with a Bradford protein assay (Bio-Rad), according to the
Figure 12. Model of dystrophic microglia induced increase in β-
amyloid. A summary ﬁgure illustrating the changes we have observed
in this study. Excess uptake of iron by microglia induces a dystrophic-
like phenotype illustrated by changes in ferritin expression and iron
storage. Increased cellular iron also increases the labile iron pool with
the consequence of increased oxidative events, which are known to
induce ER stress. The consequence of induced ER stress is changes in
markers such as SCAMP5 and EIF2a and altering protein translation
through FMRP. One consequence of induced action of FMRP is the
decreased expression of the deacetylase SIRT-1 resulting in higher
levels of acetylated NF-κB. This change is known to result in
increased release of pro-inﬂammatory cytokines indicating a switch in
the secretory phenotype to one associated with cell senescence.
Decreased SIRT1 activity is also associated with increased
phosphorylation of mTOR, resulting in reduced autophagy.
Decreased autophagy causes an increase in the levels of LC3-II by
reduction in its turnover. It also results in a decrease in the secretion
of proteins that include IDE. Reduced IDE then results in increased
extracellular levels of β-amyloid.
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manufacturer’s instructions. Protein concentrations were normalized,
and samples were boiled for 5 min with 1× Laemmli SDS-PAGE
buﬀer. Samples were loaded onto either a 10% or a 14% (depending
on molecular weight of the protein) acrylamide SDS-PAGE gel, with a
buﬀer of Tris (250 mM), glycine (1.92 M), and SDS (0.1% w/v), and
run at 250 V and 35 mA/gel for 45−60 min. Separated proteins were
transferred to a PVDF membrane (Millipore) using a semidry transfer
apparatus, run at 25 V and 100 mA/gel for 1.5 h. Membranes were
blocked in 5% w/v nonfat milk powder in Tris buﬀered saline with
0.1% Tween 20 (TBS-T) for 1 h, incubated with primary antibody for
1−2 h or overnight, and washed 3 × 15 min in TBS-T. Membranes
were blocked again for 10 min and incubated with horseradish
peroxidase-conjugated secondary antibody (DAKO) for 1 h. Addi-
tional 3 × 15 min washes were performed, and the membranes were
developed with Luminata Crescendo or Luminata Forte ECL
substrate (Thermo Scientiﬁc) and imaged with a Fusion SL CCD
imaging system (Vilber Lourmat). Antibodies used in this study
included rabbit anti-ferritin light chain (ab69090, Abcam), rabbit anti-
KV1.3 (APC101, Alomone Labs), mouse anti-GAPDH (ab8245,
Abcam), mouse anti-α-tubulin (B512, Sigma), anti-APP (ab133509,
Abcam), rabbit anti-ADAM10 (Millipore), rabbit anti-BACE1 (Cell
Signalling Technology), mouse anti-SIRT1 (1F3, Cell Signaling
Technology), rabbit anti-insulin degrading enzyme (EPR6099,
Abcam), rabbit anti-LC3 (ab48394, Abcam), rabbit anti-mTOR
(PA1-518, ThermoFisher), rabbit anti-phospho-mTOR (S2448,
ab109268, Abcam), rabbit anti-EIF2a (Cell Signalling Technology),
rabbit anti-phospho-eIF2a (Ser51, Cell Signalling Technology), rabbit
anti-NF-κB p65 (D14E12, Cell Signalling Technology), rabbit anti-
acetyl-NF-κB p65 (Lys310, Cell Signalling Technology), rabbit anti-
FMRP (ab17722, Abcam), and rabbit anti-SCAMP5 (ab3432,
Abcam). Densitometric analysis was performed with ImageJ.
Iron Assay. The levels of total iron in human microglia were
determined using a commercial assay (Abcam), following the
manufacturer’s instructions. Cellular iron content was determined
from four conﬂuent T25 ﬂasks and normalized to total protein
content determined by the Bradford assay.
Glutamate Assay. Glutamate levels in conditioned medium were
assessed using a commercial kit according to the manufacturer’s
instructions (Sigma). Microglia were plated out at equivalent
densities, and conditioned medium was generated as described
above. After collection of the conditioned medium, the microglia were
lysed, and protein concentration was measured using the Bradford
assay. The glutamate concentrations were normalized to protein
content in the lysates.
ADAM10 Activity Assay. The enzymatic activity of ADAM10 in
SH-SY5Y cells was assessed using a commercial kit according to the
manufacturer’s instructions (Anaspec). Conﬂuent SH-SY5Y cells were
treated with SFM or conditioned medium from microglia for 24 h.
The cells were lysed, and protein concentrations were measured using
the Bradford assay. Equivalent amounts of protein were used in the
ADAM10 activity assay to account for diﬀerences in cell number.
Readings were taken at 520 nm every 5 min, and the initial rate was
calculated for each condition.
Promoter Assay. The ADAM10 promoter construct was a gift
and was as previously described.102 SH-SY5Y cells were grown in 24-
well plates seeded at 5 × 104 cells/well 24 h prior to transfection.
Transfections of the promoter construct in pGL Basic (with ﬁreﬂy
luciferase activity) were performed using FuGENE HD transfection
reagent (Promega) as per manufacturer’s instructions. To control for
variation in transfection eﬃciency among replicates, promoter
constructs were cotransfected with the Renilla luciferase vector,
pRL-TK (Promega). At 24 h post-transfection, SH-SY5Y cells were
harvested, and ﬁreﬂy and Renilla luciferase chemiluminescence were
measured using the Dual-Luciferase Reporter Assay System
(Promega) in a BMG FLUOstar Omega plate reader (BMG Labtech
GmbH). Luciferase activity was calculated as the ratio of ﬁreﬂy to
Renilla luciferase activity.
APP Cleavage Luciferase reporter Assay. The luciferase
reporter assays was carried out as previously described.103 SH-SY5Y
cells were plated out at 5 × 104 cells/well in 24 well plates in triplicate
for each condition and left to reattach for 18−24 h at 37 °C, 5% CO2.
Test wells were transfected with plasmids pFR-Luc (A ﬁreﬂy
luciferase reporter construct pFR controlled by a synthetic promoter
made of ﬁve tandem repeats of the yeast GAL4 activation sequence
followed by a minimal TATA box), APP-Gal4 (pRC-CMV vector
containing APP695 cDNA and a Gal4-DNA binding domain fused to
its C-terminal end (cleavage of the AICD domain with Gal-4 domain
attached leads to it binding to the pFR vector and expressing ﬁreﬂy
luciferase) and pRL-TK (containing Renilla luciferase as above) using
the transfection reagent Fugene HD. Control wells were transfected
with pFR-Luc and pRL-TK only to assess background luciferase
activity. The cells were transfected for approximately 24 h and then
treated with SFM or microglial conditioned medium for 24 h. After
lysing and harvesting, ﬁreﬂy luciferase and Renilla luciferase activity in
the cells was measured with the Dual-Luciferase Reporter Assay
System on a FLUOstar Omega plate reader. Luciferase activity was
calculated as the ratio of ﬁreﬂy to Renilla luciferase activity.
Proliferation Assay. Proliferation of C8B4 microglia was assessed
using the Abcam BrdU proliferation ELISA kit (Abcam, ab126556)
according the manufacturer’s instructions. Both untreated and iron-
fed human microglia were plated at equal density ranging from 2000
to 20,000 cells per well in 96 well trays. The cells were exposed to
BrdU (bromodeoxyuridine) for 24 h prior to starting the assay.
Absorbance was measured at 450 nm in a FLUOstar Omega plate
reader following the colorimetric assay.
β-Amyloid Assay. Concentrations of β-amyloid (both 1−40 and
1−42) present in cell culture medium were determined using the
Meso Scale Discovery (MSD) Sector Imager S 600 multiplex plate
reader. The plate used for the analysis was the V-Plex Aβ Peptide
Panel kit 1 (MSD). Medium was collected from SH-SY5Y cells that
had been exposed either to conditioned medium or control medium
(DMEM with B27 supplement) as described above and ﬁltered
through a 0.22 μm ﬁlter before applying to the plate without dilution.
Concentrations were determined by comparison to a standard curve
for each individual β-amyloid peptide. The values were adjusted for
plating density by assessing the protein content of the cells used to
generate the conditioned medium using the Bradford assay and
dividing the β-amyloid concentration by the protein concentration.
Cytokine Assay. Cytokines secreted by the human microglia were
also measured using the MSD Sector Imager S 600 multiplex plate
reader. The cytokines were assessed using the V-PLEX Proin-
ﬂammatory Panel 1 Human Kit (MSD). This kit measured IFN-γ, IL-
10, IL-12p70, IL-13, IL-1β, IL-2, IL-4, IL-6, IL-8, and TNF-α.
Conditioned medium was collected from control and iron-fed
microglia as described above. The microglia used to generate the
conditioned medium were lysed and their protein content was
measured using a Bradford Assay to account for diﬀerences in cell
number.
Statistics. All statistical analyses were carried out in Microsoft
Excel. Statistical analyses were conducted using a two-tailed Student’s
t test, setting statistical signiﬁcance at p-value of <0.05. Data are
expressed as the mean ± standard error (SE).
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2.5 Concluding commentary 
 
The work in the preceding chapter introduced a novel model of aging microglia and 
showed that a reduction in secreted β-amyloid degrading enzyme IDE by microglia can 
result in the accumulation of β-amyloid. The characterisation of the iron-fed microglial 
model included a measurement of L-ferritin levels as a measure of iron storage. The 
speed of storage or iron in the microglia was also measured by following the increase in 
ferritin expression over time presented in figure 2.1. The levels of ferritin measured after 1 
day of supplementation were significantly elevated compared to untreated control and did 
not show further increases over the course of a month. This finding agreed with a previous 
report of iron storage by microglia that can occur very rapidly (Bishop et al. 2011). This 
suggests that any changes observed in the microglial phenotype after iron 
supplementation probably start occurring at a point after the cells have reached a 
saturation point in their iron storage capabilities.  
 
 
Figure 2.1. Increase in ferritin expression in iron-fed human SV40 microglia.  A. 
Shows western blots for L-ferritin and α-tubulin of protein extracts of control microglia and 
microglia supplemented with iron for 1 day and 1 month. B. Shows densitometric analysis 
of western blots probed for L-Ferritin and α-tubulin with specific antibodies. B 
demonstrates the relative expression of L-ferritin compared to tubulin from protein extracts 
of control microglia, microglia supplemented with iron for 1 month and microglia 
supplemented with iron for 1 day. Data plotted are mean and SEM of 4 experiments. L-
ferritin expression is significantly increased when iron is added to the cell culture medium 
but does not increase between 1 day and 1 month of supplementation.  * indicates p-
value≤0.05 compared to control. 
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The potential importance of this finding to the study of AD was discussed. While the 
previous chapter discussed the majority of our findings in regards these observations, we 
also pursued further lines of investigation in terms of the metabolism of APP. A pathway 
that may have affected β-amyloid production is changes in γ-secretase activity. The levels 
of the APP C-terminal fragments C89 and C99 were measured through western blotting in 
SHSY5Y cells treated with microglial conditioned medium. These levels can be used as 
an indicator of APP processing. Iron-fed microglia conditioned medium caused a 
significant increase in the levels of C-terminal fragments suggesting that APP cleavage 
and thus potentially β-amyloid production is also increased in the SHSY5Y cells. As APP 
cleavage by α- or β- secretase was not significantly increased, the activity of γ-secretase 
was measured using a luciferase reporter assay of Notch cleavage (another target of γ-
secretase). Thus, luciferase expression was driven by the release of the Notch 
intracellular domain (NICD). SHSY5Y cells were treated with SV40 human microglial 
conditioned medium and Notch cleavage was measured (Figure 2.2). Notch cleavage, just 
as APP cleavage shown in Fig. 6A was significantly reduced by the presence of 
conditioned medium. However, iron-fed microglia conditioned medium induced a 
significant increase of Notch cleavage compared to control indicating that γ-secretase 
activity was also increased. This increase in γ-secretase activity could also play a role in 
the increased β-amyloid levels seen in Fig. 7.  
 
The significance of the data presented in Figure 2.2 is that microglial conditioned medium 
could have a double effect on β-amyloid levels with both production and degradation 
being affected. The exact process through which β-amyloid production could increase 
under the effect of iron-fed microglia has not been determined. β-amyloid deposition has 
been shown to activate microglia resulting in the release of inflammatory cytokines. 
Previous reports have linked increased inflammation in the nervous system with increased 
β-amyloid deposition which creates a feedback loop (W.-Y. Wang et al. 2015; Sastre et al. 
2008) γ-secretase mediated cleavage of APP has been reported to be affected by 
inflammatory cytokines such as TNF-α, IL-1β and IFNγ (Liao et al. 2004). It is possible 
that elevated levels of IL-1β in the iron-fed microglia conditioned medium could have 






Figure 2.2. Altered γ-secretase APP processing in SHSY5Y cells treated with 
microglia conditioned medium. A. Conditioned medium was generated from human 
microglial cell line and was applied to SHSY5Y cells for 24h. SFM – serum-free medium 
control. Control – conditioned medium from untreated microglia. Iron-fed – conditioned 
medium from iron-fed microglia. The cells were lysed, and equal amount of protein were 
loaded onto a PAGE gel. The gel used was a 4% Tris-tricine stacking and 16% Tris-
Tricine separating gel and the lysates were electrophoresed at 35mA/80V for 15 minutes 
and then 35mA/100V for 8 hours as described in (Schagger 2006). APP C-terminal 
fragments were measured with western blotting and the signal was normalised to tubulin 
expression. The data were analysed densitometrically. The data displayed are mean 
relative signal intensity and S.E.M. of four experiments.  B. Representative western blots 
for APP CTFs. C99 and C89 and α-tubulin. C. SHSY5Y cells were transfected with a 
luciferase reporter plasmid that is activated by the release of the Notch intracytoplasmic 
domain post γ-secretase cleavage together with PRL-TK and PFR-Luc. The Notch 
cleavage luciferase reporter (Notch-Gal4), a pSecTag2 vector containing cDNA encoding 
for human Notch3 fused in frame at its C terminus to the yeast transcription factor Gal4 
was provided by Dr. Robert J. Williams (Department of Biology & Biochemistry, University 
of Bath), as described in (Cox et al. 2015). After 24h they were treated with microglial 
conditioned medium from SV40 human microglia or SFM. On the following day the cells 
were lysed, and luciferase activity was measured using a Dual-Glo luciferase assay 
system (Promega) on a FLUOstar Omega Microplate Reader (BMG LABTECH) using the 
manufacturer’s instructions. 
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Finally, Figure 2.3 is an alternative version of figure 9B that shows the entire gel for a 
western blot for eIF2a and illustrates that the ratio of p-eIF2a to total eIF2a is elevated in 





Figure 2.3. Expression of eIF2a in control and iron-fed human SV40 microglia. 
Protein extracts were prepared from control and iron-fed microglia. Western blotting and 
immunodetection were used to assess the level of p-eIF2a, total eIF2a and GAPDH.  
 
Overall, the finding of this paper is useful in the context of establishing a simple and easy 





3. Model Senescent Microglia Induce Disease Related 
Changes in α-Synuclein Expression and Activity 
3.1 Introductory commentary 
Aged microglia are thought to play a role in synucleinopathies, but the mechanisms by 
which they could influence α-synuclein expression, metabolism and aggregation have not 
been well investigated. In this paper we apply our cell culture-based aged microglia model 
to study this question.  
 
We aim to characterise both a mouse microglial cell line and primary mouse microglia 
incubated in high levels of iron as a model for aged microglia. Our second aim was to 
show whether the aged microglia model can affect α-synuclein levels in SHSY5Y neuronal 
cells and whether that results in changes in α-synuclein aggregation.  The focus of this 
paper was to document the molecular changes that occurred in the cells and to build a 
potential pathway through which α-synuclein could be perturbed.   
 
The primary microglial cells and the mouse microglial cell line were characterised in a 
similar way as the human microglial cell line in Chapter 2. Their conditioned medium was 
used to induce effects on SHSY5Y cells. Changes to SH-SY5Y cells were investigated by 
measuring levels of α-synuclein with western blotting, α-synuclein promoter activity with a 
luciferase reporter assay, levels of α-synuclein enzymatic activity with a ferrireductase 
assay and levels of tetramer and aggregate formation by western blot. This multifaceted 
approach allowed us to conclude whether the effects of microglial conditioned medium on 
α-synuclein replicated ones seen in PD and other synucleinopathies.  
 
The mouse microglial cell line C8B4 was chosen for the same considerations as in 
Chapter 2, namely that it allowed the continued generation of large numbers of microglia 
and that it expressed microglial markers. Primary microglia were harvested from mouse 
neonates, allowing a better yield and a longer lifespan in culture as compared to microglia 
from adult animals. The use of primary microglia was included to verify that the changes 
we observed were not as a result of using an immortalised cell line. However, primary 
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Abstract: Aging is the most prominent risk factor for most neurodegenerative diseases. However,
incorporating aging-related changes into models of neurodegeneration rarely occurs. One of the
signiﬁcant changes that occurs in the brain as we age is the shift in phenotype of the resident microglia
population to one less able to respond to deleterious changes in the brain. These microglia are termed
dystrophic microglia. In order to better model neurodegenerative diseases, we have developed
a method to convert microglia into a senescent phenotype in vitro. Mouse microglia grown in
high iron concentrations showed many characteristics of dystrophic microglia including, increased
iron storage, increased expression of proteins, such as ferritin and the potassium channel, Kv1.3,
increased reactive oxygen species production and cytokine release. We have applied this new model
to the study of α-synuclein, a protein that is closely associated with a number of neurodegenerative
diseases. We have shown that conditioned medium from our model dystrophic microglia increases
α-synuclein transcription and expression via tumor necrosis factor alpha (TNFα) and mediated
through nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). The conditioned
medium also decreases the formation of α-synuclein tetramers, associated ferrireductase activity, and
increases aggregates of α-synuclein. The results suggest that we have developed an interesting new
model of aged microglia and that factors, including TNFα released from dystrophic microglia could
have a signiﬁcant inﬂuence on the pathogenesis of α-synuclein related diseases.
Keywords: synuclein; tumor necrosis factor alpha; microglia; aging; iron; cytokines; tetramer
1. Introduction
The study of neurodegenerative diseases has become a major incentive. This is due to their
increased prevalence as the human population lives longer. This statement in itself immediately
implies that a clearer understanding of these diseases will only come by greater insight into how the
prevalence of these diseases is related to the aging process in the brain. Aging of the human brain is
commonly associated with cognitive decline and it is the primary risk factor for the development of
Alzheimer’s disease (AD) [1]. Despite these facts, the molecular biology of the aging brain has not
been studied extensively. Some of the factors that change as we age include: the environment the
neurons are exposed to and their transcriptome.
An example of the changing environment in the aging brain is the changes in the supporting
cells in the brain, including microglia. Healthy microglia monitor their environment, phagocytosing
debris, and releasing numerous molecules that can impact other cells [2]. They include hydrogen
peroxide (H2O2), nitric oxide (NO), inﬂammatory cytokines, proteases, and neurotransmitters.
Activated microglia can act as antigen presenting cells and activate T-cells. After an infection
has been dealt with microglia can recruit cells that are involved in neuronal repair and secrete
anti-inﬂammatory cytokines [3]. The idea of aging microglia stems from histological observations
of healthy aged brains where the cells often develop dystrophic phenotypic characteristics [4].
Biomolecules 2018, 8, 67; doi:10.3390/biom8030067 www.mdpi.com/journal/biomolecules
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Resting microglia have a ramiﬁed morphology with many ﬁne processes extending from the cell
body. Dystrophic microglia found in aging brains lose this ﬁne process ramiﬁcation. Dystrophic
microglia often develop abnormally shaped processes with spheroidal swellings and cytoplasmic
fragmentation (cytorrhexis) [5]. Dystrophic microglia have also been associated with the increased
release of toxic ROS (reactive oxygen species) and inﬂammatory cytokines and impaired phagocytic
ability [6–8]. The proinﬂammatory cytokines found to be released by dystrophic microglia include
IL-6 (interleukin-6), TNF-α (tumor necrosis factor alpha), and IL-1β (interleukin 1-beta) [7]. However,
one of the most unique changes observed in dystrophic microglia in the aging brain is the very high
accumulation of iron, which is found to be stored in proteins, such as ferritin [9–11].
The presence of healthy glial cells is critically important to neuronal wellbeing. Microglia maintain
homeostasis in the healthy brain and ﬁght infection, when it is present, through a complicated system
of signalling molecules [12]. The importance of microglia to neurons is supported by higher incidence
of dystrophic microglia and microglial apoptosis in Alzheimer’s disease [13]. The inﬂammation of the
nervous system in neurodegenerative disease was thought to be due to activated microglia. However,
low, but sustained, release of inﬂammatory factors and impaired neuroprotective ability of microglia
seen in neurodegeneration could be due to dystrophic changes instead [14].
The cytosolic protein alpha-synuclein (α-syn) is associated with a range of neurodegenerative
diseases, including Parkinson’s disease (PD) Dementia with Lewy bodies (DLB), the Lewy body variant
of Alzheimer’s disease, and multiple system atrophy. Aggregated α-syn is concentrated in structures
termed Lewy bodies and Lewy neurites that are associated with the synucleinopathies [15,16].
Extracellular α-syn is present as aggregates in both the substantia nigra of PD patients [16] and
senile plaques of AD brains in the form of the non-Aβ component (NAC) [17,18]. Clear links between
α-syn and neurodegeneration have been found. Neuronal cell loss and Lewy body-like inclusions
occur in animal models overexpressing α-syn [19] and the rescue of dopaminergic cells from death
occurs following the down-regulation of α-syn expression in the substantia nigra of a Parkinson’s
disease rat model [20].
In PD there has been discussion of the possible involvement of microglia [21] and experiments
with rodent PD models have shown that microglial activation can cause PD-like symptoms [22].
Parkinsonian changes in primate brains induced by manganese have been shown to be accompanied
by dystrophic changes in microglia [23]. Additionally, dystrophic microglia have been identiﬁed in
DLB [24]. Age-related changes in microglia have also been suggested to play a role in Parkinson’s
disease [25].
In the current work, we establish iron overload as a mechanism to switch microglial phenotype to
one that has many of the characteristics of senescent microglia. Iron overload was achieved by growing
microglia in high concentrations of iron. We also show that iron overloaded (iron-fed) microglia release
factors, including increased levels of the cytokine TNFα that caused an increased expression of α-syn,
altered its activity, and increased its aggregation. We argue that such a model of senescent microglia
could be utilized to improve models for the study of neurodegenerative diseases by the incorporation
of this age-related change.
2. Materials and Methods
Reagents were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated.
2.1. Cell Culture
SH-SY5Y (human neuroblastoma) cells were cultured in 45% DMEM (Dulbecco’s modiﬁed
Eagle’s medium)/45% Ham’s F12 (LONZA, Basel, Switzerland) supplemented with 10% FBS (foetal
bovine serum) (Labtech, Heathﬁeld, UK), and 1% penicillin/streptomycin. Cells were maintained at
5 × 106/75 cm2 at 37 ◦C and 5% CO2 in a humidiﬁed incubator. The neuronal status of SH-SY5Y cells
was monitored by reverse transcription polymerase chain reaction (RT-PCR) with primers for tyrosine
hydroxylase (TH), dopamine transporter (DAT), and vesicle monoamine transporter 2 (VMAT2).
Page 81
Biomolecules 2018, 8, 67 3 of 25
Cell lines derived from SH-SY5Y cells and overexpressing α-syn were developed by stable
transfection of plasmids (pCDNA3.1) containing the open reading frame (ORF) of the protein using
Fugene (Promega, Southampton, UK). The cell line generated was as previously described [26].
The microglial cell line used in this study was C8B4 (CRL2540, American Type Culture Collections
(ATCC), mouse). The cell line was grown in DMEM with 10% FBS, and 1% penicillin/streptomycin.
Primary microglial cells were also used for some experiments and were prepared, as previously
described [27,28]. Mouse primary microglia were generated from new born mice (balb/c). Mice were
sacriﬁced according to a schedule 1 procedure. The procedure was endorsed by the Animal Welfare
and Ethics Review Board of the University of Bath and was in accordance with the Guidance on
the operation of the Animals (Scientiﬁc Procedures) Act 1986. Brains of the mice were dissected
and dissociated by both trypsinization and mild mechanical disruption. Cultures were seeded with
cells from 4–5 brains per 75 cm2 ﬂask. Cells were grown at 37 ◦C and 5% CO2 for two weeks in the
same medium as the microglial cell lines. The resultant cultures were mixed glial cultures composed
of predominantly astrocytes and microglia. Microglia were separated from other glia by partial
trypsinization, which causes the detachment of the overlying astrocytes [28]. The remaining cells were
then collected by further trypsinization and panning. Microglia have higher adhesiveness and most
remaining contaminating cells could be removed after 20 min of plating. The remaining adherent cells
were microglia. Routine veriﬁcation of purity was determined either by phenotype or by staining
with ferritin.
Microglia were cultured in high iron to induce a dystrophic/senescent phenotype. Microglial cell
lines were grown in medium containing in 500 μM ferric ammonium citrate for a minimum of two
weeks. Ferric ammonium citrate was prepared in deionized water at 25 mM and ﬁltered (0.22 μm ﬁlter)
before addition to cultures. Cell lines were maintained under these conditions until being used for
experiments. Primary microglia were treated with 500 μM ferric ammonium citrate while in mixed
glial cultures before puriﬁcation. Prior to experiments control and iron-fed primary microglia were
isolated from the mixed cultures and plated at 30% density in six well trays. Conditioned medium was
generated from microglial cell lines and primary microglia plated at 30% density. The medium used
for the generation of conditioned medium was DMEM supplemented with B27 without antioxidants
(Gibco, ThermoFisher, Waltham, MA, USA) and 1% pen/strep. Iron-fed microglia were extensively
washed to remove excess iron before medium was applied. Conditioned medium was collected after
48 h, centrifuged at 170× g to remove debris, and ﬁltered with a 0.45 μmﬁlter before use in experiments.
The cell density that was used to generate conditioned medium was conﬁrmed by lysing the cells after
collecting the conditioned medium and measuring the protein concentration using a Bradford assay
(Bio-Rad, Watford, UK). The data was normalized to this value.
2.2. Western Blotting
Cells were lysed in PBS with 0.5% Igepal CA-630 and ‘complete’ protease inhibitor cocktail
(Roche, Welwyn Garden City, UK), sonicated 20 s on ice, incubated on ice for 20 min, and
centrifuged 10,000× g for 5 min to remove insoluble membranes. Protein concentration was determined
with a Bradford protein assay (Bio-Rad), according to the manufacturer’s instructions. Protein
concentrations were normalized and the samples were boiled for 5 min with 1× Laemmli sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) buffer. Samples were loaded into
either a 10% or a 14% (depending on molecular weight of the protein) acrylamide SDS-PAGE gel,
with a buffer of Tris (250 mM) + glycine (1.92 M) + sodium dodecyl sulfate (SDS) (0.1% w/v), run
at 250 V/35 mA for 45–60 min. Separated proteins were transferred to a polyvinylidene diﬂuoride
(PVDF) membrane by a semi-dry transfer apparatus, run at 25 V/100 mA for 1.5 h. Membranes were
blocked in 5% w/v non-fat milk powder in TBS-T (Tris-buffered saline + 0.05% tween 20) for one
hour, incubated with primary antibody for 1–2 h or overnight, and washed 3 × 15 min in TBS-T.
Membranes were blocked again and incubated with horseradish peroxidase-conjugated secondary
antibody for 1 h. A further 3 × 15 min washes were performed, and the membranes developed with
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Luminata Crescendo or Luminata Forte ECL substrate (Millipore, Watford, UK) and imaged with a
Fusion SLCCD imaging system (Vilber Lourmat, Collégien, France).
Rabbit monoclonal anti-α-synuclein (MJFR1, Abcam, Cambridge, UK) was used for human
α-synuclein detection at a dilution of 1:4000. Mouse monoclonal anti-α-tubulin (T5186, Sigma) was
used at a dilution of 1:10,000. Anti-L-ferritin mouse monoclonal (SC-25616, Santa Cruz, Dallas,
TX, USA) was used at 1:5000, anti-Kv1.3 rabbit polyclonal was used at 1:400 (APC101, Alomone,
Jerusalem, Israel), and anti- Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mouse monoclonal
was used at 1:2000 (6C5, Abcam). Densitometry was carried out using ImageJ.
2.3. Detection of α-Synuclein Tetramers and Aggregates and Ferriductase Assay
Measurement of ferrireductase activity was performed on extracts of SH-SY5Y cells transfected
to overexpress human α-syn. The stable cell line and the method to measure the activity were
as previously reported [29]. Tetramers were detected by crosslinking the extracts with the
crosslinker, disuccinimidyl suberate (DSS) (Sigma), according to the manufacturer’s instructions
and as previously described [29]. Crosslinked species were detected with western blot, as described
above, for non-crosslinked α-syn. High molecular weight aggregates of α-syn were detected, as
previously described in cross linked samples of SH-SY5Y cells overexpressing α-syn [26].
2.4. Iron Assay
The levels of total iron in C8B4 cells and conditioned medium were determined using
a commercial assay (Abcam) and following the manufacturer’s instructions. Cellular iron content was
determined from four conﬂuent T25 ﬂasks and normalized to total protein content determined by
the Bradford assay. Conditioned medium was concentrated 10-fold using a Speedvac Concentrator
(Savant, ThermoFisher).
2.5. Reactive Oxygen Species Assay
The method to determine reactive oxygen species was based on Uy et al., 2011 [30]. Microglia
(both control and iron-fed) were re-plated to equivalent density. The medium of the cells was
replaced with serum free medium (DMEM) supplemented with B27 without antioxidants. After
24 h, the medium was collected from the microglia and then cleared by centrifugation at 10,000× g for
one min. Control medium (50 μL) was used as a blank. The assay was executed in a white 96 well
plate. 10, 20 30, 40, and 50 μL of the conditioned medium was plated into the plate and made up to
100 μL with distilled water. The assay was initiated by the addition of 100 μL of chemiluminescence
reagent (Luminata Crescendo, Millipore). The plate was incubated in the dark for ﬁve min before
reading. Measurements of luminescence were performed using the Omega FLUOstar plate reader
(MBG, Labtech GmbH, Offenburg, Germany) at 482 nm. Background was subtracted for all values.
2.6. Cytokine Quantitation
Analysis of cytokines present in conditioned medium was determined while using the Meso
Scale Discovery (MSD, Rockville, MD, USA) Sector S 600 multiplex imager system. The plate used
for the analysis was the V-Plex Proinﬂammatory mouse kit 1 (MSD). This kit allowed for the
assessment of the following cytokines: TNF-α, IFN-γ (interferon gamma), IL-1β, IL-2, IL-4, IL-5,
IL6 (interleukin-6), IL-10 (interleukin-10), IL-12p70 (interleukin-12p70), and KC/GRO (keratinocyte
chemoattractant/growth-regulated oncogene). Conditioned medium was prepared as described
above and ﬁltered through a 0.22 μm ﬁlter before applying to the plate as per the manufacturer’s
instructions. Concentrations were determined by comparison to a standard curve for each individual
cytokine. The values were adjusted for plating density by assessing the protein content of the cells
used to generate the conditioned medium while using the Bradford assay and dividing the cytokine
concentration by the protein concentration.
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2.7. Promoter Assays
SNCA Promoter fragments and assay conditions were as previously described [31]. SH-SY5Y cells
were performed in 24-well plates seeded at 5 × 104 cells/well 24 h prior to transfection. Transfections
of promoter constructs in pGL Basic (with ﬁreﬂy luciferase activity) were performed using FuGENE
HD transfection reagent (Promega), as per manufacturer’s instructions. To control for variation in
transfection efﬁciency among replicates, promoter constructs were co-transfected with the Renilla
luciferase vector, pRL-TK (Promega). At 24 h post transfection, SH-SY5Y cells were harvested and ﬁreﬂy
and Renilla luciferase chemiluminescence were measured while using the Dual-Luciferase Reporter
Assay System (Promega) in a BMG FLUOstar Omega plate reader (BMG Labtech GmbH, Offenburg,
Germany). Luciferase activity was calculated as the ratio of ﬁreﬂy to Renilla luciferase activity.
2.8. Proliferation Assay
Proliferation of C8B4 microglia was assessed using the Abcam BrdU proliferation ELISA kit
(ab126556, Abcam) according the manufacturer’s instructions. Both untreated and iron-fed C8B4
microglia were plated at equal density ranging from 2000 to 20,000 cells per well in 96-well trays.
The cells were exposed to BrdU (bromodeoxyuridine) for 24 h prior to starting the assay. Absorbance
was measured at 450 nm following the colorimetric assay.
2.9. Toxicity Assay
The level of cell death during treatment of C8B4 cells with 500 μM ferric ammonium citrate
was measured using the Roche Cell Death Detection ELISAPLUS kit. The procedure was carried out
following the manufacturer’s instructions. C8B4 cells were plated into 24 well trays at low density
(10%). The treatment was carried out over ten days (medium changed every two days). Measurements
of cell death were carried at 1, 2, 4, 6, 8, and 10 days of treatment. The level of cell death in iron-fed
cells was compared to that of untreated cells as a percentage.
2.10. Statistics
All of the statistics were carried out in Microsoft Excel. Statistical analyses were conducted using
a two-tailed Student’s t test, with statistical signiﬁcance at p-value of <0.05. Data are expressed as the
mean ± standard error (S.E.M.).
3. Results
3.1. Generation and Characterisation of a Senescent Phenotype in Microglia
We hypothesized that the senescent microglial phenotype might be related to changes in iron
storage. Iron (particularly Fe(II)) causes damage to macromolecules [32] and simply increasing the
levels of iron that is stored may be sufﬁcient to induce changes seen in the aged phenotype. For this
reason, we grew the murine microglial cell line C8B4 in 500 μm ferric ammonium citrate for at least two
weeks. The C8B4 cell line was used because it allowed for the production of large numbers of microglia
to facilitate the study. C8B4 cells grown under these conditions will be referred to as iron-fed microglia.
Iron-fed C8B4 microglia showed morphological changes that are similar to dystrophic microglia.
Under normal culture conditions (Figure 1A) C8B4 cells showed a small cell body with multiple
projections and frequent ramiﬁcation. In contrast, iron-fed microglia (Figure 1B) showed no
ramiﬁcation and little to no projections and frequent membrane fragmentation. We also examined
primary microglia for evidence of similar phenotypic changes. While primary microglia under normal
culture conditions showed projections (Figure 1C), iron-fed primary microglia were largely ameboid
with no projections at all (Figure 1D).
After two weeks of treatment, iron-fed microglia were analysed for changes in both iron content
and the iron storage protein ferritin. Cells were washed free of serum and iron and left for 24 h in
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serum free medium before harvesting in serum free medium. Analysis of the iron content of C8B4
microglia showed that there was an approximate ﬁve-fold increase in the amount of iron that is
present in the cells when iron-fed (Figure 2A). Conditioned medium generated from iron-fed microglia
showed no signiﬁcant increase in the amount of iron released (Figure 2B). Also, the level of iron
released/present in the medium conditioned by the microglia was lower than the amount if iron
present in the medium that these cells were normally cultured in (with 10% serum). Iron is mostly
stored within the protein ferritin in microglia and increased ferritin expression is associated with
a change to a dystrophic phenotype [9]. We assessed the level of L-ferritin in iron-fed C8B4 by western
blot (Figure 2C,D). Iron-fed microglia showed a very high (ﬁve-fold) increase in the level of ferritin
expressed. These results show that iron-fed microglia have a similar pattern of increased iron storage
as dystrophic microglia.
 
Figure 1. Phenotype of iron-fed microglia. Photomicrographs of microglia were prepared from both
C8B4 (A,B) and primary mouse microglia (C,D) in culture. The microglia were either grown in control
conditions (A,C) or grown in 500 μM ferric ammonium citrate (iron-fed, B,D). Both C8B4 and primary
microglia showed clear phenotypic changes when iron-fed. These include loss of the projections seen
in control cells (large arrow head) and the appearance of cytoplasmic fragmentation (small arrow).
Scale bare = 50 μm.
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Figure 2. Changes in iron storage C8B4 microglia that had been grown in the presence of high ferric
ammonium citrate were analysed for changes in iron content, iron release, and ferritin expression.
(A) We used a commercial kit to analyse the iron content of microglia grown in 500 μM iron for at
least two weeks. Microglia were washed three times before analysis to remove excess iron from the
medium. Extracts were then made from the microglia and the iron content determined for both control
and iron-fed microglia. The analysis showed a high and signiﬁcant (p < 0.05) change in the iron within
C8B4. (B) The level of iron released into the culture medium was assessed similarly. Conditioned
medium (B27 supplemented DMEM was produced from control and iron-fed C8B4 microglia by
exposing them for 24 h. The medium was concentrated 10-fold by lyophilisation and the concentration
compared to serum containing medium used to maintain the C8B4 microglia. While iron-fed microglia
showed no signiﬁcant increase in iron released in the medium compared to controls (p > 0.05) this
concentration was signiﬁcantly lower than found in normal serum supplemented conditioned medium
(p < 0.05). (C) The levels of L-ferritin were determined in iron-fed microglia by western blot. Protein
extracts were prepared and equal amounts of protein from control and iron-fed microglia were run
on a 10% PAGE gel, transferred to a membrane and L-ferritin was detected on the membrane with
a speciﬁc antibody. Another antibody was used to detect GAPDH to conﬁrm equivalent protein
loading. (D) The densitometric quantitation following normalization to GAPDH levels showed there
was a major and signiﬁcant (p < 0.05) increase in L-ferritin expression levels in iron-fed microglia.
Shown are the mean and S.E.M. of four experiments for each part.
3.2. Proliferation and Cell Death
We determined the impact of the iron-fed phenotype on the rate of proliferation of C8B4 microglia.
We used an ELISA assay based on BrdU (bromodeoxyuridine) incorporation. Both control and iron-fed
microglia were plated at a range of densities in serum free medium supplemented with B27 and
exposed to BrdU overnight. The level of incorporation of the label was then assessed according to
the manufacturer’s instructions. The level of BrdU incorporation was signiﬁcantly different between
iron-fed and control microglia at all plating densities except for the highest (Figure 3A). At the highest
density, cellular crowding probably impacted the rate of proliferation. However, the results suggest
that iron-fed microglia proliferate at a signiﬁcantly lower rate than control microglia.
We also wished to determine if C8B4 microglia experience cell death during the treatment that
results in the iron-fed phenotype. C8B4 microglia were exposed to 500 μM ferric ammonium citrate for
10 days. Cell death wasmeasured using an ELISA kit that assesses cytoplasmic histone-associated DNA
fragments. The assessment was carried out at 1, 2, 4, 6, 8, and 10 days of treatment and compared to the
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value that was obtained from the untreated control as a percentage. After one day of treatment there
was no signiﬁcant difference to the untreated control (Figure 3B). However, on all subsequent days
the level of cell death detected fell signiﬁcantly below that of the untreated control and the one-day
treatment. After day 2, there was no signiﬁcant change in the level of cell death. These results suggest
that the treatment with iron had no signiﬁcant toxic effect, and in fact there was a signiﬁcant reduction
in spontaneous cell death. However, it should be kept in mind that there was also a signiﬁcant
reduction in cell proliferation in iron-fed microglia, which would suggest that the difference observed
is a result of reduced cell number rather than reduced spontaneous cell death.
 
Figure 3. Proliferation and Cell Death (A) The rate of proliferation of C8B4 microglia was assessed
using a bromodeoxyuridine (BrdU) based ELISA kit. Both control and iron-fed microglia were plated
into a 96 well plate at a range of densities and grown overnight. BrdU was then added for a further 16 h
before the ELISA assay was used to assess incorporation levels. The level of incorporation was assessed
by a colorimetric assay with a read out at 450 nm. Iron-fed microglia showed signiﬁcantly lower levels
of proliferation at all plating densities other than the highest (p < 0.05). Shown are the mean and S.E.M.
of four separate experiments. (B) The level of cell death in C8B4 cells was assessed during their initial
treatment with 500 μM ferric ammonium citrate. C8B4 cells were plated in 24-well trays at low density
(20% conﬂuency). The cells were then treated with iron for up to 10 days. The level of cell death was
assessed using a commercial ELISA kit that determines the levels of histone associated DNA fragments
in the cytoplasmic fraction. The results showed a signiﬁcantly lower level of cell death in cells treated
with iron for 2–10 days (p < 0.05). Only cells treated for one day showed no signiﬁcant difference to the
untreated cells (p > 0.05). Shown are the mean and S.E.M. of four separate experiments.
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3.3. Altered Protein Expression in Iron-Fed Microglia
The characterization of the senescent microglia phenotype by altered protein expression remains
elusive, as there are currently no agreed changes that conclusively deﬁne microglia as being dystrophic.
However, a recent study suggested that aged microglia show an increase in the potassium channel
Kv1.3 [33]. We analysed the expression of Kv1.3 by iron-fed C8B4 using western blotting and found
a signiﬁcant increase relative to control cells (Figure 4). This suggests that similar to aged microglia,
iron-fed microglia expressed increased levels of this potassium channel.
Figure 4. Expression of the potassium channel Kv1.3. Protein extracts were prepared from control
and iron-fed C8B4 microglia. Western blot analysis was carried out to determine the level of Kv1.3
in the microglia. Bands for the protein were observed in both control and iron-fed microglia. Levels
of tubulin were also determined to verify protein loading. The results showed a signiﬁcant (p < 0.05)
elevation of Kv1.3 in iron-fed microglia. Shown are the mean and S.E.M. of four separate experiments.
3.4. Reactive Oxygen Species Production
One of the most common changes in microglia is an increased production of (ROS)upon activation.
We wished to assess whether iron-fed microglia also show a change in ROS production. We used
a simple spectrophotometric assay to assess the change in ROS generated by iron-fed C8B4 microglia
compared to control microglia. We generated conditioned medium from both kinds of microglia plated
at an equal density by exposure of the microglia to serum free medium with the B27 antioxidant free
supplement overnight. We applied increasing volumes of the medium to the assay and measured the
ROS generated. Iron-fed microglia produced signiﬁcantly higher levels of ROS than control microglia
(Figure 5). This suggests that iron-fed microglia show some aspects of an activated phenotype similarly
to aged microglia.
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Figure 5. Reactive oxygen species (ROS). Control and iron-fed C8B4 microglia plated at equal density
were exposed to serum free medium (without phenol red) for 24 h. Medium was collected and
centrifuged and assessed for ROS using a luminescence assay with detection at 482 nm. Medium
from iron-fed microglia showed signiﬁcantly (p < 0.05) higher levels of ROS than control microglia.
Shown are the mean and S.E.M. of ﬁve separate experiments.
3.5. Cytokine Expression
Cytokines produced by microglia constitute the single most signiﬁcant way that microglia interact
with other cells. Therefore, changes in cytokine expression would indicate a potential mechanism
by which dystrophic microglia could inﬂuence neuronal activity. A sensitive assay system was used
to measure the level of multiple proinﬂammatory cytokines produced by both C8B4 and primary
mouse microglia in culture. We analysed 12 different cytokines secreted into conditioned medium.
However, in both primary and C8B4 microglia a number of tested cytokines had expression levels
below the detection limits of the assay (IFNγ, IL-2, IL-4, IL-5, IL-8, IL-12p70, and IL-13). KC/GRO
was signiﬁcantly elevated in iron fed primary microglia but could not be detected in C8B4 microglia
(Table 1). IL-1β, IL-6, IL-10, and TNFα were detected in the conditioned medium of both cell types,
but the changes that were observed in the two cell types were only the same for TNFα and IL-6.
TNFα was signiﬁcantly elevated for both cell types when iron-fed and IL-6 was signiﬁcantly decreased.
Iron-fed C8B4 cells also showed an elevated level of IL-1β, but decreased levels of IL-10. In contrast,
iron-fed primary microglia showed decreased levels of IL-1β and increased levels of IL-10.
Table 1. Cytokine released into conditioned medium.
C8B4 Microglia Primary Mouse Microglia
Cytokine (ng/mg) Control Iron-Fed Control Iron-Fed
TNFα 142.82 ± 12.40 192.46 ± 5.52 * 37.42 ± 3.74 84.19 ± 3.45 *
IFNγ n.d. n.d. n.d. n.d.
KC/GRO n.d. n.d. 698 ± 16 2113 ± 398 *
IL-1b 2.93 ± 0.27 3.83 ± 0.22 * 0.99 ± 0.08 0.34 ± 0.03 *
IL-2 n.d. n.d. n.d. n.d.
IL-4 n.d. n.d. n.d. n.d.
IL-5 n.d. n.d. n.d. n.d.
IL-6 490.96 ± 49.77 430.77 ± 18.05 356.09 ±4 7.84 117.56 ± 24.22 *
IL-8 n.d. n.d. n.d. n.d.
IL-10 6.20 ± 1.04 0.84 ± 0.26 * 5.00 ± 0.37 10.34 ± 0.98 *
IL-12p70 n.d. n.d. n.d. n.d.
IL-13 n.d. n.d. n.d. n.d.
Serum free conditioned medium was generated from cultured microglia over 24 h and the levels of cytokines
assessed with the Meso Scale Discovery (MSD) ELISA system. Cytokine concentrations were determined by
comparison to a standard curve for each cytokine. Values were the concentration in the medium (ng/mL) divided
by the concentration of the protein in the cells that were used to generate the conditioned medium (mg/mL).
Shown are the mean (ng/mg) and S.E.M. for ﬁve (C8B4) and three (primary) different experiments. * Indicates
a signiﬁcant difference between control and iron-fed (p < 0.05). n.d. indicates not detectible due to the levels detected
being below the level of lowest standard on the standard curve for that cytokine.
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3.6. Conditioned Medium from Iron-Fed Microglia Caused Increased α-Synuclein Expression
Changes in α-syn expression can easily be assessed using western blotting of protein extracts
from cell lines, such as SH-SY5Y. Conditioned medium was generated from both control and iron-fed
C8B4 microglia plated at equal density (40%). Iron-fed C8B4 cells had been grown in 500 μM ferric
ammonium citrate for at least two weeks before use. The iron-fed cells were washed with fresh medium
to remove trace iron before production of conditioned medium. Serum free medium (DMEM and B27
without antioxidants) was applied to the C8B4 cells and the conditionedmedia were collected after 48 h.
The media were cleared of debris by centrifugation and ﬁltered before application to SH-SY5Y cells.
The conditioned media were applied to the SH-SY5Y cells for 24 h after which time protein extracts
were prepared from the cells. The level of expression of α-syn was determined by western blotting
and detection with a speciﬁc antibody to α-syn. Conditioned medium from control microglia had no
effect on α-syn expression while conditioned medium from iron-fed microglia showed an approximate
three-fold increase in the level of α-syn detected (Figure 6A). In comparison, 50 μM ferric ammonium
citrate had no effect on α-syn expression (Supplementary Figure S1). Additionally, conditioned
medium from the microglia had no effect on SH-SY5Y cell viability (Supplementary Figure S2).
As the effect on α-syn expression may have been related to the use of microglial cell lines
we sought to conﬁrm the effect by using primary mouse microglia isolated from new-born mice.
Mixed glial cultures were prepared and treated with 500 μM ferric ammonium citrate for at least two
weeks. Microglia were then isolated and puriﬁed from these cultures (along with controls that were not
iron-fed). Conditioned medium was then generated from these cultures and applied to SH-SY5Y for
24 h. Conditioned medium from iron-fed microglia but not controls caused an increase in expression
of α-syn, as assessed by western blotting (Figure 6B).
Figure 6. Increased levels of α-synuclein protein. SH-SY5Y (human neuroblastoma) cells were treated
for 24 h with serum free medium (control) conditioned medium from control (CM) and iron-fed
microglia (Iron-fed CM). The level of α-syn expressed by SH-SY5Y cells was assessed by western blot
using a speciﬁc antibody. Protein loading levels were assessed using western blot for tubulin. The effect
of conditioned medium from either (A) C8B4 or (B) Primary microglia was assessed and densitometric
analysis carried out (C). Compared to SH-SY5Y cells grown in serum free medium (control) conditioned
medium from control microglia (CM) had no signiﬁcant effect (p > 0.05). In comparison, conditioned
medium from iron-fed microglia (Iron-fed CM) caused a signiﬁcant increase (p < 0.05) in the levels of
α-syn protein detected. Conditioned medium from both C8B4 and primary microglia has a similar
effect. Shown are the mean and S.E.M. of four separate experiments.
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3.7. SNCA Promoter Activity Is Increased by Conditioned Medium from Iron-Fed Microglia
Change in α-syn expression may come from either increased transcription or decreased
breakdown of the protein. The ﬁrst step in assessing this process is to assay transcription of the protein
from its gene. In order to do this, we used three luciferase reporter constructs based on the α-syn SNCA
promoter [31]. The largest of these promoter fragments was 6.1 kb in size. Its 3′ end coincided with the
start codon of the α-syn ORF and was termed −6.1/ATG (Figure 7). Two further constructs included
smaller regions of this fragment. −6.1/−1.3 was missing a large 3′ section prior to the start codon
and −4.1/ATG was missing 2 kb from the 5′ end. The fragments were cloned into a ﬁreﬂy luciferase
expression vector and transiently transfected in SH-SY5Y cells in parallel with a renilla luciferase
expressing plasmid driven by the thymidine kinase promoter (pTK) to control for differences in cell
number and transfection efﬁciency. 24 h after transfection, the cells were treated with conditioned
medium either from control or iron-fed C8B4 microglia plated at equivalent density. After 24 h a dual
luciferase assay was performed on extracts from the SH-SY5Y cells. A signiﬁcant increase in luciferase
activity was seen with the reporters −6.1/ATG and −6.1/−1.3 when SH-SY5Y cells were treated with
conditioned medium from iron-fed microglia (Figure 7). No change was observed when conditioned
medium from control microglia was used. The smaller fragment −4.1/ATG showed a signiﬁcant
decrease in reporter activity when conditioned medium from both control and iron-fed microglia was
applied. The response of this smaller fragment did not explain the differences in protein expression
observed when conditioned medium from iron-fed microglia was applied to SH-SY5Y cells, whereas
the response of the −6.1/−1.3 reporter fragment matched the increase. These results suggest that the
increase in α-syn expression may be induced at the transcriptional level and it involve a transcription
factor that binds between −6.1 and −4.1 in the SNCA promoter.
3.8. Neutralisation of Cytokines Released from Iron-Fed Microglia Blocks Increased α-Synuclein Expression
We measured changes in the level of cytokines that is released by iron-fed microglia, as indicated
above. The most consistent change was in TNFα. There was also an increase in IL-1β for C8B4
microglia. Decreased cytokine levels were considered of no interest, as conditioned medium from
control microglia had no effect on α-syn levels. Therefore, we attempted to neutralize the increase
in α-syn that occurred in SH-SY5Y cells in response to treatment with conditioned medium from
iron-fed microglia. Conditioned medium from iron-fed microglia was applied to SH-SY5Y cells as
before. Some samples of conditioned medium were pre-treated with either an antibody to TNFα, IL-1β,
or an anti-rabbit IgG (150 ng/mL). After 24 h, the level of α-syn protein in the cells was determined
by western blot. Only neutralization with the TNFα antibody resulted in the reduction in measured
α-syn levels (Figure 8). This implies that the increased level of α-syn induced by iron-fed conditioned
medium is possibly caused by TNFα.
We tested whether TNFα or IL-1β could increase the expression of α-syn in SH-SY5Y cells.
SH-SY5Y cells were treated with 50 nM TNFα, 50 nM IL-1β, or both in serum free medium
supplemented with B27. After 24 h the levels of α-syn were assessed by western blot. Only TNFα
caused a signiﬁcant increase in α-syn levels (Figure 9A,B). The combination of TNFα and IL-1β was
not signiﬁcantly different to TNFα alone. We also tested the effects of the same cytokines on the activity
of the SNCA promoter fragment −6.1/−1.3. The luciferase reporter fragment was transfected into
SH-SY5Y cells and treatedwith 50 nMTNFα, 50 nM IL-1β, or both in serum freemedium supplemented
with B27. The measured luciferase activity showed a signiﬁcant increase in the promoter activity in
SH-SY5Y cells when treated with TNFα but not IL-1β (Figure 9C). These results combined suggest
that the molecule released from iron-fed microglia that increased α-syn expression is TNFα.
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Figure 7. SNCA transcriptional activity. We wished to determine if the change in α-syn protein
levels in cells treated with iron-fed microglial conditioned medium was due to a change in activity of
the promoter of cytosolic protein alpha-synuclein (α-syn), SNCA. We used three reporter constructs
containing fragments of the SNCA promoter that drive luciferase expression when transcriptionally
active. The fragments are illustrated by the schematic which shows the overlap with the main features
of the SNCA promoter. −6.1/ATG covers the majority of the promoter as well as the 5′ non-coding
domain prior to the start codon. −6.1/−1.3 covers the same part of the promoter as −6.1/ATG but
excludes the non-coding exons. The fragment −4.1/ATG excludes 2 kb of the sequence at the 5′ end of
the promoter. SH-SY5Y cells were transiently transfected with the three constructs and the cells were
treated for 24 h with either serum free medium (control), conditioned medium from C8B4 microglia
(CM) or conditioned medium from iron-fed C8B4 microglia (FeCM). Readout of luciferase activity
showed that conditioned medium from C8B4 microglia had no signiﬁcant effect on the −6.1/ATG
or −6.1/−1.3 promoter fragment, while iron-fed conditioned medium caused a signiﬁcant increase
(p < 0.05) in activity. In contrast the conditioned medium from both kinds of microglia decreased
the activity seen with the −4.1/ATG fragment. The difference in activity suggests that the change in
expression of α-syn may come from binding of a transcription factor between −6.1 and −4.1 on the
SNCA promoter in response to a factor in iron-fed microglia conditioned medium. Shown are the mean
and S.E.M. of four separate experiments.
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Figure 8. Cytokine Neutralization SH-SY5Y. Cells were treated with conditioned medium from iron-fed
C8B4 microglia pre-treated with antibodies in an attempt to neutralize cytokines present that may be
responsible for inducing increased expression of α-syn. We tested the effect of antibodies to TNFα,
IL-1β and as a control, rabbit IgG. Medium was treated with 150 ng/mL of the speciﬁc antibody for
one hour before applying to the SH-SY5Y cells. After 24 h western blot was used to assess the level
of α-syn protein and tubulin to compare loading. On the antibodies tested only anti- TNFα caused
a signiﬁcant (p < 0.05) reduction in the level of α-syn detected. Shown are the mean and S.E.M. of four
separate experiments.
3.9. Increased α-Synuclein Expression Induced by Iron-Fed Microglia Was Mediated by the NF-κB Pathway
The two predominant pathways that are involved in signalling to the nucleus via TNFα occur
through either JNK(c-Jun N-terminal kinase)/AP-1 or NF-κB (nuclear factor kappa-B). Potentially,
increased α-syn expression that is caused by the conditioned medium from iron-fed microglia could
be mediated through either pathway (or both). We used inhibitors of both JNK and NF-κB to
determine whether blocking these pathways could prevent the increase in α-syn that is caused
by the conditioned medium. 200 nM JNK inhibitor II (CAS129-56-6) [34], 25 μM JNK inhibitor XV
(IQ-1S, CAS1421610-21-0) [35], and 300 nM NF-κB inhibitor IV (CAS 139141-12-1) [36] were applied
to SH-SY5Y cells treated with C8B4 iron-fed conditioned medium for 24 h. The concentrations used
were based on concentrations used effectively in the cited papers. After western blotting and detection
of α-syn, the strongest inhibitory effect on α-syn expression was seen with the NF-κB inhibitor IV
(Figure 10). While signiﬁcant inhibition was also seen with the JNK inhibitor XV, there was no
signiﬁcant inhibition with JNK inhibitor II. These results suggest that the increased expression of
α-syn induced by the iron-fed microglia conditioned medium is mediated through NF-κB but with the
possibility that some of the effect is also mediated by the JNK pathway.
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Figure 9. Cytokines and α-synuclein expression. (A) We tested cytokines to determine if they could
induce increased expression of α-syn in SH-SY5Y cells. SH-SY5Y cells were grown in serum free
medium and 50 ng/mL of either mouse TNFα, IL-1β, or both was applied to the cells twice in a 24 h
period. Western blot was then carried out to assess α-syn expression levels. Tubulin was also assessed
as a loading control. (B) Analysis showed that only TNFα or TNFα/IL-1β caused an increase in
α-syn expression. As IL-1β had no signiﬁcant effect this result was only due to the presence of
TNFα. (C) We also tested the effects of the cytokines on the activity of the SNCA promoter reporter
−6.1/−1.3 which showed the strongest response to iron-fed conditioned medium. The SH-SY5Y cells
transiently transfected with the reporter were treated similarly with the cytokines. Luciferase activity
was signiﬁcantly (p < 0.05) increased only for cells treated with TNFα alone or in combination with
IL-1β. Shown are the mean and S.E.M. of four separate experiments.
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Figure 10. Inhibitors of signaling pathways. In order to assess the role of both the JNK pathway and
NF-κB pathway in the increased expression of α-syn in response to conditioned medium from iron-fed
C8B4 microglia, we applied a series of inhibitors of these pathways to SH-SY5Y cells during treatment
with the conditioned medium. The compounds used were two inhibitors of the JNK pathways (JNK 2
and JNK 15) and one inhibitor of the NF-κB pathway (NF-κB 4). As the inhibitors were soluble in
methanol we also included a methanol control at the highest volume used. After a 24 h treatment,
the levels of α-syn and tubulin were assessed by western blot. The strongest inhibition was seen with
the NF-κB 4 inhibitor. The inhibitory effect of JNK 2 was also signiﬁcant (p < 0.05) but the effect of JNK
15 was not. Shown are the mean and S.E.M. of four separate experiments.
3.10. Conditioned Medium from Iron-Fed Microglia Caused a Decrease in α-Synuclein Activity
We have shown previously that α-syn is able to reduce iron through ferrireductase activity [37].
This activity is present in vivo [38] and the active form of the protein is a tetramer [29]. Tetrameric
α-syn has also been suggested to be the native form of α-syn [39] and its loss from the cell might
lead to the formation of disease speciﬁc oligomers [40]. We analysed ferrireductase activity in cells
overexpressing α-syn when exposed to the conditioned medium from iron-fed microglia. Conditioned
medium from C8B4 control microglia had no signiﬁcant effect on the measured ferrireductase activity
(Figure 11), whereas conditioned medium from iron-fed microglia caused a signiﬁcant reduction in the
activity measured. As ferrireductase activity is associated with the tetrameric form of the protein we
also assessed whether there was a change in the level of tetramers present in α-syn overexpressing cells
that are exposed to conditioned medium from iron-fed microglia. α-syn tetramers can be identiﬁed
in SH-SY5Y cells by cross-linking protein extracts from the cells. Tetramers can then be observed by
western blot. SH-SY5Ys that are treated with conditioned medium from iron-fed microglia showed
signiﬁcantly reduced levels of tetramers when compared to cells treated with conditioned medium
from control microglia (Figure 11). This data suggests that conditionedmedium from iron-fedmicroglia
reduced the formation of α-syn tetramers, and consequentially reduced the ferrireductase activity of
α-syn measured in SH-SY5Y cells.
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Figure 11. Ferrireductase activity and tetramers. (A) α-syn possesses ferrireductase activity and
SH-SY5Y cells overexpressing α-syn show increased levels of iron reduction. We measured the
ferrireductase activity in SH-SY5Y cells stably overexpressing α-syn. The cells were exposed to
conditioned medium from either control C8B4 microglia or iron-fed microglia for 24 h. Protein extracts
were made and the initial rate determined for a concentration of 500 μM ferric ammonium citrate
using a standard ferrireductase assay based on colour change associated with the binding of Fe(II) to
ferrozine. The results show that conditioned medium from iron-fed microglia signiﬁcantly (p < 0.05)
decreased measured ferrireductase activity while that from control microglia did not. Shown are the
mean and s.e. of four separate experiments. (B,C) α-syn ferrireductase activity has been shown to be
due to the presence of tetramers of α-syn in the cell membrane. We therefore measured the presence of
α-syn tetramers in membrane extracts of α-syn overexpressing SH-SY5Y cells. Protein extracts were
prepared from membrane fractions and cross-linked with DSS. Western blot was then used to assess
the presence of monomers, dimers and tetramers of α-syn in the extracts. While treatment with C8B4
conditioned medium had no effect on the ratio of tetramers to dimers and monomers, treatment with
conditioned medium from iron-fed C8B4 microglia caused a signiﬁcant (p < 0.05) reduction in the levels
of both tetramers and dimers. Shown are the mean and S.E.M. of four separate experiments.
3.11. Aggregation of α-Synuclein
The aggregation of α-syn into oligomeric species is considered to be a major hallmark of diseases
that are associated with α-syn. Aggregates of α-syn can frequently be detected in cells overexpressing
the protein. We had previously developed a western blot assay to detect oligomeric aggregates
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of α-syn [26]. SH-SY5Y cells overexpressing α-syn were treated with conditioned medium from
primary control microglia or iron-fed microglia for 24 h. Extracts were prepared from the SH-SY5Y
cells and electrophoresed on a PAGE gel. After western blot and detection with a speciﬁc antibody,
high molecular weight (>300 kD) bands of α-syn oligomers were detected. Treatment with control
microglia conditioned medium had no signiﬁcant effect on the levels of aggregates detected (despite
a high level of variability). However, treatment with conditioned medium from iron-fed microglia
results in a large and signiﬁcant increase in the level of aggregates detected (Figure 12). This implies that
conditioned medium from iron-fed microglia is able to induce the aggregation of α-syn independently
of its effect on protein expression. A similar result was observed with conditioned medium from C8B4
cells (data not shown).
Figure 12. Aggregation of α-syn. Western blot was used to detect high molecular weight aggregates
of α-syn in extracts from SH-SY5Y cells treated with conditioned medium from primary microglia.
SH-SY5Y cells were treated for 24 h with medium from control microglia (CM) or iron-fed microglia
(Iron-Fed CM). Some cells were treated with just serum free medium (control). Extracts were prepared
and electrophoresed on a 6% PAGE gel. The protein was then transferred by blot to a PVDF membrane
(3 h, 100 mA) and α-syn detected with a speciﬁc antibody. High molecular weight bands for α-syn
were indicative of aggregates. We also veriﬁed protein loading by re-probing the same blots for tubulin.
Bands for α-syn were then analysed densitometrically. Values for control were normalised to 100% and
values for the treated samples compared. Only treatment with iron-fed conditioned medium caused
a signiﬁcant (p < 0.05) increase in α-syn detected in the aggregate band. Shown are the mean and S.E.M.
for four separate experiments.
4. Discussion
The aim of the work presented here was to establish a model of microglia that could be used
to replicate aspects of the aging brain. The study of both normal aging and neurodegenerative
diseases is compromised by the lack of effective models of the aging brain. Neurodegenerative
diseases are predominantly associated with aging, as it is considered the single most important risk
factor for their development. However, studies rarely ever incorporate conditions related to the
aging phenotype. This is particularly hampered by poor deﬁnition of exactly what changes are
important to consider. Numerous reports described changes in oxidative stress [41], by-products of
oxidative damage [42], or trace metals that can themselves induce oxidative stress and subsequent
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by-products [43]. Here, we have utilized knowledge of the phenotype of dystrophic microglia to
modify a microglial cell line and combine it with the study of disease-associated changes in α-syn.
Developing amodel of senescent/dystrophic microglia in vitro has numerous issues. Chief among
these is the lack of clarity in deﬁning dystrophic microglia [13]. There is currently no single molecular
marker that would deﬁne a dystrophic or senescent microglial cell. Proteomics/transcriptomics based
studies comparing microglia from old and young brains have been carried out for both mouse and
human but have yielded conﬂicting results [44–47]. However, there is a general cellular senescence
signature that all cells show and this is no different for microglia, which also show characteristics
aligning with a senescence-associated secretory phenotype [48].
The second hurdle for generating an in vitro model is the difﬁculty in using primary microglia.
Isolated primary microglia rapidly change phenotype [49–51], microglia from adult mice are
difﬁcult to maintain [52] (there are still very few studies using them), and pushing microglia
into a senescent/dystrophic phenotype reduces both their yield and viability. For these reasons,
we predominantly used a microglial cell line as this allowed for us to generate large numbers of
microglia with our iron-fed phenotype.
Dystrophic microglia in the aging brain do have a number of clear differences to normal resting
microglia. These include morphological changes, such as loss of processes, increased iron storage,
and increased expression of ferritin [9,10,13,53–55]. Of considerable interest to us was the evidence
for increased iron storage. While in a normal aging situation the accumulation of iron is likely
a consequence of the aging process, iron is highly associated with the risk of oxidative damage,
a hallmark of aging. Therefore, a possibility exists that increasing iron storage experimentally would
induce the changes observed in dystrophic microglia in vivo. There is already considerable evidence
that iron-overload can induce senescent changes in cells including microglia [56–58]. In this light,
our ﬁnding that cultured microglia maintained in a high iron environment adopt characteristics of
dystrophic microglia is not surprising.
As our iron-fedmicroglia are amodel of dystrophic microglia they also demonstrate characteristics
of the senescence-associated secretory phenotype (SASP) referred to previously. This includes the
reduced proliferation and increased release of pro-inﬂammatory cytokines such as TNFα. A recent
study has suggested that the potassium channel Kv1.3 is increased in expression in aged microglia [33].
This was a ﬁnding we also conﬁrmed in our iron-fed microglia. Further study from the same group
showed that in aged mice, Kv1.3 was associated with release of pro-inﬂammatory cytokines including
TNFα [59]. Therefore, increased expression of Kv1.3 and its subsequent down-stream effects are likely
a part of SASP.
As mentioned above, our aim was to develop a model of aged microglia that could be applied to
the study of neurodegenerative diseases. Microglia and also dystrophic microglia have been implicated
in many neurodegenerative diseases [5,55,60]. We chose to concentrate on synucleinopathies on the
basis of our previous experience studying the role of α-syn in disease models. There is strong evidence
that microglia play a role in synucleinopathies, such as PD [61], multiple system atrophy [62], and
Dementia with Lewy Bodies [24,63]. There is currently also considerable interest in the impact of
age-related changes to microglia in PD [8,64] and it has even been suggested to be causative of
neurodegeneration in the substantia nigra [23,65].
Synucleinopathies are associated with the aggregation of α-syn in cells and this is believed to
stem from two causative processes. The ﬁrst and most well recognized is an increased expression
of α-syn, resulting in molecular crowding [66,67]. The second and more controversial is the more
recent suggestion that the native and functional form of α-syn is a tetramer and loss of tetramer
formation increases the likelihood of aggregation [40]. Using conditioned medium from our model
dystrophic microglia, we were able to induce increased α-syn expression, reduced tetramer formation
and increased aggregation in SH-SY5Y cells. Thus, by the incorporation of an aspect of brain aging we
were able to induce several aspects of the disease state in neuronal cells. For this reason, we believe
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that we have developed a simple and valuable tool for the exploration of the molecular mechanisms
behind synuclein related diseases and possibly other neurodegenerative diseases.
The ability of conditioned medium from iron-fed microglia to induce changes in α-syn in SH-SY5Y
cells implies that a soluble factor released by the microglia is responsible. We showed that the levels
of iron released from the iron-fed microglia are small and application of iron to SH-SY5Y does not
cause the same response. There is also no evidence in the literature that iron levels alter α-syn
transcription. In contrast, we were able to show that iron-fed microglia release increased levels of
TNFα, neutralization of TNFα blocks the increased α-syn expression and that exogenous TNFα also
induced increased α-syn expression and transcription. This implies that TNFα mediates the effects
we observed. This result is further supported by ﬁndings showing that an inhibitor of NF-κB blocks
the increased expression as well. TNFα effects on protein expression via transcriptional activation
are frequently mediated through an NF-κB controlled pathway [68]. There have been few papers
linking TNFα and α-syn, but one paper has shown that TNFα increases α-syn in control human iPS
cells [69]. Another paper did suggest that TNFα released by microglia could impair autophagic ﬂux
and this increased α-syn levels through decreased breakdown of the protein [70]. It is also possible
that decreased autophagy could contribute to the increased levels of α-syn that we observed. Similarly,
there been very few reports that α-syn expression can be increased by NF-κB, even though it has been
reported there are NF-κB binding sites on SNCA [69]. Our data showed that there is a fragment of
the SNCA promoter that appears to be necessary for TNFα-driven induction of expression (between
−6.1 and −4.1 kb) and analysis with online transcription factor binding site software (Match, Biobase,
Germany) identiﬁed at least three potential binding sites in this region for NF-κB. Analysis of patients
with PD has shown increased TNFα levels and increased nuclear localisation of NF-κB in neurons and
microglia in the substantia nigra [71]. In general, there is a signiﬁcant amount of data implying that
NF-κB activation might be relevant to PD [72–74]. This suggests our model might have relevance to
the changes observed in PD.
TNFα is not the only cytokine that is altered in Parkinson’s disease [75]. Many studies look at
cytokines that are released by microglia in response to α-syn rather than changes in microglial released
cytokines that could alter neuronal activity in PD [76]. In this regard, aggregates of α-syn induced
neurotoxic effects that are mediated by microglia through the activation of Toll-like receptor 2 [77].
We also observed other changes in cytokines other than TNFα. However, these appeared to have no
impact on α-syn expression such as IL-1β or were higher in control microglia than the iron-fed ones.
In this case, as we saw no change in α-syn expression when treated with control conditioned medium
versus untreated, the levels of these cytokines, regardless of how they changed, had no impact on
α-syn. While the microglia that we used were murine in origin and the SH-SY5Y cells were human,
most murine cytokines are able to bind to human cytokine receptors, the most notable exception being
IL-10 where the murine form cannot bind to the human IL-10 receptor [78].
We noted other changes in α-syn that we have not linked to TNFα. These include tetramer
formation and ferrireductase activity. However, the regulation of both of these aspects of α-syn activity
is currently unknown. We have previously shown that tetramer formation is connected to increased
ferrireductase activity, while increased aggregation is linked to a loss of this activity [29,38]. The process
of aggregation of α-syn is likely to require the protein to initially pass through small oligomeric states.
However, the stable tetramer that is expressed in cells is supposed to be highly structured with
a helical conﬁguration and its formation is suggested to prevent higher order oligomerization and
aggregation [39,79]. We also observed that conditioned medium from iron-fed microglia induced
increased levels of aggregation. Aggregation of α-syn into potentially toxic oligomeric species is
considered to be one of the hallmarks of synucleinopathies [80,81]. As this is accompanied by
a reduction in tetramer formation, this change possibly represents themechanism bywhich aggregation
could occur in diseases, like PD. This model system therefore may be of beneﬁt in analysing the
mechanics of conversion of α-syn from its normal cellular isoform to the oligomeric aggregates
generated in disease.
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5. Conclusions
In summary, we have created a model to incorporate an aspect of brain aging into the study
of α-syn. This model is able to recapitulate a number of changes that are observed in diseases,
like Parkinson’s disease. These changes include increased expression, aggregation, reduced tetramer
formation and ferrireductase activity of α-syn. The model incorporates a potential in vitro dystrophic
microglia component. By overloading microglia with iron, we have shown that they behave similarly
to dystrophic microglia, altering their morphology, iron storage, protein expression and cytokine
release. The utility of these model dystrophic/senescent microglia will allow for further study of both
the ontology of dystrophic microglia and the potential role of such microglia in neurodegenerative
disease. This may allow for more robust in vitro models for the study of these complex diseases.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/8/3/
67/s1. Supplementary Figure S1 Iron and α-synuclein expression, Supplementary Figure S2 Toxicity of
Conditioned Medium.
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Supplementary Figure 1 Iron and α-synuclein expression. 
SH-SY5Y cells were grown in serum free medium for 24 h. Control cells were grown only in the 
serum free medium while iron treated cells (Fe) were grown in 50 ?M ferric ammonium citrate. After 
24 h the cells were harvested, and protein extracted. Equal amounts of protein were eletrophoresed 
on a 14% PAGEgel. After semi-dry transfer to a membrane α-syn was detected with a specific 
antibody (MJFR1) and bands detected with chemiluminescence.  The detected bands were 
quantitated densitometrically. The process was repeated after stripping the blot and tubulin was 
detected with a monoclonal antibody. Treatment with iron had no effect on the levels α-syn detected. 
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Supplementary Figure 2: Toxicity of conditioned medium.  
The toxicity of conditioned medium from C8B4 microglia was tested on SH-SY5Y cells. The cells 
were treated for 24 h with either serum free medium (SFM), conditioned medium from control 
microglia (Control) or iron-fed microglia (Iron-Fed). The survival after 24 h was determined using an 
MTT viability assay. Neither the medium from control microglia nor iron-fed microglia had any 
significant (p > 0.05) effect on SH-SY5Y cell viability when compared to SFM. Shown are the mean 
and S.E.M for four separate experiments with three replicates each.  
© 2018 by the authors. Submitted for possible open access publication under the  

















3.5 Concluding commentary 
 
The findings of the previous chapter suggest that the changes in microglia induced by iron 
are broadly replicated between species and in primary culture. This suggests that our 
model of senescent microglia is robust and reproducible can be used in different model 
systems with similar effect.  
 
Although the changes we saw in human and mouse microglial cells were similar, some 
discrepancies were noted. Namely, differences in cytokine production were present in 
human and mouse microglia. Even though the cytokine expression profile in both iron-fed 
human and mouse microglia was decidedly pro-inflammatory, no changes in TNFα levels 
in iron-fed human microglia were reported while in Chapter 3 elevated TNFα was central 
to the effect observed on α-synuclein. As TNFα secretion is known to be increased in 
aged human microglia and in the context of PD it is possible that the very low TNFα levels 
seen in the human microglial cell line are a feature of this specific cell line.  
 
Figure 3.1 shows an alternative western blot to Figure 10 presented in the paper and 
illustrates that the NF-κB and possibly the JNK pathways are likely involved in mediating 
the effect of TNFα on α-syn. 
 
 
Figure 3.1 Inhibitors of signalling pathways. In order to assess the role of both the JNK 
pathway and NF-ᴋB in the increased expression of α-syn in response to conditioned 
medium from iron-fed microglia, we applied a series of inhibitors of these pathways to SH-
SY5Y cells during treatment with the conditioned medium. The compounds used were two 
inhibitors of the JNK pathways (JNK 2 and JNK 15) and one inhibitor of the NF-ᴋB 
pathway (NF-ᴋB 4). As the inhibitors were soluble in methanol, we also included a 
methanol control at the highest volume used. After a 24 h treatment the levels of α-syn 
and tubulin were assessed by western blot. 
 
The effects of microglial TNFα on α-synuclein in neuronal cells shown in this paper 
provide a link between age-related changes in microglia and the pathology of PD as it 
demonstrates that a cytokine released by aged microglia has the ability to increase the 
expression of α-synuclein. The downstream effects of elevated α-synuclein levels will be 
investigated in the work presented in the next chapter. 
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4. Levels of α- and β-synuclein regulate cellular 
susceptibility to toxicity from α-synuclein oligomers 
4.1 Introductory commentary 
In chapter 3 it was demonstrated that the senescent microglia model can increase α-
synuclein levels in SHSY5Y neuronal cells. Increased α-synuclein expression has been 
linked to the pathology of PD and other synucleinopathies.  
 
In this paper we investigate how increased expression of α-synuclein can affect neurons 
and how those effects are mediated. It was found that elevated levels of α-synuclein affect 
the susceptibility of SHSY5Ys to toxic α-synuclein oligomeric species generated in vitro 
using an MTT assay. This was investigated not only in cells that overexpressed α-
synuclein but also in cell lines overexpressing structural mutant forms of α-synuclein to 
understand whether particular domains of α-synuclein play a role in the susceptibility to 
toxic oligomers. β-synuclein has been reported to be protective against α-synuclein 
neurotoxicity. β- and γ-synuclein were also overexpressed and their effects on neuronal 
viability were compared. 
 
As detailed in Chapter 1 FOXO3a is a transcription factor whose activity is heavily 
implicated in neurodegeneration including PD and in aging. FOXO3a can trigger neuronal 
apoptosis. Therefore it was highly likely that FOXO3a activity mediated the neuronal 
toxicity caused by elevated α-synuclein levels. We investigated the FOXO3a pathway in 
the context of α-synuclein toxicity by measuring FOXO3a levels with western blotting and 
inhibiting FOXO3a. Inhibition of FOXO3a in SHSY5Y cells was protective against α-
synuclein toxic oligomers. As presented in chapter3 increased levels of α-synuclein 
resulted in elevated ferrireductase activity. In this chapter we investigated whether the 
increased levels of Fe2+ generated by α-synuclein can increase FOXO3a activation by 
altering iron levels in the cell and measuring FOXO3a levels by western blot. We found 
that both increased iron and overexpressing the ferrireductase Steap3 resulted in elevated 
FOXO3a levels while elevated β-synuclein did not.  
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ABSTRACT: a-Synuclein (a-syn) is associatedwith a range of diseases, includingParkinsondisease. Indisease,a-syn
isknowntoaggregateandhas thepotential tobeneurotoxic.Theassociationbetweencopperanda-synresults in the
formation of stellate toxic oligomers that are highly toxic to cultured neurons. We further investigated the mecha-
nism of toxicity of a-syn oligomers. Cells that overexpress a-syn showed increased susceptibility to the toxicity of
the oligomers, while those that overexpressed b-syn showed increased resistance to the toxic oligomers. Elevated
a-syn expression caused an increase in expressionof the transcription factor ForkheadboxO3a (FoxO3a). Inhibition
of FoxO3a activity by the overexpression ofDNAbindingdomain of FoxO3a resulted in significant protection from
a-syn oligomer toxicity. Increased FoxO3a expression in cells was shown to be caused by increased ferrireductase
activity and Fe(II) levels. These results suggest that a-syn increases FoxO3a expression as a result of its intrinsic
ferrireductase activity. The results also suggest that FoxO3aplays apivotal role in the toxicity of both Fe(II) and toxic
a-syn species toneuronal cells.—Angelova,D.M., Jones,H.B. L.,Brown,D.R.Levels ofa- andb-synuclein regulate
cellular susceptibility to toxicity from a-synuclein oligomers. FASEB J. 32, 000–000 (2018). www.fasebj.org
KEY WORDS: FoxO3a • iron • Parkinson disease
a-Synuclein (a-syn) is associated with a number of neu-
rodegenerativediseases, includingParkinsondisease (PD),
dementia with Lewy bodies, the Lewy body variant of
Alzheimer disease (AD), and multiple system atrophy.
Fibrillar aggregates of a-syn are the main constituent of
Lewy bodies and Lewy neurites associated with these
diseases (1, 2). Extracellular a-syn is present as aggregates
inboth the substantia nigraofpatientswithPD(2) andsenile
plaques ofADbrains in the formof the non-Ab component
ofAD,knownasNAC(3, 4).Clear linksbetweena-synand
neurodegeneration have been found. Neuronal cell loss
and Lewy body–like inclusions occur in animal models
overexpressing a-syn (5), and the rescue of dopaminergic
cells from death occurs after down-regulation of a-syn
expression in the substantia nigra of a PD rat model (6).
Inherited mutations in familial cases of PD also illustrate
the importance of a-syn to pathology. Inherited cases are
linked to bothpointmutations (7, 8), leading to single point
changes in the protein sequence (e.g., A30P, E46K, A53T),
and triplication of the a-syn gene (SNCA) locus (9).
The prevalence of fibrillar aggregates of a-syn asso-
ciated with neurodegenerative diseases has led many
authors to hypothesize that the aggregates cause cell
death (1, 10, 11). However, the survival of neurons with
intracellular Lewy bodies shows that the presence of
intracytoplasmic a-syn aggregates is not toxic to all cells
(2). Considerable evidence suggests that oligomers, formed
as prefibrillar intermediates, may be the toxic component
(12–14). In addition, there is evidence that extracellular
a-syn is neurotoxic. Recombinant a-syn, which readily
assembles into filaments in vitrowith similarmorphology,
staining, and structure to a-syn filaments extracted from
diseased brains, is toxic to cells when added to the culture
medium, particularly in its aggregated form (15–22). The
higher levels of a-syn oligomers in cerebrospinal fluid of
patients with PD support a hypothesis that extracellular
a-syn oligomers may be neurotoxic (23). However, the
toxic species and mechanism of toxicity are still unclear.
Although there is considerable and extensive evidence
for the role of aggregates of a-syn in a variety of diseases,
there is less evidence for its normal cellular role. There are
currently two theoriesabout the functionofa-syn.The first
suggests that it mediates the release of dopamine (24),
while the second and more recent suggests that it enzy-
matically reduces iron (25). There is considerable evidence
ABBREVIATIONS: AD, Alzheimer disease; a-syn-TO, toxic oligomers of
a-syn; D2–9, mutant of a-syn or b-syn lacking amino acid residues 2–9;
D2–9/H50A, mutant of a-syn lacking amino acid residues 2–9 and with
histidine residue at position 50 mutated to alanine; D2–9/H65A, mutant
of b-syn lacking amino acid residues 2–9 and with histidine residue at
position 65 mutated to alanine; DBD, DNA-binding domain; FoxO3a,
Forkhead box O3a; H50A, histidine residue at position 50 mutated to
alanine in a-syn; H65A, histidine residue at position 65 mutated to alanine
in b-syn; MTT, (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide; ORF, open reading frame; PD, Parkinson disease; p-FoxO3a,
phosphorylated FoxO3a; ROS, reactive oxygen species; syn, synuclein; T-
FoxO3a, all forms of FoxO3a; ThT, thioflavine T; WT, wild type
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that a-syn binds to copper and iron (25–30). a-Syn has
been shown to be a ferrireductase both in vivo and in vitro,
and it has also been shown to have reduced activity in PD
(31). Detail kinetics studies have shown a-syn ferrir-
eductase activity is regulatedby substrate inhibition and is
membrane associated, and that the active form is a tetra-
mer (32). Overall, there is strong evidence for a link
between a-syn and iron metabolism.
There is compelling evidence for a role in many neu-
rodegenerative diseases for the loss of homeostasis of the
redox active transition metals iron and copper and the
resulting oxidative stress. High levels of copper, zinc, and
iron are found in and around amyloid plaques in AD
brains (33). In PD brains, high levels of iron and zinc are
found in the substantia nigra (34) and high levels of copper
in the cerebrospinal fluid (35).Whilea-synbinds to copper
and iron (25–30), a-syn aggregation is also stimulated in
the presence of these metals (26, 29, 36). This has led us to
examine whether the toxicity of extracellular synuclein
proteins is exacerbated in the presence of metals. We have
shown that the toxicityofa-synaggregates increases in the
presence of metals, in particular copper (37). This effect
was not replicated with the a-syn homologs b-syn or
g-syn. The toxicity is caused by unique stellate soluble
a-syn oligomers formed through morphologic change
in the presence of copper. Our findings suggested that
oligomerization of a-syn, combined with a loss of metal
homeostasis, may be a key to the neurodegeneration ob-
served in these diseases.
While initiation of cell death is a critical point in
understanding the possible role of a-syn in cell loss in
diseases like PD, cell death execution is possibly more in-
teresting for potential intervention. From this point of
view, the Forkhead box transcription factor family has
gained increasing prominence both in the study of aging
and neurodegeneration (38, 39). The relevance of Fork-
head box O3a (FoxO3a) to the study of a-syn and PD has
recently been shown by two articles. The first demon-
strated increased and ectopic expression of FoxO3a in PD
brains (40). The second study, using transgenic rats,
demonstrated that the level of a-syn–induced neuron loss
in the substantia nigra was increased by increase FoxO3a
expression or reduced by overexpression of the DNA
binding domain of FoxO3a (41). Therefore, understanding
the potential role of FoxO3a in a-syn toxicity is of great
importance.
In the current study, we found that FoxO3a plays a
major role in toxicity induced by aggregated a-syn. Levels
of expression of FoxO3a were modulated by levels of
iron, which were dependent on ferrireductase activity of
cellulara-syn.We found that the relative expression levels
of botha-syn andb-syn play a critical role in susceptibility
of SH-SY5Y cells to the toxicity of exogenous a-syn olig-
omers. These findings may have important implications
for neuronal loss in PD and other neurodegenerative
diseases.
MATERIALS AND METHODS
Reagents were purchased from Sigma-Aldrich (St. Louis, MO,
USA) unless otherwise stated.
Purification of synuclein proteins
Expression and purification of recombinant a-syn and its muta-
tions were as previously described (30). Using pET expression
vectors in BL21 Escherichia coli cells, untagged synuclein protein
expression was induced at OD600 0.5 to 1.0 with 1mM isopropyl
b-D-1-thiogalactopyranoside for 4 h. Cells were collected by
centrifugation (8000 g) and lysed mechanically in 20 mM Tris-
HCl/1mMEDTA/pH8.0 (bufferA), 1mMPMSF, and50mg/ml
DNase. Streptomycin sulfate was added to a final concentration
of 1% to the lysate solution, then centrifuged at 8000 g. Ammo-
niumsulfate (0.295 g/ml)was added to the supernatant (15%w/
v solution) and stirred at 4°C for at least 1 h. After centrifugation
at 10,000 g, the pellet was resuspended 50 ml buffer A. The
semipurified lysate solution was loaded onto a 50 ml Q Sephar-
ose column (Amersham Biosciences, Little Chalfont, United
Kingdom). The columnwaswashedwith 100ml buffer A; then a
2-column volume isocratic elution step to 25% buffer A + 1M
NaCl (buffer B) was performed. Synuclein proteins were eluted
with a broad-gradient elution (10 column volumes) from 25%
buffer B to 50% buffer B (all synuclein proteins eluting at
;350 mM NaCl). SDS-PAGE analysis of Q Sepharose fractions
was performed, and fractions enriched for synuclein were
pooled. Synuclein proteinswere collected as flowthrough from a
PM30 cellulosemembrane (EMDMillipore, Billerica, MA,USA),
then concentratedwith a PM10PESmembrane (EMDMillipore).
Purified synuclein proteins were dialyzed extensively at 4°C in
Chelex-treated Milli-Q (EMD Millipore). Protein concentration
was measured by absorbance at 275 nm with extinction
coefficient 5600 M/cm for a-syn (and mutants) and b-syn.
Production of synuclein fibrils
Five hundred microliters of 20 mM synuclein proteins in 10 mM
Tris pH7.4 was formed into aliquots into 1.5 ml screw-capped
tubes. CuCl2 was added to a final concentration of 100mM.After
incubationat roomtemperature for 45min, tubeswere laid flat on
an orbital shaker and incubated at 37°C shaking at 600 rpm for
6 d. Formation of fibrilswasmonitoredusing thioflavine T (ThT).
Fivemicroliters of each samplewasmixedwith 95ml 10mMThT
in 10 mM Tris pH7.4. Increased ThT fluorescence, indicating in-
creased b-sheet structures, was monitored in 96-well plates with
the FluoStar Omega (BMG Labtech, Ortenberg, Germany).
Cell culture
SH-SY5Y (human neuroblastoma) cells were cultured in 45%
DMEM/45% Ham F-12 (Lonza, Basel, Switzerland) supple-
mentedwith10%fetalbovineserumandpenicillin–streptomycin.
Cells were maintained at 13 106/75 cm2 at 37°C and 5% CO2 in
a humidified incubator. The neuronal status of SH-SY5Y cells
was monitored by reverse transcription PCR with primers for
tyrosine hydroxylase, dopamine transporter, and vesicle
monamine transporter 2.
Cell lines derived from SH-SY5Y cells and overexpressing
a-syn, b-syn, or mutations of either were developed by stable
transfection of plasmids (pCDNA3.1) containing the open read-
ing frame (ORF) of either protein using Fugene (Promega,




For toxicity experiments, cellswereplatedat 23105 cells perwell
ofa 24-wellplate inDMEM(Lonza) supplementedwith 10%fetal
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bovine serum and penicillin–streptomycin, then grown over-
night. Cells were treated for 48 h with recombinant proteins
at different concentrations. The (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reagent was resuspended
at 2.5 mg/ml in water. Medium and treatments were removed
from the wells, and 0.5 ml 50 ml of MTT in Hanks solution was
added per well and incubated for 30 min. After removal of the
MTT solution, cells and the resulting reduced tetrazolium were
solubilized in 800ml DMSOperwell. Readingswere taken at 570
nmusing FLUOstar Omega (BMGLabtech). Each treatmentwas
conducted in triplicate, averaged, and represented as the per-
centage of untreated control (vehicle alone). Each experiment
was repeated 3 to 5 times.
Western blot analysis
Cells were lysed in 0.5% Igepal CA-630 and Complete protease
inhibitor cocktail (Roche, Basel, Switzerland), sonicated 3 3 3 s
on ice, and centrifuged 10,000 g for 3 min to remove insoluble
membranes. Protein concentration was determined with a
Bradford protein assay (Bio-Rad, Hercules, CA,USA), according
to the manufacturer’s instructions. Protein concentrations were
normalized and boiled for 5 min with 13 Laemmli SDS-PAGE
buffer. Samples were loaded into either a 10% (for FoxO3a) or a
12% (for a-syn) acrylamide SDS-PAGE gel, with a buffer of Tris
(250mM) + glycine (1.92M) + SDS (0.1%w/v), run at 250 V and
35 A for 45 min. Separated proteins were transferred to a PVDF
membrane by a semidry transfer apparatus, then run at 25V and
100A for 1.5 h.Membraneswere blocked in 5%w/vnonfatmilk
powder in Tris-buffered saline and Tween 20 for 30 min, in-
cubatedwithprimaryantibodyfor1 to2h,andwashed335min
in Tris-buffered saline and Tween 20. Membranes were blocked
again and incubated with horseradish peroxidase–conjugated
secondary antibody for 1 h. A further 3 3 10-min washes were
performed, and the membranes were developed with Luminata
Crescendo or Luminata Forte ECL substrate (Thermo Fisher
Scientific, Waltham, MA, USA), then imaged with a Fusion SL
CCD imaging system (Vilber Lourmat, Colle´gien, France).
Rabbit monoclonal anti–a-syn (MJFR1, immunogen human
a-syn 1–150;Abcam,Cambridge,UnitedKingdom)wasused for
human a-syn detection at a dilution of 1:4000. Total FoxO3a
(75D8) and phosphorylated FoxO3a (p-FoxO3a; ser253) were
detected with rabbit antibodies at 1:1000 (Cell Signaling Tech-
nology, Danvers, MA, USA). Mouse monoclonal anti–a-tubulin
(T5186; Sigma-Aldrich, immunogen acetylated tubulin from
Strongylocentrotus purpuratus sperm axonemes) was used at a
dilution of 1:10,000. Mouse monoclonal anti-dopamine trans-
porter (AB2231; EMDMillipore) was used at 1:1000 dilution.
Iron and reactive oxygen species assays
The assay for iron concentrations in cell lines was as previously
described (25). Basically, a commercial kit (Abcam) was used,
following the manufacturer’s instructions, to measure Fe(II) and
total iron from a confluent T75 cell culture flask of each cell type
per assay point. Reactive oxygen species (ROS) were measured
by using the fluorescent indicator CM-H2DCFDA as previously
described (43). Cells were plated in 96-well plates at 75% con-
fluency and returned to the incubator overnight. Medium was
removed fromtestwells andreplacedwith 50ml of 5mMprobe in
PBS, then incubated in the dark at 37°C for 20 min. Probe was
removed from the cells and replaced with 100 ml of prewarmed
DMEM. Fresh Fe(II) at a final concentration of 20mMwas added
to 4 wells per experiment, and fluorescence intensity was mea-
sured using a microplate reader with FluoStar Omega (BMG
Labtech) at excitation and emission wavelengths of 488 and
534 nm, respectively, at times 0, 1, and 2 h. The change in
fluorescenceof treatedcells compared tountreatedcellswasused
as a measure of ROS generated by Fe(II) in the treated cells over
time.
Statistical analysis
Statistical analyses were conducted by 2-tailed Student’s t test,
with statistical significance considered at P , 0.05. Data are
expressed as means6 SEM.
RESULTS
Synucleins and exogenous oligomer toxicity
Therehasbeen considerable interest in the toxicityofa-syn
oligomers when applied from outside the cell (44). We
have previously shown that toxic oligomers of a-syn can
be generated by reacting recombinant a-syn protein with
copper (37). These stellate oligomers were found to be
highly toxic to neuronal cells compared to fibrils or olig-
omers prepared in the absence of copper. We therefore
wished to further understand the mechanism of action of
these stellate oligomers. We looked at the impact of in-
creased cellular expression synuclein expression on the
toxicity of recombinant a-syn oligomers applied exoge-
nously. For clarity, the toxic a-syn oligomers will be
referred to as a-syn-TO.
Stable cell lines overexpressing 1 of the 3 main synu-
cleinswerepreparedby transfectionof SH-SY5Ycellswith
pCDNA3.1 containing theORF of humana-syn, b-syn, or
g-syn. The increased expression was confirmed by West-
ern blot analysis as previously described (42). The stable
cell lineswere then treatedwithwild-type (WT)a-syn-TO
at various concentrations. Survival of the treated cells was
then determined. As can be seen in Fig. 1A, a-syn-TOwas
toxic to SH-SY5Y cells transfected with the empty vector
(pCDNA3.1) in a concentration-dependent manner. In
comparison, cells overexpressing g-syn showed no sig-
nificant difference in the response to a-syn-TO compared
to the controls. However, cells overexpressing a-synwere
significantly more sensitive to a-syn-TO at concentrations
between 0.5 and 5.0 mM,while cells overexpressing b-syn
were more resistant to the toxicity at 5.0 mM and above.
These results suggest that the cellular levels of both a- and
b-syn influence the toxicity of a-syn-TO.
Increased expression of a-syn in cells resulted in in-
creased sensitivity toa-syn-TO.Wewished todetermine if
this effect could be altered by mutations in a-syn. We
therefore produced stable cell lines expressing a range of
structural mutations of a-syn. a-Syn-TO was applied
to these cell lines at a range of concentrations in parallel
with cells expressing WT a-syn or the empty vector
(pCDNA3.1) as previously described (Fig. 1B). The mu-
tations included a point mutation of the 1 histidine to an
alanine (H50A). Thismutation had no significant effect on
the toxicity of a-syn-TO compared to the effect on cells
expressing WT a-syn. We also included deletion muta-
tions of both the N- and C-terminus. Deletion of the
C-terminus (1–100) also had no significant effect on the
toxicity of a-syn-TO. In contrast, deletion of the N
terminus (D2–9) did have significant effect on the toxicity
ofa-syn-TO compared to the effect on cells expressingWT
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a-syn. It was reduced for concentrations 0.5 and 5.0 mM.
However, the toxicity at these concentrations was still
significantly higher than the toxicity to control cells
(pCDNA). Last, we also tested the toxicity of a-syn-TO on
cell expressing a doublemutation of both D2–9 andH50A
(D2–9/H50A). In this case, the toxicity of a-syn-TO to
these cells was not significantly different than that of the
toxicity to control cells. This implies that the mutation
D2–9/H50A abolished the effect of overexpressed a-syn
that increased cell sensitivity to a-syn-TO toxicity.
We also wished to assess whether similar structural
changeswouldalter the toxicityofa-syn-TO.We therefore
generated recombinant protein for a-syn and generated
aggregated protein through the same method as WT
a-syn. The mutant forms of a-syn-TO generated were
applied to SH-SY5Y cells for 48 h, and the viability mea-
sured and compared to the toxicity of WT a-syn-TO (Fig.
2A). A deletion from the C-terminus (D119–126) had no
significant effect on the toxicity ofa-syn-TO.However, the
point mutation H50A significantly reduced toxicity at
concentrations between 2.0 and 7.5 mM, but not at higher
concentrations. In contrast, the N-terminal mutation D2–9
abolished toxicity. We assessed the ability of these muta-
tions to form aggregates using a ThT assay (Fig. 2B). The
ThT assay verified that all proteins used in these studies
were able to form aggregates. Therefore, the differences in
toxicity were not due to differences in ability to aggregate.
a-Syn and FoxO3a
FoxO3a is a transcription factor associated with cell death
inneurodegenerativediseases. There is goodevidence that
increased expression of active FoxO3a increases neuronal
loss in transgenic rats overexpressing a-syn (41). We
wished to determine if the increased cell loss seen in our
model was related to a change in FoxO3a expression. We
grew SH-SY5Y cells either overexpressingWT a-syn or its
mutantD2–9/H50A and control cells transfected with the
emptyvector (pCDNA3.1).Protein extractswereprepared
from the cells, and Western blot analysis and immuno-
detection were performed. Blots were analyzed for the
expression of total FoxO3a, p-FoxO3a, and tubulin as a
loading control (Fig. 3). The results showed that total
FoxO3a but not p-FoxO3a were elevated in cells over-
expressingWTa-syn but not themutantD2–9/H50A. The
lack of altered expression of the phosphorylated form is
indicative that the change in expression is not due to an
increase in the inactive form of FoxO3a. The lack of in-
creased expression of FoxO3a in the mutant D2–9/H50A
as opposed to WT a-syn correlated with their relative
susceptibility to a-syn-TO toxicity.
FoxO3a is a transcription factor. As such, it acts via
binding to DNA. Inhibition of FoxO3a activity can be
achieved through prevention of DNA binding. We there-
fore created SH-SY5Y cell lines that overexpressed either
WT FoxO3a (FoxO3a-WT) or the DNA-binding domain
(DBD) of FoxO3a. Either the ORF of FoxO3a or the DNA
binding domain (encoding 139 aa without the trans-
activation domain, residues 138–277) were cloned into
pCDNA3.1. Both constructs also include a hemagglutinin
tag for easy detection of the overexpressed protein. Cells
were transfected with the constructs and stable cell lines
selected by exposure to G418. Once overexpression in the
cells was verified (data not shown), the cell lines and con-
trolswere treatedwithWTa-syn-TOandsurvival assessed
after 48 h (Fig. 4). Cells overexpressing FoxO3a-WT























































Figure 1. Toxicity of a-syn-TO to SH-SY5Y cell lines. A) SH-
SY5Y cells overexpressing a-syn (alpha), b-syn (beta), or g-syn
(gamma) were grown in parallel with SH-SY5Y transfected with
empty vector control (pCDNA). Cells were treated for 48 h
with varying concentrations of recombinant a-syn-TO. Next
cells were treated with MTT, and survival was assessed relative
to untreated control. Cells overexpressing g-syn showed no
signiﬁcant difference (P . 0.05, Student’s t test) compared to
control cells. However, cells overexpressing a-syn showed
signiﬁcantly more cell loss (P , 0.05) at concentrations
between 0.75 and 4 mM compared to controls. In contrast,
a-syn-TO was less toxic to b-syn–overexpressing cells at
concentrations of 4 mM and higher. Shown are means 6 SEM
for 4 experiments with 3 replicates for each value per
experiment. B) SH-SY5Y cells overexpressing either WT a-syn
(alpha) or various mutants of a-syn were grown in parallel with
SH-SY5Y transfected with empty vector control (pCDNA). Cells
were treated for 48 h with varying concentrations of
recombinant a-syn-TO. Next cells were treated with MTT,
and survival was assessed relative to untreated control. Two
mutants (H50A and 1–100, the latter mutant of a-syn or b-syn
lacking residues after 100) showed no signiﬁcant difference
from WT a-syn in terms of sensitivity to a-syn-TO toxicity. Both
D2–9- and D2–9/H50A-overexpressing cells were both signif-
icantly less sensitive to a-syn-TO toxicity than WT a-syn–
overexpressing cells at concentrations between 0.75 and 4 mM.
D2–9/H50A-overexpressing cells were not signiﬁcantly differ-
ent than pCDNA cells in terms of their sensitivity. This suggests
that this mutant abolishes impact of increased a-syn expression
on toxicity of a-syn-TO to cells. Shown are means 6 SEM for 4
experiments with 3 replicates for each value per experiment.
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to a-syn-TO toxicity compared to toxicity to pCDNA
control cells. In contrast, cells overexpressingFoxO3a-DBD
were strongly and significantly protected from a-syn-TO
toxicity. These results suggest that FoxO3a plays an im-
portant role in cell death causedbya-syn-TO.These results
suggest that elevated FoxO3a expression inducedbya-syn
is the cause of the increased susceptibility of SH-SY5Y cells
to a-syn-TO toxicity.
FoxO3a and iron reduction by a-syn
Having established a role for FoxO3a in cell death induced
by a-syn-TO, and having also established that increased
expression of FoxO3a is related to increased expression of
a-syn, it is important to try and identify how a-syn in-
creases FoxO3a expression. We have shown previously
that a-syn possesses ferrireductase activity and causes an
increase in cellular reduced iron [Fe(II)] (25). Therefore we
set out to determine if altering iron levels in cells would
alter FoxO3a expression. SH-SY5Y cells were treated with
50 mM Fe(II) in serum-free conditions for 24 h. Extracts
were then prepared from the cells and untreated controls,
and Western blot analysis for FoxO3a levels was carried
out (Fig. 5A). Treatmentwith Fe(II) resulted in a significant
increase in FoxO3a expression compared to controls. Ad-
ditionally, we treated a-syn–overexpressing cells with the
iron chelator deferiprone (250 mM) for 24 h under serum-
free conditions. Deferiprone is a strong, cell-permeable
Fe(II) chelator.We thenmeasured the level of expressionof
FoxO3a usingWestern blot analysis (Fig. 5B). Deferiprone

















































Protein Concentration in μM
1 10 100
H50A Δ2-9 Δ119-126
Figure 2. Toxicity of a-syn-TO mutants. A) Puriﬁed recombi-
nant a-syn was generated and used to form a-syn-TO. As well as
WT a-syn (WT), mutant forms of a-syn were also expressed
and puriﬁed to generate a-syn-TO with different mutations.
These mutants included N-terminal (D2–9) and C-terminal
mutant (D119–126), and single-point mutation (H50A). Cells
were treated for 48 h with varying concentrations of different
recombinant a-syn-TOs in parallel. Next cells were treated with
MTT, and survival was assessed relative to untreated control.
D119–126 mutation had no signiﬁcant effect on a-syn-TO
toxicity compared to WT. In contrast, both H50A and D2–9
reduced a-syn-TO toxicity signiﬁcantly at concentrations
between 2 and 7.5 mM. D2–9 mutant showed no signiﬁcant
difference between different concentrations, suggesting it was
not toxic at concentrations tested. Shown are means 6 SEM for
4 experiments with 3 replicates for each value per experiment.
B) Mutations of a-syn used in experiments were tested for their
ability to form b-sheets as determined by ThT assay. Puriﬁed
protein of different mutants and WT a-syn were shaken to
generate a-syn-TO. After 7 d, samples of aggregated proteins
were taken and reacted with ThT along with samples of
protein that had not been subjected to shaking (nonaggre-
gated). Fluorescence at 482 nm was determined for all
samples. No signiﬁcant difference (P . 0.05) was seen for
aggregated protein of different mutants compared to aggre-










































Figure 3. FoxO3a and a-syn expression. Protein extracts were
prepared from SH-SY5Y cells overexpressing either WT a-syn
or a-syn mutant D2–9/H50A as well as cells transfected with
empty vector (pCDNA). Protein extracts were electrophoresed
on PAGE gels and Western blot analysis performed. Speciﬁc
antibodies were used to detect total FoxO3a (T-FoxO3a),
p-FoxO3a, a-syn, and tubulin. a-Syn detection was included to
verify overexpression of protein. Densitometric analysis was
then performed for FoxO3a bands and normalized to tubulin.
Average values and SEM for n = 4 blots were determined
and plotted relative to levels of pCDNA. Statistically signiﬁcant
(P , 0.05) increase was observed for total FoxO3a in
a-syn–overexpressing cells but not for p-FoxO3a, and no
signiﬁcant change was observed for either in D2–9/H50A cells.
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controls cells treated only with the vehicle (DMSO). These
results suggest that the levels of Fe(II) might alter the ex-
pression of FoxO3a.
Wewished to testwhether another ferrireductase could
alter FoxO3a expression. A known mammalian ferrir-
eductase, Steap3 (45), was cloned into pCDNA3.1 and
overexpressed in SH-SY5Y cells. We then determined
whether total and p-FoxO3a levels were altered in these
cells. In parallel, we also looked at FoxO3a expression in
cells overexpressing b-syn, which has no ferrireductase
activity (25). Cells overexpressing Steap3 showed sig-
nificantly increased levels of total FoxO3a but reduced
levels of p-FoxO3a,while thoseoverexpressingb-syndid
not (Fig. 6). These results suggest that overexpressing a
ferrireductase can alter FoxO3a expression, but over-
expression of another synuclein does not.We then tested
the toxicity of a-syn-TO to Steap3-overexpressing cells
(Fig. 7A). Compared to the survival of control cells,
a-syn-TOwasmore toxic to Steap3-overexpressing cells.
Therefore, another known ferrireductase overexpressed
in cells leads to increased FoxO3a expression and in-
creases sensitivity toa-syn-TO. This is similar to the effect
of a-syn overexpression. When combining these findings
with the data mentioned above on iron and FoxO3a ex-
pression, the most likely explanation for the alteration in
FoxO3a levels is due to the increased levels of Fe(II) gen-
erated through iron reduction by a-syn.
b-Syn and a-syn-TO toxicity
Having elucidated a possible mechanism for how a-syn
enhanced the toxicity of a-syn-TO, we wished to look
further at howb-syn canhave theopposite effect.Weused
a battery of b-syn structural mutants, which included
deletion of the N terminus (D2–9) or the C-terminus
(1–100), pointmutation of the single histidine (H65A), and
a doublemutation of theN terminus (D2–9/H65A). Stable
cell lines were generated overexpressing each of these
mutants. The cell lines were then treated with a-syn-TO
and compared to cell lines overexpressing WT b-syn of
controls cells transfectedwith the empty vector (pCDNA).
Survival of the cell lines was measured after 48 h with an
MTT assay (Fig. 7B). Neither the C-terminal mutant or
the point mutation has any significant effect on the tox-
icity compared to WT b-syn. However, the N-terminal
mutation did significantly alter the toxicity, reducing the
protective effect of b-syn. In comparison, the mutant
D2–9/H65A had an even stronger effect. There was no
significant difference in toxicity between D2–9/H65A
and pCDNA at any point, suggesting that this mutation
abolished toxicity.
We have shown that b-syn has no effect on FoxO3a
levels. Therefore, it is unlikely that theprotective effect of
b-syn against a-syn-TO toxicity is related to altered
FoxO3a levels. We have previously shown that b-syn
reduced the level of Fe(II) present in cells overexpressing
the protein (25). We therefore looked at the levels of
Fe(II) in both b-syn–overexpressing cells and themutant
D2–9/H65A, which has no protective effect against
a-syn-TO toxicity. Figure 8A shows that overexpression
of b-syn decreases Fe(II) levels in cells but that over-
expression of D2–9/H65A has no significant effect. The
presence of Fe(II) in cells is known to potentially increase
generation of ROS. Therefore, we also measured ROS
levels in cells with and without exposure to exogenous
Fe(II). Overexpression of b-syn caused a decrease in the
levels of ROS detected in SH-SY5Y cells, while over-
expression of the mutant D2–9/H65A did not (Fig. 8B).
Therefore, the protective effect of b-syn against a-syn-
TO toxicity may be due to a reduction in cellular sensi-
tivity to ROS generated by Fe(II). Because a-syn is a
known ferrireductase (32) that increases Fe(II) levels in
cells, this fits well with b-syn’s known role as antago-
nistic to pathologic changes caused by a-syn.
DISCUSSION
The research presented here provides evidence for signif-
icant advancements in the understanding of the toxicity of
oligomeric species of a-syn. First, toxicity is mediated
through increased activity of FoxO3a. This protein is
stronglyassociatedwith cell-deathpathwaysandhasbeen
previously shown to be increased in the Lewy bodies of
patients with PD (40). Second, increased expression of
a-syn causes increased sensitivity to oligomer toxicity.
This is likely due to increased expression of FoxO3a in the
a-syn–overexpressing cells. Third, increased b-syn ex-
pression has a protective effect against oligomer toxicity.
This fits well with numerous reports that b-syn has a
protective role against the negative effects of increased
a-syn expression. This may be a result of interaction with
a-syn (46–49) or other means (50).
The involvement of FoxO3a in cell death in a-syn



























Figure 4. Toxicity of a-syn-TO and FoxO3a. SH-SY5Y cells
overexpressing either WT FoxO3a (WT) or just DBD along
with control cells (pCDNA) were treated for 48 h with varying
concentrations of recombinant a-syn-TO. Next cells were
treated with MTT, and survival was assessed relative to
untreated control. Increased expression of WT FoxO3a had
no effect on survival of cells compared to empty vector. In
contrast, DBD-overexpressing cells showed signiﬁcant (P ,
0.05) difference from controls at 1.0 mM and above. Presence
of DBD showed high levels of protection from a-syn-TO
toxicity. Shown are means 6 SEM for 4 experiments with 3
replicates for each value per experiments.
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model (41). In this model, pathologic effects of a-syn
transgenic overexpression are reversed by inhibition of
FoxO3a activity. This inhibition was induced by coex-
pression of the dominant negative inhibitor of FoxO3a
activity, namely theDNAbindingdomainof FoxO3a.Our
results support this role, as we used a similar construct,
overexpressed it in SH-SY5Y cells, and showed that this
inhibited the toxicity of a-syn toxic oligomers. In contrast,
overexpressingWTFoxO3ahadnosucheffect. In this case,
it is possible that the extra FoxO3a did not increase the
amount of active (nonphosphorylated) FoxO3a that en-
tered the nucleus. Alternatively, a second factor may also
be necessary for a-syn-TO toxicity, which would remain
limiting despite the increased levels of FoxO3a. Either
way, these data suggest that FoxO3a activity is necessary
for a-syn-TO toxicity.
FoxO3a expression in SH-SY5Y cells was shown to be
increased by the overexpression ofa-syn or Steap3 but not
b-syn. Amutant of a-syn (D2–9/H50A) also had no effect
on FoxO3a expression. This implies that the mutation
alters a-syn sufficiently so that its overexpression
no longer affects the expression of FoxO3a. In each case,
increased FoxO3a expression was not accompanied by
increased p-FoxO3a expression, confirming that the in-
crease is not just elevatedaccumulationof inactiveFoxO3a
(51). The increased expression of FoxO3a correlated with
higher susceptibilityof SH-SY5Ycells toa-syn-TOtoxicity.
In other words, overexpression of a-syn and Steap3 both
increased FoxO3a expression and susceptibility to a-syn-
TO toxicity, but for D2–9/H50A and b-syn there was no
increase in FoxO3a and no observed increase in a-syn-TO
toxicity. These results also support the suggestion that
FoxO3a expression mediates the toxicity of a-syn-TO.
These findings, in combination with previous work in
transgenic rats, imply that FoxO3a is of major significance
in terms of neuronal death mediated by a-syn.
It is also important to consider themechanismbywhich
FoxO3a activity or expression is increased. Botha-syn and
Steap3 show ferrireductase activity, while D2–9/H50A




















































Figure 5. Iron and FoxO3a expression. A) SH-SY5Y cells were treated with 50 mM Fe(II) for 24 h. Protein extracts were prepared
from treated cells (Fe) and untreated controls. Protein extracts were electrophoresed on PAGE gels and Western blot analysis
performed. Speciﬁc antibodies were used to detect total FoxO3a (T-FoxO3a), p-FoxO3a, and tubulin. Densitometric analysis was
then performed for FoxO3a bands and normalized to tubulin. B) SH-SY5Y cells overexpressing a-syn were treated with 250 mM
deferiprone for 24 h. Protein extracts were electrophoresed on PAGE gels and Western blot analysis performed. Speciﬁc
antibodies were used to detect total FoxO3a (T-FoxO3a), p-FoxO3a, a-syn, and tubulin. Densitometric analysis was then
performed for FoxO3a bands and normalized to tubulin. C) Changes in total FoxO3a for treatments with iron and deferiprone
are shown as percentage of control value for each experiment. Fe treatment signiﬁcantly increased levels of total FoxO3a in SH-
SY5Y cells. In contrast, deferiprone signiﬁcantly (P , 0.05) decreased expression of FoxO3a in a-syn–overexpressing cells. Shown
are means 6 SEM of 4 different experiments. D) Ratio of p-FoxO3a to T-FoxO3a was also determined. Densitometric values were
normalized to tubulin; then value for p-FoxO3a was divided by value for T-FoxO3a for each group and converted to percentage.
Treatment with Fe signiﬁcantly decreased ratio of p-FoxO3a/T-FoxO3a despite overall increase in T-FoxO3a. In contrast,
deferiprone treatment led to signiﬁcant (P , 0.05) increase in ratio of p-FoxO3a/T-FoxO3a. Shown are means 6 SEM of 4
different experiments.
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common factor resulting in increased FoxO3a expression
is the generation of elevated levels of Fe(II), the product of
reactions catalyzed by ferrireductases. We verified this
finding by demonstrating that increased iron caused an
increase in FoxO3a expression in SH-SY5Y cells. The rel-
ative change in p-FoxO3a was much less, thus implying
that the increase was active FoxO3a. We showed the rel-
evance of this finding for our system by applying an iron
chelator to SH-SY5Y cells overexpressing a-syn and
observing a reduced expression of FoxO3a. The change
resulted in a high level of p-FoxO3a compared to the total,
indicating the reduction was in active FoxO3a. Therefore,
the fundamental factor that both regulates FoxO3a and
susceptibility of SH-SY5Y cells to the toxicity of a-syn-TO
may be Fe(II).
While our findings are novel, there havebeen a number
of studies relating increased iron levels with increased




























































Figure 6. FoxO3a expression and ferrireduction. A) Protein
extracts were prepared from SH-SY5Y cells overexpressing
either Steap3 or b-syn as well as from cells transfected with
empty vector (pCDNA). Protein extracts were electrophoresed
on PAGE gels and Western blot analysis performed. Speciﬁc
antibodies were used to detect total FoxO3a (T-FoxO3a), p-
FoxO3a, and tubulin. B) Densitometric analysis was then
performed for total FoxO3a bands and normalized to tubulin.
C) Ratio of p-FoxO3a to T-FoxO3a was also determined.
Shown are means 6 SEM of 4 different experiments. *Values
for Steap3, but not b-syn are signiﬁcantly different from






















































Figure 7. a-Syn-TO toxicity to b-syn–expressing cell line. A)
SH-SY5Y cells overexpressing Steap3 were grown in parallel
with SH-SY5Y transfected with empty vector control (pCDNA).
Cells were treated for 48 h with varying concentrations of
recombinant a-syn-TO. Next cells were treated with MTT, and
survival was assessed relative to untreated control. Steap3 cells
showed signiﬁcantly (P , 0.05) greater sensitivity to toxicity of
a-syn-TO at concentrations between 2 and 8 mM compared to
pCDNA cells. Shown are means6 SEM for 4 experiments with 3
replicates for each value per experiment. B) SH-SY5Y cells
overexpressing either WT b-syn (alpha) or various mutants of
a-syn were grown in parallel with SH-SY5Y transfected with
empty vector control (pCDNA). Cells were treated for 48 h
with varying concentrations of recombinant a-syn-TO. Next
cells were treated with MTT, and survival was assessed relative
to untreated control. Two mutants (H65A and 1–100, the latter
mutant of a-syn or b-syn lacking residues after 100) showed no
signiﬁcant difference from WT b-syn in terms of sensitivity to
a-syn-TO toxicity. Both D2–9- and D2–9/H65A-overexpressing
cells were signiﬁcantly (P , 0.05) less sensitive to a-syn-TO
toxicity than WT b-syn–overexpressing cells at concentrations
between 4.0 and 40 mM. D2–9/H65A-overexpressing cells were
not signiﬁcantly different than pCDNA cells in terms of their
sensitivity. This suggests that this mutation abolishes impact of
increased b-syn expression on protection from toxicity of
a-syn-TO to cells. Shown are means 6 SEM for 4 experiments
with 3 replicates for each value per experiments.
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such study implies that the increase of FoxO3a ismediated
by the PI3K/AKT pathway. It has also been shown that
iron overload increases FoxO3a expression (54). It is well
known that FoxO3a expression is increased under oxida-
tive stress and that Fe(II) is readily able to catalyze reac-
tions that increase oxidative stress such as the Fenton
reaction (55). Iron-induced oxidative damage has fre-
quently been shown to be mediated through the PI3K/
AKT pathway (56–58). Therefore, it is possible that the
increased active FoxO3a seen in our findings is a result of
down-regulation of the PI3K/AKT pathway caused be
oxidative stress from Fe(II).
These findings suggest that elevated cellular Fe(II)
caused by overexpression of a-syn increases cellular sus-
ceptibility to the toxicity of oligomers of exogenous a-syn.
Previous studies have also provided evidence that iron
anda-syncanact in concert tocause celldeath (59, 60).This
is of considerable interest because of the possible role of
this mechanism in diseases such as PD. Neuronal loss in
the substantia nigra is the hallmark of the disease. Patients
with PD show both elevated levels of a-syn and increased
levels of Fe(II) (61). There is a long history of the relation of
altered iron levels and PD, but there has never been a
causal connection established between elevated iron
and loss if dopaminergic neurons in PD (62–67).
However, a study in transgenic rodents suggested that
iron chelation reducedpathologic changes causedbya-syn
overexpression (68), and another study suggested that iron
chelation also protected against the toxicity of 6-hydroxy
dopamine in a mouse model (69).
Ambivalence exists as to whether a-syn is genuinely
toxic in vivo, and the form of the toxic species is also in
question. There is strong evidence that a-syn can be toxic,
especially when overexpressed or introduced exoge-
nously (70, 71). For some time toxicity was thought to
come from fibrils, but this has largely been dismissed in
favor of the “toxic oligomer” hypothesis (72). There are
manycontenders for themechanismof action of these (44).
We developed a method to generate highly toxic oligo-
mers by reacting recombinant a-synwith copper during a
shaking process (37). The oligomers generated were stel-
late, and their toxic action was not dependent on the
copper required for their formation. However, there are
other kinds of oligomers, such as the pore-forming variety
(73, 74). While no one could claim to have generated the
single toxic oligomer that best models an in vivo oligomer,
we think our oligomer model is a good one because of its
uniquenature, reproducibilityof toxicprofile,high toxicity,
and ability to induce changes seen in vivo (such as those
described in this report).
We showed in our data that b-syn overexpression
protects against the toxicity of a-syn oligomers. Because
this is the opposite of the effect of overexpression of a-syn,
it further emphasizes the potential role of b-syn as a reg-
ulator of the activity of a-syn. Expression of both a-syn
and b-syn is regulated by similar pathways and tran-
scription factors (75). This systemprobably exists to ensure
that levels of the two proteins are in balance. This balance
would then protect against problems such as aggregation
and toxicity of a-syn. Expression patterns and levels of
a-synandb-synmost closelyoverlap (3).b-Syn is themost
abundantly expressed synuclein in the brain, comprising
75% to 80% of the total mRNA of the synucleins (76). In
both the mouse brain and the human substantia nigra,
a-syn mRNA decreases and b-syn mRNA increases with
age (77). In contrast to control patients, there is a dramatic
increase in a-syn and a decrease in b-syn mRNA levels in
the substantia nigraofPD,diffuseLewybodydisease, anda
Lewy body variant of AD (76). The importance of the
balance between levels of the synucleins is highlighted by
the observation that b-syn inhibits a-syn aggregation in
vitro and in vivo (78–80). In addition, b-syn prevents ag-
gregated a-syn from inhibiting the 26S proteasome (81).
These functions lead to expression of b-syn in transgenic
a-syn mouse models ameliorating neurodegenerative
alterations, decreasing Lewy body formation and pre-
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Figure 8. b-Syn– and iron-induced ROS. A) Ratio of Fe(II) to
total Fe within cells was determined for SH-SY5Y cells
overexpressing either b-syn or mutant of b-syn, D2–9/H65A,
and compared to cells transfected with empty vector using
commercial kit. Shown are means 6 SEM for 4 experiments.
*Values for b-syn were signiﬁcantly different (P , 0.05) than
for pCDNA. B) Levels of ROS in same cell lines were
determined by ﬂuorescent compound CM-H2DCFDA. Cells
loaded with CM-H2DCFDA were treated with 20 mM Fe(II) for
0, 1, or 2 h. Measurements were made of cells with and
without treatment with Fe(II). Increase in ROS detected in
Fe(II)–treated cells above that of untreated cells was measured
and plotted as fold increase. As can be seen, Fe(II) increased
ROS levels in all cell lines when comparing time points.
Increase in ROS detected in b-syn–overexpressing cells was
signiﬁcantly lower (*P , 0.05) than in other cell lines at both
1- and 2-h time points. Shown are means 6 SEM for 3
experiments.
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The nature by which b-syn exerts these effects is not
understood. However, it is possible that it occurs through
direct interactions. Both synucleins are able to formdimers
and tetramers (83, 84), and the latter is believed to be the
correct form for cellulara-syn. Therefore, it is possible that
heterotetramers exist that includeboth synucleins and that
lack activities such as the proposed ferrireductase activity
(25). We have previously demonstrated that cells over-
expressingb-syn have lower Fe(II) levels than control cells
(25). It is possible that this reduced level of Fe(II) protects
cells when exposed to a-syn-TO. However, this is not
reflected in a change in FoxO3a, as levelswere not reduced
in cells overexpressing b-syn. We showed that a mutant
formofb-syn (D2–9/H65A)didnothave the sameeffect as
WTb-syn inprotecting cells froma-syn-TOtoxicity.While
cells overexpressing b-syn showed both lower levels of
intracellular Fe(II) and Fe(II)-generated ROS, D2–9/H65A
did not. This may be because it is unable to interact with
a-syn or is unable to be incorporated in synuclein tetra-
mers. We have shown that membrane associated tetra-
mers of a-syn are the form that has iron-reducing activity
(32). If the mutant D2–9/H65A has a reduced ability to
inhibit this activity, then cells would generate more Fe(II).
As we have shown, Fe(II) can increase FoxO3a levels,
which mediates the toxicity of a-syn-TO.
In summary,wehave demonstrated that FoxO3aplays a
pivotal role in the toxicityofa-synoligomers. Inhibitionof its
activityblocks toxicity.Overexpressionofa-syn increasesFe
(II) levels in cells, which then increases FoxO3a levels,
leadingtoelevatedcellularsensitivity tooligomer toxicity. In
contrast, b-syn overexpression decreases Fe(II) levels and
decreases cellular sensitivity to toxic oligomers. We believe
these findings provide an insight into the mechanism of
dopaminergic neuronal loss in the synucleinopathies. We
suggest that FoxO3a and increased Fe(II) levels are key
factors in the pathway that leads to cell death.
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4.5 Concluding commentary 
 
In the chapter above, we presented a potential mechanism through which elevated α-
synuclein can contribute to neuronal death. According to our results increased α-synuclein 
expression results in increased ferrireductase activity and thus elevated levels of Fe2+. 
Elevated Fe2+ caused oxidative stress and triggered the activation of the FOXO3a 
pathway leading to cell death. The data suggested that it was the ferrireductase activity of 
α-synuclein that elicited these effects as they were replicated by the overexpression of 
another ferrireductase – STEAP3. β-synuclein on the other hand did not replicate the 
effect α-synuclein had and in fact overexpressing it resulted in lower levels of iron and 
ROS, suggesting that β-synuclein was protective against toxicity. 
 
This finding together with the studies presented in previous chapters point to one thing – 
that increased iron levels can replicate the age-related changes seen in microglia and that 
those changes can influence the proteins directly linked to the pathology of 
neurodegenerative disease (α-synuclein and β-amyloid). All work described in the above 





5.1 Summary of results 
 
The major findings of this thesis can be summarised as follows:  
 
Chapter 2 presented and characterised a novel aged microglia model by using the human 
microglial cell line SV40. It was found that their morphology changed to a less ramified 
and more amoeboid one when treated with iron. They had elevated iron storage and 
increased ferritin expression. Iron-treatment did not affect their levels of proliferation. The 
expression of some inflammatory cytokines was altered by iron treatment, namely IL-1β, 
IL-6 and IL-8 similarly to aged microglia while others such as TNFα, IL-2, IL-10 and IL-13 
were unchanged. Iron-fed microglia also showed changes in other aged microglia markers 
such as decreased glutamate release, decreased SIRT1 expression and increased KV1.3 
expression. 
 
Conditioned medium from the iron-fed human microglia cell line was used to investigate 
the effects of iron-fed microglia on APP processing in SHSY5Y cells. It was found that 
reduced levels of IDE in the conditioned medium resulted in reduced β-amyloid 
degradation. The reduced secretion of IDE was due to ER stress induced by the elevated 
iron and the resultant reduction in autophagic flux in the iron-fed microglia. 
 
Chapter 3 characterised the aged microglia model using the mouse microglial cell line 
C8B4 and mouse primary microglial cells. C8B4 and primary microglia showed a loss in 
projections and C8B4 showed deramification and membrane fragmentation. Iron-fed 
C8B4 microglia origin were found to store significantly higher levels of iron and express 
more ferritin but not to release that iron into their conditioned medium. Their proliferation 
and cell death rates were found to be lower than control cells. Iron-fed microglia also 
exhibited increased expression of KV1.3 and increased secretion of reactive oxygen 
species. The levels of inflammatory cytokines released by iron-fed C8B4 and primary 
microglia were also found to change, where TNFα consistently elevated and IL-6 
decreased in both cell types. Other cytokines such as IL-1β were elevated in C8B4 
microglia and decreased in primary microglia, while IL-10 showed an increase in primary 
microglia and decreased in C8B4. The chemokine KC-GRO was only detected in primary 
microglia and was found to be elevated.  
 
Conditioned medium from both iron-fed C8B4 and iron-fed primary microglia was found to 
increase α-synuclein levels in SHSY5Y cells. That was probably mediated by a 
transcription factor that bound the promoter of α-synuclein. This increase was most likely 
caused by the elevated levels of TNFα in the iron-fed microglia conditioned medium and 
mediated through the NFκB pathway. The effects of iron-fed microglia seen in Chapter 2 
and 3 are summarised in figure 5.1. 
Chapter 4 found that elevated levels of α-synuclein in SHSY5Y cells increased the toxicity 
of α-synuclein toxic oligomers. This was most likely mediated through the activity of 
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FOXO3a.  The elevation in FOXO3a expression was found to be caused by increased 
levels of ROS. The elevated levels of ROS were generated by an increased level of Fe2+ 
which is a product of the ferrireductase activity of α-synuclein.  
 
Figure 5.1. Microglial aging model induced by iron. This figure summarises the effects 
caused by iron accumulation in aging microglia. It leads to an altered microglial 
morphology and altered intracellular processes namely increased ER stress leading to 
decreased autophagy. That leads to decreased release of IDE which results in decreased 
degradation of β-amyloid in the extracellular space. Iron accumulation also leads to 
increased secretion of inflammatory cytokines and ROS from which TNF-α causes 
increases in α-synuclein levels and toxicity in neurons mediated through FOXO3a.  
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5.2 Comparison of the different iron-fed microglial models 
The treatment of microglia with iron resulted in a largely similar phenotype in all three 
models, namely: increased iron storage, a more deramified morphology, and generation of 
more proinflammatory cytokines. However, some discrepancies between the different cell 
lines and between cell lines and primary cells were noted.  
The first difference of note was the proliferation rates of iron-fed microglia compared to 
untreated. The proliferation of the iron-fed human microglial cell line was not found to 
change while in the C8B4 mouse microglial cell line they were found to proliferate 
significantly slower. Proliferation of cells in culture is generally controlled by tumour 
suppressor proteins such as pRb, p53, p16 and p27(Rayess et al. 2012; Kossatz and 
Malek 2007; Giacinti and Giordano 2006; Harris 1996). It can also be activated by 
mitogens such as EGF or the activation of MAP kinase (Sontag et al. 1993; Hebert et al. 
2009).  Microglial  proliferation is a slow process but its rate can be increased by 
inflammatory signals such as IL-1β and TNFα but also hydrogen peroxide (Mander et al. 
2006). In the cell lines used in this project proliferation was induced artificially or 
spontaneously and it’s possible that the effects of these external interventions could have 
obscured any expected changes in proliferation. Yet, that still doesn’t explain how the iron 
treatment could have induced different effects on the different cell lines. The human cell 
line was immortalized by transfection with the SV40 viral vector. SV40 can inactivate 
tumour suppressor pathways such as p53 and pRb and also induce telomerase activity in 
order to prevent replicative senescence (Hubbard and Ozer 1999). C8B4 on the other 
hand was a spontaneously transformed cell line without the addition of any carcinogens or 
oncogenic viruses (Alliot et al. 1996). It is possible that iron treatment could have activated 
tumour suppressor pathways which was masked in the human microglial cell line but 
observed in C8B4 cells because their tumour suppressor pathways were not artificially 
inactivated. Additionally, the background rate of proliferation of the two cell lines would 
have affected the measurements. The human microglia cell line proliferated significantly 
faster than C8B4s which could have also obscured any effects on proliferation that iron 
may have had. 
Secondly, the cytokine profile of the three cell types measured was different to begin with 
and in some cases reacted differently when the cells were treated with iron. Firstly, IL-1β 
was elevated in iron-fed cell lines but decreased in iron-fed primary microglia. Additionally, 
IL-6 was found to increase in human iron-fed microglia and the C8B4 mouse microglia but 
decreased in iron-fed primary mouse microglia. On top of that IL-10 was unchanged in 
human microglia, decreased in C8B4 and increased in primary microglia. TNFα was also 
unchanged in iron-fed human microglia but elevated in both types of mouse microglia. 
Finally, primary mouse microglia were found to release large amounts of the chemokine 
KC-GRO while C8B4 cells did not release it at all.  
In terms of the studies presented in this thesis, these discrepancies raise a question about 
the consistency of the iron-fed microglia model. Most importantly as the human iron-fed 
microglia cell line didn’t express significantly more TNF-α than controls it is doubtful that 
conditioned medium from human microglia would be able to replicate the effects seen with 
C8B4 or primary microglia conditioned medium such as the increased expression of α-
synuclein  in SH-SY5Y cells treated with conditioned medium. That could potentially also 
be explained through the basal difference in proliferation rates between the two cell lines. 
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It is possible that these rates are an autocrine system related to the sensitivity of the cells 
to their own cytokines which would also alter their secretory phenotype.  Additionally, iron-
fed primary microglia had the largest amount of discrepancies from all cell types used. It 
has been demonstrated in multiple studies that primary microglia cannot be cultured in 
isolation as they de-differentiate soon after that. However, a recent report has suggested 
that this de-differentiation can occur within hours of isolation (Bohlen et al. 2017). This 
could provide a possible explanation for the surprising discrepancy in cytokine release 
between cell lines and primary microglia which had to be purified from a mixed culture to 
perform the measurements. Cytokine signatures in microglia are dynamic and can rapidly 
change due to a change in environment which means that the cytokine expression pattern 
of iron-fed microglia could have been altered by the de-differentiation processes induced 
by their isolation. 
The differences in the effects of iron between the different cell lines and the primary 
microglia could be due to intrinsic differences in the biology of the different cells. The two 
cell lines have been shown by the manufacturers and us to retain many microglial 
characteristics, however they are unlikely to retain all of them considering that they 
underwent an immortalisation process. Additionally, the discrepancies seen between the 
primary microglial cells and the mouse microglia point to the possibility that different 
culturing conditions possibly induce different responses to iron in microglia. The C8B4 
cells were cultured by themselves while primary microglia were grown in mixed glia 
culture that was treated with iron for prolonged periods. It is possible that altered 
intercellular communication in the mixed culture was responsible for some of the 
unexpected responses in primary microglia in terms of their cytokine profile.  
 
5.3 Validity of the Microglial Models 
5.3.1 Validity of iron-fed microglia as a model for aged microglia 
The microglial model of aging presented in this thesis replicates many qualities of aged 
microglia. Firstly, it was demonstrated that microglia can accumulate iron similarly to how 
they do in aging. Additionally, they were shown to exhibit impaired autophagy. They also 
displayed similar changes in the expression of proteins related to aging such as SIRT1 
and KV1.3. Their secretory phenotype was also similar to aged microglia – reduced 
glutamate release, increased reactive oxygen species and increased inflammatory 
cytokines. Additionally, the successful replication of the role of microglia in major aspects 
of age-related neurodegenerative disease such as α-synuclein and β-amyloid deposition 
suggested that this model is a valid representation of aged microglia.  
However, despite the many similarities of iron-fed microglia to real aged microglia some 
important differences should also be noted. Data on microglial numbers in the aged brain 
points to an overall maintenance of microglial density maintained through proliferation and 
apoptosis (Askew et al. 2017). In contrast to this data iron-fed C8B4 cells exhibited lower 
proliferation rates than controls. On the other hand, they also exhibited lower death rates 
which did result in a similar situation to that observed in the brain. Due to the immortalised 
nature of the C8B4 cell line it is difficult to make any conclusions on whether this 
difference could be used to explain any other differences observed between iron-fed and 
aged microglia.  
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The cytokine profile of iron-fed microglia compared to real aged microglia also exhibited 
some discrepancies. In aged mice overall microglia have been found to show an 
increased expression of both proinflammatory (IL-6, IL-1β, TNF-α) and anti-inflammatory 
cytokines (IL-10) (Mosher and Wyss-Coray 2014; Norden and Godbout 2013). Aged 
microglia in the mouse brain have been found to produce more IL-6 while iron-fed primary 
mouse microglia produced less (Ye and Johnson 1999). They have also been found to 
produce more IL-10 which was also seen in primary mouse microglia but not in C8B4 
mouse microglia. IL-10 was found to be elevated in aged mouse brains stimulated by LPS 
too. Aged mouse microglia exhibit increased levels of IL-1β while iron-fed mouse primary 
microglia secreted less IL-1β. On the other hand, TNF-α, found to be increased in aged 
mouse microglia and similarly in iron-fed C8B4 and primary microglia was unchanged in 
human microglia.  
Changes in cytokine expression have been better studied in aged mouse microglia and 
less well in humans. The cytokine profile of microglia in the aged human brain in one gene 
expression study shows decreased levels of IL-10, IL-1β and unchanged TNFα (Olah et 
al. 2018). On the other hand, another older study shows an increase of IL-1β positive 
microglia in the aging brain (Sheng et al. 1998). Iron-fed microglia from the human cell line 
however showed discrepancies in the levels of some of the cytokines mentioned above.  
These discrepancies point to the fact that the iron-fed microglia model, while promising is 
still in its initial stages of development and would need further refining and 
characterisation in order to understand if it is capable of fully replicating the complex and 
often conflicting phenotype of aging microglia.  
As it has been recently argued, due to the difficulty and costs of culturing real aged 
microglia and the unsuitability of ex vivo microglial harvesting for many types of studies it 
is still vital that more efficient and practical aged microglial models such as iron-fed 
microglia are developed and optimised (Koellhoffer et al. 2017). 
5.3.2 Validity of other models of microglial aging 
The Ercc1Δ/− mouse model exhibits accelerated aging due to the deletion of the DNA 
excision repair protein ERCC. That results in genomic instability, one of the hallmarks of 
aging and a root cause for cellular senescence. Ercc1Δ/− mouse microglia have been 
shown to have some characteristics similar to aging (Raj et al. 2014). They exhibited a 
primed phenotype which has been linked to microglial aging. They were shown to have a 
larger size and process length compared to control microglia. Their proliferation was also 
significantly increased. The levels of cytokines such as IL-1β. TNF-α and IL-6 were 
unchanged until the microglia were stimulated with LPS, when they reacted more strongly 
than control replicating the actions of primed microglia found in aged mice (Godbout et al. 
2005). However they did not replicate the basal increase in cytokine production seen in 
aged mice (Sierra et al. 2007). They were also found to have increased phagocytosis and 
increased ROS production. On the other hand aged mouse microglia have been observed 
to phagocytose less material (Njie et al. 2012) Their transcriptional profile showed 
changes similar to those in aged microglia such as increase in interferon and chemokine 
signalling and antigen presentation. Interestingly, they further showed increased EIF2 
signalling similarly to iron-fed human microglia(Hickman et al. 2013).  
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The mouse model of accelerated aging through telomere shortening models aging in a 
similar way to ERCC deletion (Raj et al. 2015). Telomere shortening causes genomic 
instability and potentially triggers cellular senescence. also shows microglia that exhibit 
some aging characteristics. They display a phenotype of increased inflammatory response 
to LPS but similarly to the Ercc1Δ/− mouse they did not show any changes in inflammation 
under physiological conditions. Additionally, they did not show a gene expression pattern 
of age-associated microglial priming making them an unlikely candidate for an aging 
microglia model.    
The in vitro aging mouse microglia model has suggested that microglia convert to an aged 
phenotype with time in culture (Caldeira et al. 2014). The mechanism for this phenomenon 
has not been explained but is likely to be a form of replicative senescence. Changes in 
purified microglia grown in vitro for 16 days replicate many age-related changes when 
compared to freshly purified microglia. They showed reduced autophagy, reduced motility 
and reduced phagocytosis and increased expression of markers of senescence like SA-β-
GAL activity and miR-146a. In a second study they were also shown to be less able to be 
activated by β-amyloid (Caldeira et al. 2017).  However, they displayed characteristics of 
reduced reactivity such as decreased NFκB signalling and reduced cytokine release which 
are uncharacteristic of aging microglia (Sierra et al. 2007).  
Another in vitro model of aging microglia was induced by treating rat microglia in culture 
with the molecule dexamethasone (Park et al. 2018). Dexamethasone is supposed to 
mimic microglial exposure to steroid hormones in times of stress and was intended to 
model microglial behaviour in depression. However, the microglial phenotype that was 
induced displayed markers of senescence and reduced neuroprotection which were 
similar to changes as seen in the extended time in culture model such as reduction of 
cytokine release and phagocytosis and increased SA-β-GAL activity. The morphology of 
the phenotype they induced was ramified similar to resting microglia. This fact and their 
reduced cytokine release challenge this model’s validity in aging microglia research as 
mentioned in the study.  
 
5.3.3 Validity of LPS activation studies in microglia 
Models of microglial states are used in situations other than aging. Microglial activation is 
a major area of study because of the role activated microglia play in many diseases that 
affect the brain. Microglial activation is most commonly modelled by stimulation with 
bacterial lipopolysaccharide (LPS). LPS can be injected into animals or directly 
administered to cell culture. It results in a strong inflammatory response which is often 
used to study microglial response to neurodegeneration or protein aggregates in AD and 
PD (Nazem et al. 2015) . LPS injection has been used to induce microglial activation and 
neurotoxicity in the substantia nigra of rats(Subramaniam and Federoff 2017). In AD 
models, LPS has been found to induce microglia to phagocytose more β-amyloid in some 
studies (Mandrekar-Colucci and Landreth 2010; Herber et al. 2007; Liu et al. 2005; 
DiCarlo et al. 2001).   On the other hand LPS treatment has been shown to increase β-
amyloid deposition in a mouse model of AD (Sheng et al. 2003).  Some of the 
heterogeneity in these results could possibly be explained by administration methods 
where different amounts of LPS reach the brain depending on whether in was injected 
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peripherally or intracerebrally because of blood-brain barrier penetration. Additionally, LPS 
can produce different effects on microglia depending on the number of times they are 
exposed to it. Repeated LPS administration of LPS was reported to induce higher SA-β-
GAL activity indicating senescence in BV2 microglial cells. Alternatively, in a mouse model 
of AD one-off exposure to LPS can result in increased inflammation and amyloidosis while 
multiple exposures result in an anti-inflammatory response which is more neuroprotective 
termed as tolerance (Wendeln et al. 2018). Similar results have been seen in another 
study on repeated LPS injection in mouse models of acute brain injury (Chen et al. 2012).  
What this study suggests is that microglia have a complex response to LPS that can 
change over time and in different models. This finding is not surprising considering that 
microglia are highly heterogeneous cells but is indicative of the unsuitability of LPS for 
aging microglia studies. 
 
5.3.4 Validity of quantitating morphological changes in microglia 
Microglia are naturally highly reactive cells and are capable of changing their morphology 
in response to any external circumstances. Morphological changes in microglia have been 
observed with microscopy for a long time and are interesting visual cue for the changing 
phenotype of a cell. Newer methods have been described that allow 3D modelling and 
tracking of live movement and large-scale automated quantitation of microscopy data 
(Verdonk et al. 2016; Heindl et al. 2018; Ljosa and Carpenter 2009; Weinhard et al. 2018).  
Additionally, live imaging techniques allow for microglia to be monitored without fixing 
which can alter morphology and can be used on microglia behavioural studies.  (Dailey et 
al. 2013).   However, quantifying morphological changes doesn’t present much value in 
terms of characterising the molecular phenotype of these cells. Microscopy data is 
normally not truly quantitative as getting an unbiased sample with manual measurements 
is very difficult. Morphological changes is an abstract quality that historically has not been 
not as much measured as it was judged by the person analysing the data (Hamilton 
2009). Only recently have more quantitative methods been described that attempt to give 
a more unbiased measurement of microglial morphology (Davis et al. 2017) However, the 
morphological changes in microglia are driven by changes in the molecular environment 
of the cell, changes in transcription, levels and activity of proteins, signalling molecules 
and metabolites – all molecules that can be measured more precisely with biochemical 
assays. Thus, even though morphological changes are interesting to observe, the real 
value in studying changes in microglia comes from measuring changes on the molecular 
level.  
 
5.3.5 Relevance of general activation state studies. 
As explained in the Introduction, microglia have been shown to have a spectrum of 
activation states that are difficult to put into specific categories. Studying activation states 
of microglia is therefore important for the purpose of understanding their role in the brain 
more fully. This heterogeneity means that microglia will react differently to damage or 
infection depending on where they are located in the brain and what type the insult. Many 
studies have attempted to track microglial activation in different models of neuronal injury 
or disease (Thiel and Heiss 2011; Bosco et al. 2011; Morrison and Filosa 2013; Deng et 
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al. 2009; Mac Nair et al. 2016; Wohl et al. 2010). Methods for identifying and classifying 
activation states in microglia are currently being developed. Those are largely morphology 
based and are particularly relevant in in vivo studies (Megjhani et al. 2015; Hovens et al. 
2014; Eggen et al. 2013; Verdonk et al. 2016; Zanier et al. 2015; Davis et al. 2017).  
However, it has proven difficult to define specific activation states that microglia can fall 
into such as the likes of M1 and M2 for macrophages(Boche et al. 2013; Ransohoff 
2016).The evidence of microglial priming in the aging brain suggests that aged microglia 
would react differently to damage or insult to young microglia(Dilger and Johnson 
2008).Examples of cases where the activation of aged microglia has been studied are 
peripheral LPS injection in aged mice and peripheral E.coli injection in aged rats (Godbout 
et al. 2005; Wynne et al. 2010; Barrientos et al. 2009; Barrientos et al. 2006). In both 
cases aged microglia were shown to release increased levels of proinflammatory 
cytokines. In other studies aged microglia have been observed to show reduced 
migration, phagocytosis and recruitment of immune cells when activated by damage in 
murine models(Norden and Godbout 2013). A potential future avenue for characterisation 
of the iron-fed microglia aging model would be to study it in the context of murine models 
and assess whether iron-fed microglia react similarly to aged microglia in this context in 
terms of their cytokine release and other markers of activation.  
 
5.3.6 Senescence and SASP in aged and iron-fed microglia 
Cellular senescence has been shown to occur in many replication competent cell types in 
the brain and is thought to be a major contributor to inflammation in the brain in old age 
(Chinta et al. 2014). It is characterised by arrested growth due to elevated DNA damage 
and oxidative stress that results in increased SA-β-GAL activity, p16INK4a expression and 
the SASP among others. Interestingly, cells in vitro have been found to also naturally 
accumulate iron as a characteristic of the process of acquiring senescence (Masaldan et 
al. 2018; Killilea et al. 2003). SASP is an integral part of the characteristics of a senescent 
cell. It includes many signalling molecules such as proinflammatory cytokines, 
chemokines, reactive oxygen species, growth factors and proteases that can cause a 
significant negative impact on surrounding cells and is linked to the aging and ND brain 
(Chinta et al. 2014).  
Aged microglia have been shown to display many characteristics of senescence including 
iron accumulation and SASP-congruent increased secretion of cytokines and ROS. As a 
persistent population of cells that maintain their numbers through division they are at high 
risk for senescence. However, identifying and purifying senescent microglial cells in vivo 
in order to characterise their specific SASP has not been achieved yet. In chronic 
senescence which would be the type present in brain microglia, SASP can be more 
heterogenous than in cases of in vitro replicative senescence (van Deursen 2014).  
Nevertheless, understanding better how microglia undergo senescence by characterising 
their specific senescent phenotype and SASP is very important for determining how they 
affect the molecular environment of the aging brain, especially in terms of inflammation. 
Iron-fed microglia also display many signs of cellular senescence. Those include iron 
accumulation, mTOR activation, NFκB activation, increased proinflammatory cytokine 
release (IL-1β, IL-6, IL-8, KC-GRO) and ROS secretion. Additionally, they showed lower 
Page 132
rates of proliferation in the C8B4 cell line whose proliferation was not artificially 
manipulated. These similarities position iron-fed microglia as a useful model for 
characterising the SASP that aged microglia can have. Further investigation into how well 
iron-fed microglia replicate other markers of senescence would be essential if they are to 
be applied as a model of senescent cells. 
 
5.4 Future work 
5.4.1 Further characterisation of the iron-fed microglial phenotype. 
 
The changes that microglia undergo when treated with iron resemble those of aged cells. 
In order to comprehensively study the phenotypic changes that iron-fed microglia undergo 
it would be useful to have a complete dataset of their transcriptional phenotype. 
Performing RNAseq on the iron-fed SV40 human and C8B4 microglial cell lines and also 
on primary mouse microglia and comparing those to untreated controls and existing 
datasets for aged and diseased human and mouse microglia would help to identify major 
pathways that are affected in iron-fed microglia and how those compare to the changes 
seen in aged or diseased microglia. That would allow us to identify molecules and 
pathways to target in order to understand how the senescent phenotype can be replicated 
by iron accumulation. It will also allow us to study how iron-fed microglia resemble or differ 
from microglia in neurodegenerative disease. Additionally, this will make it possible to 
screen aged tissue samples for markers of microglial dystrophy as very few of those have 
been identified to date. Other senescence markers identified in the literature such as SA-
β-GAL activity, p16INK4a, CD200 and CX3CR1 expression and activity could also be 
investigated. Measuring changes in activity in iron-fed microglia is also very important for 
fully characterising the model. Microglial motility and phagocytic ability could be measured 
in the cell culture models to identify if those are reduced as seen in aged microglia. An 
ATP-triggered motility assay and a latex bead or β-amyloid phagocytosis assay could be 
employed to assess those effects. Phagocyting status of microglia could also be 
measured by Galectin-3 staining (Shobin et al. 2017). Additionally, even though the 
cytokine profile of iron-fed microglia has been characterised, TGF-β – an important anti-
inflammatory cytokine found to be altered in aged microglia in some studies is yet to be 
measured. That could be achieved through utilising an immunoassay in a similar manner 
as other cytokines in the conditioned medium were measured. Finally, decreased 
expression of SIRT1 has been seen in iron-fed microglia. A possible outcome of less 
SIRT1 activity can be increased levels of acetylated FOXO3a which can lead to increased 
levels of oxidative stress in microglia. Measuring SIRT1 activity and levels of FOXO3a 
acetylation would allow for assessing if the FOXO3a pathway is also involved in the iron-
fed microglia phenotype. 
 
Gathering this information would make is possible to assess how iron supplementation 
pushes microglia into the aged phenotype. This may be due to membrane oxidation and 
DNA damage which can be measured with standard biochemical techniques. In order to 
fully understand this mechanism phenotype reversal will also have to be attempted. 
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5.4.2 In vivo application of iron-fed microglia 
 
Another important avenue to investigate would be the application of the aged microglia 
model in vivo. Therefore, it is very important to determine if iron-fed microglia transplanted 
into mouse brains will induce phenotypic changes in neuronal cells similar to those seen 
in the culture models. For this to be achieved control and iron-fed microglia could be 
transplanted in to live rodent brains. This has been previously attempted with both primary 
and cell line microglia (Leovsky et al. 2015; Narantuya et al. 2010; Watanabe et al. 2002; 
Takata et al. 2007). The areas where transplantation would be attempted would ideally be 
areas of the brain that are affected by aging such as the substantia nigra. The microglia 
would be transplanted using stereotaxic injection. The first hurdle to overcome would be to 
confirm microglial survival. This can be done by labelling the microglial cells with a long-
term fluorescent marker such as carboxyfluorescein succinimidyl ester. In the initial stages 
post transplantation mice would be sacrificed and brain sections probed for the 
fluorescent marker and for microglia with high levels of ferritin expression. An important 
issue to be considered is that iron-fed microglia may have a lower rate of survival 
compared to healthy controls which may affect the results of further tests. After confirming 
the survival of the microglia in mouse brains the mice would be monitored for changes in 
behaviour such as decreased locomotion and general ill health. Tests such as rotarod and 
forepaw stride length could be utilised. The effect of iron-fed microglia on neuronal viability 
and signs of neurodegenerative disease could be measured. Standard methods such as 
TUNEL staining could be used to assess neuronal viability. α-synuclein and β-amyloid 
levels together with signs of aggregation and changes in markers of dopamine 
metabolism could also be measured to assess the effect of iron-fed microglia on markers 
of neurodegenerative disease. Additionally, microglia could be monitored for signs of 
dystrophy in situ which would be a much more appropriate environment to investigate 
such changes compared to in vitro. If changes related to neurodegeneration can be 
replicated it would be important to attempt microglial phenotype reversal in vivo to find out 
if that can prevent downstream pathological changes in the CNS. 
 
 
5.4.3 Phenotype reversal 
 
Understanding what produces the phenotype caused by iron supplementation can be 
greatly aided by attempting to reverse it. The effects could be caused by the elevated 
levels of iron themselves or by lasting molecular damage to the microglia caused by the 
iron accumulation. One avenue of investigation is applying iron chelators to the iron-fed 
microglia to find out if lowering the levels of iron reverses, the senescent phenotype. 
Common iron-chelators that can cross the blood-brain barrier are deferiprone and 
deferoxamine. Deferiprone has been shown to improve the pathology of 
neurodegeneration with brain iron accumulation (Abbruzzese et al. 2011). Deferoxamine 
is used to treat iron accumulation following brain haemorrhage (He et al. 2016; Hua et al. 
2008).Those can be applied to the cell culture model and in vivo models to reduce iron 
levels. That can be estimated through measuring iron storage, ferritin levels and iron 
staining. Improvements in migration, phagocytosis, cytokine release, autophagy and ER 
stress would suggest that the phenotype has been reversed. If that is the case, other iron 
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chelators can be investigated. A potential avenue of research can be phytochemicals such 
as polyphenols and flavonoids are molecules contained in plants with reported beneficial 
effects on neurodegeneration. They are a type of natural iron chelators and have been 
shown to be very effective in cell culture (Reznichenko et al. 2006; Hatcher et al. 2009; 
Ferlazzo et al. 2016). Epigallocatechin gallate (EGCG) is a polyphenol contained in green 
tea and has been proposed as a potential therapeutic for neurodegeneration as it has 
shown neuroprotective and antioxidant effects in vitro. EGCG has also been found to 
chelate iron but its ability to cross the blood-brain barrier has been shown to be quite low 
thus limiting its potential effectiveness in vivo (Singh et al. 2016; Pervin et al. 2017).  
Quercetin, a flavonoid shown to chelate iron similarly has low blood brain barrier 
permeability but that could potentially be enhanced by co-administration of α-tocopherol 
(Ferri et al. 2015).     
 
A possible outcome of iron depletion would be that the damage caused by iron is 
irreversible. In that case it would be important to pinpoint which changes in the cellular 
metabolism are mechanistic to the senescent phenotype. If for example iron caused DNA 
damage removing iron from the system would not reverse that. However, by stimulating 
DNA repair mechanisms the phenotype could possibly be reversed suggesting that DNA 
damage is the underlying mechanism of the senescent phenotype. When looking into 
reversing iron-mediated damage it is important to consider the increased division rates of 
cell lines. That presents a limited window of opportunity for reversing damage as 
proliferation will obscure any measurable changes. A slower proliferating cell line like 
C8B4 would be more suitable for these experiments than fast proliferating ones like BV2 
or the SV40 human microglia cell line.  Even then, attempting this type of phenotype 
reversal would be best in primary microglia or in vivo.  
 
Another potential strategy to reverse the aged microglial phenotype is exposing them to 
young microglia. In a mouse brain slice culture model, it was observed that treating aged 
microglia with the conditioned medium of young microglia restored their viability and ability 
to phagocytose β-amyloid (Daria et al. 2017). That was also replicated by treating the 
aged cells with granulocyte‐macrophage colony‐stimulating factor (GM-CSF). Treating 
iron-fed microglia with conditioned medium from young microglia may result in a reversal 
of the aged phenotype in a similar way. GM-CSF is known to drive microglial proliferation 
which was necessary for the enhanced amyloid clearance in that model. It is possible that 
in our model more factors secreted by young microglia such as cytokines may play a role 
in reversing all the age-related changes observed.  
 
Resveratrol treatment has been shown to reverse cellular senescence in vitro and to have 
a direct action on reducing the release of SASP cytokines, activating SIRT1 and 
modulating levels of mRNA splicing factors (Fuggetta et al. 2016; Sinclair and Guarente 
2014; Markus et al. 2011; Matos et al. 2017; Latorre et al. 2017). Treating iron-fed 
microglia with resveratrol could result in a recovery in SIRT1 levels and a reduction in 
inflammatory cytokine levels and possibly the amelioration of other markers of the aged 
phenotype. Different molecular analogues of resveratrol have also been developed that 
have an action on a smaller subset of resveratrol targets (Latorre et al. 2017). If 
resveratrol is effective in reversing the phenotype, testing which of those analogues if 
capable of doing the same would allow to trace back which particular pathway causes the 
iron-fed microglia phenotype. 
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Finally, reversing the phenotype of iron-fed microglia could potentially be achieved by 
applying the drug metformin that has in a number of studies been shown to extend human 
lifespan through a number of potential mechanisms that have been linked to nutrient 
sensing including decreased IGF-1 signalling, inhibition of mTOR, reducing ROS and DNA 
damage and lowering inflammation. As it is very likely that these pathways are involved in 
the generation of the iron-fed aged microglial phenotype it is possible that metformin could 
be used to improve their viability. Additionally, metformin has recently been applied to 
induce alternative activation in microglia and promote microglia assisted healing in 
different conditions which suggests that it has a beneficial effect on pathological 
conditions in the brain (Inyang et al. 2016; Ge et al. 2018; Jin et al. 2014). Metformin’s 
long-standing usage as a drug in humans and the numerous studies done on animal 
models make it an interesting potential candidate for microglial aged phenotype reversal 
for in vivo applications.  
 
Being able to reverse the aged phenotype would be of benefit not only to the aged 
microglia cell culture model but also to its in vivo application and potentially for developing 
treatments for age-related neurodegenerative disease.  
 
5.4.4 Role of microglia in other neurodegenerative diseases with an 
iron accumulation component 
 
Iron homeostasis in the brain is finely tuned and the iron content of different parts of the 
brain is heterogenous. The aging process can lead to the accumulation of iron in certain 
cell types and brain regions. Iron has been found to be naturally stored in 
oligodendrocytes, but it accumulates with age in microglia and astrocytes.  An increase in 
iron-positive microglia and astrocytes have been found in the hippocampus, cortex, basal 
ganglia and the cerebellum. Iron has also been found to accumulate as ferritin in specific 
areas of the brain such as the globus pallidus, substantia nigra and the cortex. 
Additionally, increases of iron as neuromelanin have been found in catecholaminergic 
neurons in the substantia nigra. The reason behind this accumulation has not been fully 
elucidated. A possible explanation is increased vascularization of the brain. Alternatively, 
a leaky blood-brain barrier could result in the penetration of excess iron into the brain. 
Increased inflammation could also be the underlying reason for the increase in brain iron 
(Angelova and Brown 2015; Ward et al. 2014). Whatever the cause for the increases in 
brain iron it is important to point out that the regions where it accumulates with age are 
often affected by ND as well.  
Iron can have a multitude of negative effects in an organism. In fact, there are some 
diseases in which accumulation of iron or dysregulation of iron metabolism could be a 
central disease driving mechanism.  
Neurodegeneration with brain iron accumulation (NBIA) is a cluster of diseases that are 
characterised by intellectual disability, movement impairment and abnormal deposition of 
iron in the basal ganglia. There are ten subtypes of NBIA currently identified 
(pantothenate kinase-associated neurodegeneration (PKAN); phospholipase A2-
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associated neurodegeneration (PLAN); mitochondrial membrane protein-associated 
neurodegeneration (MPAN); and beta-propeller protein-associated neurodegeneration 
(BPAN), fatty acid hydroxylase-associated neurodegeneration (FAHN), coenzyme A 
synthase protein-associated neurodegeneration (CoPAN), neuroferritinopathy (NF), Kufor-
Rakeb syndrome (KRS) and aceruloplasminemia (ACP)) where PKAN is the most 
common (Gregory and Hayflick 2011). All these heritable diseases are caused by a 
mutation in a single gene and are considered ultra-rare. An interesting form of NBIA is 
neuroferritinopathy (NF) as it demonstrates a direct link between dysregulated iron 
storage and neurodegeneration. It is caused by mutations in the gene FTL1 coding for the 
ferritin light chain protein (Chinnery 2010; Kumar et al. 2016; Levi and Rovida 2015). This 
leads to low serum ferritin levels but accumulation of iron and ferritin inclusions both in the 
basal ganglia in a pattern similar to normal aging and in other tissues in the body. The 
disease manifests usually late in adulthood as progressive chorea and dystonia and many 
other motor symptoms and also cognitive decline. The iron and ferritin deposits are found 
both extracellularly and in various cell types in the brain including astrocytes, 
oligodendrocytes, cerebellar granule cells, Purkinje cells and microglia. The proposed 
molecular mechanism for the disease is that the mutations that are linked to NF seem to 
reduce the ability of ferritin to store iron. The increased free iron can then cause oxidative 
damage to which the brain is particularly sensitive thus explaining why it’s only the 
nervous system that is affected. Even though iron accumulation is seen in microglia in NF 
their role in the disease has not been studied. 
Another disease directly linked to iron is Friedrich’s ataxia (FA). FA is a hereditary 
neurodegenerative disease and is the most common of all hereditary ataxias. It usually 
develops in childhood and leads to the degeneration of the spinal cord and peripheral 
nerves and also the cerebellum leading to motor symptoms but cognitive ability is not 
impaired in FA (Bürk 2017). Other commonly found symptoms include heart problems and 
diabetes. FA is a serious condition and often results in a severely reduced lifespan. It is 
caused by a mutation in the gene coding for the protein frataxin. The mutation causing FA 
is an expansion of a trinucleotide repeat in the first intron of the frataxin gene leading to 
reduced expression of the protein (Bürk 2017). Frataxin is a mitochondrial protein that is 
thought to act as an allosteric modulator of iron-sulphur-cluster protein assembly. It has an 
essential role in cellular function as frataxin KO in mice is lethal. Frataxin deficiency 
results in mitochondrial iron accumulation and cytosolic iron depletion. It also results in 
respiratory chain disruption which elevates the amounts of H2O2 in mitochondria that 
oxidise the accumulated iron and thus resulting in further oxidative stress through the 
Fenton reaction. The potential role of microglia in FA has not been extensively studied but 
increased ferritin staining in microglia has been found in the dentate nucleus of FA 
patients. Additionally frataxin deficiency in the microglial cells of a FA mouse model has 
been shown to induce DNA damage and increase microglial inflammatory response (Shen 
et al. 2016). Treatment of FA patients with the iron chelator deferiprone has resulted in 
reduced iron accumulation in the cerebellar dentate nucleus and an improvement in motor 
and speech symptoms further confirming the central role iron accumulation plays in this 
condition (Bürk 2017; Koeppen et al. 2007).  
From these examples it is clear that iron plays an important role in the brain and that iron 
dyshomeostasis is implicated in some way in many ND and can potentially cause a lot of 
damage in the nervous system. This topic has been also reviewed in Angelova and Brown 
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2015 (Appendix 7.1). Therefore, the accumulation of iron in microglia seen with aging is 
unlikely to be without negative consequences as also demonstrated in the iron-fed 
microglial model. 
 
5.5 Applying iron-fed microglia to the study of β-Amyloid 
5.5.1 Relevance  
 
The main finding of chapter 2 that reduced IDE secretion by microglia results in reduced 
β-amyloid degradation has been observed in literature. Reduced IDE levels have been 
measured in AD brains and mouse models of AD. However, in AD, the levels of β-amyloid 
are not only maintained by levels of other proteases but also by microglial phagocytosis, a 
process that was not investigated in this study.  
 
5.5.2 Advantages and disadvantages of using the iron-fed microglia 
model in the study of β-amyloid  
 
Using iron-fed microglia to model microglia in AD has its benefits and drawbacks. The 
human microglial cell line that was used in chapter 2 shows many changes similar to 
microglia in AD.  
The morphological changes that were seen in the microglial cell line have been identified 
in the microglia of human AD brains, namely reduced process length and branching 
(Davies et al. 2017). The increased ferritin expression in the aging microglia model has 
also been seen in AD. Ferritin positive microglia have been identified in human AD brains 
in an even higher proportion than normal aging (Lopes et al. 2008). Additionally, increases 
in ferritin bound iron have been linked to earlier age of onset of AD in men (Bartzokis et al. 
2004). However, both of these studies only show a tangential link between increased 
ferritin expression and the microglial phenotype in AD. Decreased autophagy in microglia 
is a marker of aging that not been heavily researched in AD. Primary microglia from 
human AD brains show reduced expression of beclin 1, an early stage driver of 
autophagy. Additionally, inhibiting key activators of autophagy in microglia has been 
shown to reduce β-amyloid clearance and also to increase the release of proinflammatory 
factors (Lucin et al. 2013; Cho et al. 2014). Also, ER stress has been implicated in AD and 
is thought to be one process through which neurons can die, while microglia have not yet 
been observed to exhibit more of it in AD (Salminen et al. 2009).   
The expression of protein markers of microglial aging has also been validated by studies 
on microglia in AD. KV1.3 expression, perhaps unsurprisingly is another factor where the 
aged microglia model replicated changes seen in AD, as KV1.3 positive microglia are 
present in both human and rodent models of AD (Maezawa et al. 2018; Rangaraju et al. 
2015). The SIRT1 deficiency observed in the aging microglia model replicated changes 
seen in aging microglia. Microglial SIRT1 decline has been linked to increased IL-1β 
production as seen in microglia in AD (Cho et al. 2015). Additionally, overall decline in 
SIRT1 has been correlated with AD pathology (Julien et al. 2009). Even though the data 
available points in this direction, there is no data on the actual levels of SIRT1 in microglia 
in AD. 
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All these points suggest that the iron-fed aged microglia model replicates the behaviour 
and markers of microglia in AD well and is therefore a viable tool for incorporating 
microglia into AD studies. 
 
5.5.3 Future Work 
 
The production of β-amyloid was also affected by microglial conditioned medium. As α- 
and β-secretases expression was already investigated the data suggest that the observed 
increase in β-amyloid could be due to an increase in γ-secretase activity, confirmed by the 
results from the Notch cleavage assay. More γ-secretase activity could be caused by an 
increase in the expression of the components of this protease. The expression of PS1, a 
main component of γ-secretase has been shown to be induced by impairment in 
autophagy (Ohta et al. 2010). Measuring PS1 levels and then assessing neuronal cells 
treated with microglial conditioned medium for autophagy impairment would be a potential 
strategy to explain another avenue through which β-amyloid levels could increase.  
Another avenue through which this work could be taken further would be to investigate if 
iron-fed microglia are capable of phagocytosing β-amyloid. In AD β-amyloid phagocytosis 
by microglia is reduced. This could be investigated through an in vitro assay on 
fluorescently tagged β-amyloid internalisation as described previously (Lian et al. 2016).  
Another question that is yet to be investigated in the context of the effect of iron-fed 
microglia on β-amyloid deposition is whether iron-fed microglia affect β-amyloid 
oligomerisation. It has already been shown that protofibril forms of β-amyloid are more 
readily internalised by microglia than monomers and lead to greater levels of 
activation(Gouwens et al. 2016). Oligomers and protofibrils also seem to lead to 
differential modes of activation in microglia (Sondag et al. 2009). However, whether 
factors released by microglia affect oligomerisation rates of β-amyloid is not known. The 
oligomerisation process is thought to occur intracellularly in neurons but also 
extracellularly and is possibly driven by β-amyloid fibrils (Walsh et al. 2000; Cohen et al. 
2015). Therefore applying conditioned medium from iron-fed microglia to neuronal 
cultures would allow for any changes in β-amyloid oligomer levels to be measured using 
molecular probes or antibodies (Lee et al. 2017).  
 
5.6 Applying iron-fed microglia to the study of α-Synuclein 
5.6.1 Relevance  
 
α-synuclein levels have been shown to be elevated in areas of the brain affected by PD in 
multiple studies. The finding presented in Chapter 3 provides one possible explanation for 
how this can occur. The role of microglia in PD pathology has been generally recognised 
as many studies have described how α-synuclein can induce microglial activation. TNF-α 
levels have been shown to be increased in PD and Microglia positive for TNF-α have been 
identified in the substantia nigra in PD. Additionally, the toxicity of TNF-α produced by 
microglia on dopaminergic neurons has been observed in many studies (Lull and Block 
2010).  However, the finding that TNF-α released by aging microglia can increase the 
expression of α-synuclein has had very limited coverage in literature as mentioned in the 
discussion of chapter 3. A cell culture study investigating TNF-α released by activated 
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microglia also found an increase in α-synuclein levels but explained them through reduced 
degradation by reduced lysosome acidification induced by TNF-α. They observed no 
change in mRNA levels for α-synuclein in contrast to results reported in this thesis that 
suggested elevated α-synuclein transcription. That could be due to differences between 
the cell lines used in the two studies. However, disrupted autophagic flux is another 
potential pathway that could also have affected the α-synuclein levels in SHSY5Y cells 
treated with microglial conditioned medium(M.-X. Wang et al. 2015).  
The main finding of chapter 4 that increased levels of α-synuclein increase the toxicity of 
α-synuclein oligomers through elevated oxidative stress is novel but is generally 
supported by the findings of many other studies. As mentioned previously elevated levels 
of wild type α-synuclein are causative of a form of parkinsonism so therefore must 
contribute to toxicity (Olgiati et al. 2015). Additionally, elevated oxidative stress has been 
recognised as a disease driving process in PD with significant evidence for oxidative 
damage in various cellular components and as already discussed PD patients have been 
found to have elevated Fe2+(X. Chen et al. 2012). Fe2+ as a source of ROS has also been 
identified in PD with some dopaminergic neurons also presenting increased iron levels in 
the substantia nigra. Interaction and subsequent reduction of iron by dopamine or other 
ferrireductases have been proposed to be the source of Fe2+ in PD (Ponting 2001; Hare 
and Double 2016).Therefore the finding that elevation of α-synuclein – another 
ferrireductase could lead to the same elevation in Fe2+ is not surprising. Additionally, 
increased levels of α-synuclein have been shown to increase the toxicity of other 
exogenous factors such as copper, suggesting that appropriate α-synuclein levels are 
important for cellular homeostasis (Anandhan et al. 2015). As discussed in chapter 4 the 
balance in expression between α- and β-synuclein also seems to be implicated in α-
synuclein toxicity.  These results point to another potential avenue for how PD pathology 
can proceed through aged microglia causing elevated α-synuclein, disrupting α and β-
synuclein homeostasis and driving neurotoxicity through elevated oxidative stress as a 
result. 
 
In conclusion, the data presented in this thesis provide a valid pathway on how aged 
microglia can influence PD pathology from a previously unexamined angle that fits with 
the current knowledge on how PD proceeds in humans (Imamura et al. 2003; 
Subramaniam and Federoff 2017).  
 
5.6.2 Advantages and disadvantages of using the iron-fed microglia 
model in the study of α-synuclein 
 
Using the iron-fed microglial model in the study of α-synuclein in disease has undeniable 
merits. Microglia have been shown to play a major role in PD or other synucleinopathies. 
The iron-fed aged microglial model shows changes in their phenotype and behaviours that 
are similar to changes detected in microglia in PD or other synucleinopathies. Firstly, the 
increase in ferritin bound iron in iron-fed microglia replicates the increases in ferritin bound 
iron and ferritin positive microglia in the substantia nigra seen in PD (Jellinger et al. 1990). 
Microglial activation is thought to be a major pathological process in PD. In fact, 
inactivating microglia ameliorates PD pathology in mouse models treated with MPTP (M. 
Lu et al. 2016). Microglia in PD have been shown to release higher levels of IL-6, TNFα 
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and IL-1β similarly to iron-fed C8B4 microglia. Additionally, microglial KV1.3 has been 
found to be essential for the killing of neurons (Fordyce et al. 2005). On top of that 
microglia in PD have been found to release increased levels of ROS(Peterson and Flood 
2012). On the other hand, the cytokine profile observed in iron-fed primary mouse 
microglia is not as similar to microglia in PD as the iron-fed C8B4 cell line. They only 
showed an increase in the secretion of TNF-α suggesting that the iron feeding protocol at 
its’ current iteration doesn’t replicate the changes seen in microglia in PD in primary cells 
as well as it does in cell lines.   
 
5.6.3 Future Work 
 
Future work that can benefit from using model senescent microglia is assessing other 
ways in which aged microglia could affect α-synuclein deposition. Microglia have been 
shown to be effective at phagocytosing extracellular α-synuclein. Iron-fed microglia can be 
utilised to investigate whether aged microglia which have been shown to have impaired 
phagocytic ability are less capable of clearing extracellular α-synuclein deposits. 
Internalisation of fluorescently labelled α-synuclein by microglia can be measured by 
confocal microscopy. Additionally, neuronal co-culture can be used to assess whether 
levels of α-synuclein phagocytosis are altered.  
Another potential mechanism through which iron-fed microglia could increase α-synuclein 
aggregation is through the release of nitric oxide (NO). Increased release of NO can lead 
to α-synuclein nitration which has been reported to increase rates of aggregation(Shavali 
et al. 2006). Additionally, elevated α-synuclein nitration has been observed in the aging 
primate substantia nigra(McCormack et al. 2012). Measuring NO released in the 
conditioned medium of iron-fed microglia, applying a NO synthase inhibitor and comparing 
α-synuclein nitration in neuronal cells will make it possible to assess whether aged 
microglia can affect α-synuclein deposition in that manner. 
The effect of microglia on neuronal FOXO3a activation could also be further investigated. 
As it was demonstrated that iron-fed microglial conditioned medium resulted in increased 
α-synuclein expression and increased α-synuclein expression led to increased pro-
apoptotic FOXO3a activity it is important to understand the mechanism of activation of 
FOXO3a more fully. Acetylated FOXO3a has been shown to have proapoptotic activity 
and can be affected by declining levels of SIRT1.  Recent work in our lab performed by 
Verity Mitchener showed that applying conditioned medium from iron-fed microglia onto 
SHSY5Y cells resulted in a reduction of SIRT1 expression. Therefore, assessing 
acetylated FOXO3a levels in cells treated with conditioned medium would provide 
evidence for another potential pathway for FOXO3a activation in this context.  
 
5.7 Applying iron-fed microglia to the study of aging 
5.7.1 Relevance of the iron-fed microglial model to the study of aging 
 
Even though the iron-fed aged microglial model was not applied to the study of brain 
aging, it could replicate major changes seen in the aging brain the role of aged microglia 
in which has not been well studied. Brain aging even in non-pathological conditions is 
characterised by diminished cognitive ability that could be due to impaired synaptic 
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plasticity. Maintenance of synaptic plasticity has recently been recognised as an important 
role for microglia both in development but also in the adult organism (Wu et al. 2015). 
Iron-fed microglia as a model for aging microglia could be used to investigate the role of 
microglia in these processes. A well-studied form of synaptic plasticity is long-term 
potentiation. Appropriate levels of reactive oxygen species have been shown to play an 
important role in long-term potentiation in the hippocampus (Serrano and Klann 2004). 
Both aged and iron-fed microglia show dysregulated release of ROS which could affect 
these processes. Additionally, overproduction of IL-1β by microglia has also been linked to 
impaired long-term potentiation in the hippocampus (Patterson 2015). IL-1β levels are 
increased in iron-fed microglia providing another potential avenue through which brain 
aging could be replicated by the aged microglia model. 
 
Genomic instability is another hallmark of aging that aged microglia could play a role in. It 
has been shown that chronic inflammation can lead to genomic instability in studies in the 
context of cancer (Lin et al. 2016; Yan et al. 2009). The fact that aged microglia drive 
increased inflammation in the aging nervous system suggests that they also play a role in 
the genomic instability seen in aging neurons (Burhans and Weinberger 2007). Lower 
levels of SIRT1 may be a key player in these events (Oberdoerffer et al. 2008) and 
conditioned medium from iron-fed microglia was shown to reduce SIRT1 levels in 
neuronal cells. This suggests that iron-fed microglia could potentially induce genomic 
instability in neurons thus expanding the role that aged microglia could play in inducing 
overall brain aging.  
 
5.7.2 Future Work 
 
This model can be used to further the study of brain aging.  Iron-fed microglia that show a 
dysregulated release of ROS and increased IL-β production can be used to model the role 
that aged microglia could play in long-term potentiation. That can be achieved by using 
the conditioned medium model in cultured neurons and measuring but can also be applied 
to in vivo transplantation of iron-fed microglia and testing for changes in memory or 
behaviour. If long-term potentiation is affected by microglial conditioned medium the 
molecule or molecular responsible for those changes could be identified. The effect of 
microglia in neuronal SIRT1 expression could also be pursued further by measuring 
genomic instability that could result as reduced levels of SIRT1. Additionally, identifying 
any particular components of iron-fed microglia conditioned medium that triggered the 
change would also be beneficial. 
 
5.7.3 Likelihood of iron-fed microglia being used as a model of aged 
microglia and potential drawbacks 
 
The main advantages of this model are its simplicity and ease of use. It can be induced in 
multiple types of cells and can be maintained for long periods. Additionally, using 
microglial cell lines allows for generating large amounts of cells for studies. That 
theoretically makes the model easily applicable to many types of studies and thus likely to 
be used in the future. However, at this point in time the iron-fed microglia aging model has 
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drawbacks. The treatment with iron seems to induce a slightly different phenotype in 
different cell lines and in primary microglia. That may be due to the specific biological 
characteristics of the cell lines used or due to the natural variation in microglial 
phenotypes. Comprehensively characterising the effects on iron on microglia on the 
transcriptional and protein expression level in multiple versions of the model is an 
important step in applying it to aging research. Additionally, the lack of data on the 
genotype of dystrophic microglia in the brain makes it difficult to compare iron-fed 
microglia model to them.   
Another potential drawback of using cell lines in this model is the low proliferation rates 
and long lifespan of human microglia. Those characteristics have been linked to hallmarks 
of aging such as stem cell exhaustion and telomere shortening and also in potential 
generation of very heterogenous populations of microglia in the aging brain parenchyma 
(Mosher and Wyss-Coray 2014). Rapidly dividing genetically homogenous cell lines may 
have reacted differently to iron accumulation than microglia in the brain would have over 
the decades of their lifetime. 
On the other hand, using primary microglia to generate the model has its own unique set 
of drawbacks as maintaining microglial phenotype ex vivo is more technically challenging 
and can be influenced by the culturing methods applied to the cells. It has been shown 
that primary microglial cells undergo significant gene expression changes when acutely 
isolated and that can occur very rapidly. This suggests that isolated primary microglia also 
don’t fully match the gene expression profile of microglia in situ which can also apply to 
aged microglia (Bohlen et al. 2017).  
 
5.7.4 Improving the model 
 
Taking into account the drawbacks of this model it’s important to explore whether a better 
model of aging microglia could be made. One of the most important issues to address 
would be the discrepancies in the response of different microglial cells to the same 
treatment with iron. It is possible that due to differences in biology such as division rates 
different cell lines and primary cells have a different optimal concentration of iron that 
generates the iron-fed aged phenotype. Optimising that concentration would be central to 
improving the versatility of the model. Additionally, if data were to become available on the 
actual concentrations of iron in the microglia of the aged brain the model could be 
tweaked to reflect those more closely. 
 
Another avenue to look into would be a more direct approach. Understanding which genes 
drive the changes detected in the iron-fed phenotype and manipulating their activation to 
replicate the same effects could generate a very effective model. The gap in knowledge 
about the molecular root of the changes that occur in aged microglia would make that very 
difficult. It is possible that when it comes to iron-fed microglia the changes that occur as in 
aging are multifactorial and seemingly cannot converge down to a change in a single 
pathway. That leaves the iron supplementation method as a much more easily achievable 
strategy to model aged microglia. 
 
 
5.7.5 Issues with using neuronal cell lines 
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Another factor that affects the applicability of iron-fed microglia to the study of aging is 
their interaction with neurons. The studies described in this thesis have used an 
immortalised neuronal cell line to study the effect of iron-fed microglia on neurons. 
However, that made it difficult to measure the model’s long-term effects as cell lines are 
not as differentiated as neurons and also have high division rates. An additional drawback 
was the difficulty in measuring effects on neuronal viability and synaptic transmission. 
Therefore, primary neuronal culture would be necessary in order to fully explore these 
important research questions. 
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5.8 Other Future Work 
The iron-fed aged microglia model has been shown to have utility in the study of ND and 
in particular in influencing β-amyloid and α-synuclein production and metabolism. It would 
be beneficial to apply this model to the study of other proteins implicated in common ND.  
5.8.1 Tau 
Dystrophic microglia have been identified in the vicinity of tau pathology in AD brains 
(Streit et al. 2009). Microglia have also been found to phagocytose tau and to be activated 
by the presence of tau aggregates(Morales et al. 2013; Bolós et al. 2015).  Microglial 
neuroinflammation is also thought to promote the hyperphosphorylation of tau and drive 
tau pathology (Maphis et al. 2015; Cherry et al. 2016). Therefore, the aged microglial 
model could be used to investigate further the role of these cells in tau deposition. The 
effect of microglial conditioned medium on tau expression and hyperphosphorylation rates 
in neuronal cells are potential strategies to investigate how iron-fed microglia could affect 
this protein. If those are found to be affected the molecules present in conditioned medium 
that cause these changes could be identified. Those could be cytokines, ROS or other 
signalling molecules. Another potential process through which microglia could increase 
tau deposition could be through reduced phagocytosis. Measuring tau phagocytosis by 
iron-fed microglia would allow to test whether the model can replicate disease conditions 
and provide another explanation for how microglia drive AD pathology. 
 
5.8.2 Prion protein 
The aggregation of the prion protein is a major driving mechanism of prion disease. 
Activated microglia have been found to co-localise with PrPSc deposits in the brain of CJD 
patients. Microglia in the prion diseased brain exhibit a mixed cytokine profile with 
elevated TNF-α and IL-1β. Additionally, inflammation in CJD has been associated with 
elevated NFkB pathway activation (Obst et al. 2017). Inflammation driven by microglia is 
thought to play a major role in prion diseases some of which such as sporadic CJD have a 
late age of onset (Mead et al. 2009). Therefore, the aged microglia model could be 
applied to the study of prion diseases. Initially conditioned medium from iron-fed microglia 
can be applied to neuronal cells and the expression and levels of prion protein could be 
measured by luciferase reporter assays and western blotting. The propensity and levels of 
aggregation of the prion protein in neuronal cells under the influence of iron-fed microglia 
could also be measured. If those are affected this could be pursued further by identifying 
which molecules present in the medium act to elicit those changes.  
 
5.8.3 Multiple sclerosis  
Microglial cells are thought to play a significant role in MS but it has not been established 
whether the role is mostly beneficial or detrimental (Luo et al. 2017). Iron-rich microglia 
have been detected at the edges of lesions in MS and are thought to drive inflammation 
(Gillen et al. 2018). Iron-fed microglia could be applied to other models of MS in order to 
simulate this effect. In vitro co-culture models would be especially suitable for this 
purpose. For example, in CNS spheroid cultures myelination can occur in a manner that is 
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very similar to in vivo and introducing microglia to this model can be useful in 
understanding the actions of this cell type in the context of MS models (Vereyken et al. 
2009). Firstly, it could be observed whether iron-fed microglia have any effect on 
myelination through their conditioned medium. Secondly, demyelination can be 
experimentally induced in this model by using antibodies to myelin oligodendrocyte 
glycoprotein, IFNγ or lysophosphatidylcholine (Kipp et al. 2012). The speed of re-
myelination in the presence of iron-fed microglia conditioned medium as compared to 
controls could be measured through electron microscopy of fixed sections of the 
spheroids. If a difference in the speed is detected, different components of the secretory 
profile of the iron-fed microglia could be tested to replicate the effect. The same 
experiments could also be attempted in the presence of iron-fed microglia in the spheroids 
in order to incorporate cross-talk between the cell types and to potentially assess if 
microglial phagocytosis can also play a role in de/remyelination.  
5.8.4 Huntington’s disease 
Microglia in HD have been found to be activated in regions affected by the disease with an 
increase in microglial density correlating with an increase in neuronal loss (Yang et al. 
2017). The cause of this activation are thought to be mutant huntingtin aggregates in 
neurons but the result has largely not been agreed upon – they could fulfil not only a 
detrimental but also a protective role (Crotti and Glass 2015; Yang et al. 2017). However, 
expression of mutant huntingtin in microglia also seems to alter their behaviour, as it leads 
to increased levels of activation without any exposure to neuronal aggregates (Yang et al. 
2017). Interestingly, similar to aging, dystrophic microglia in HD have been found to 
accumulate ferritin (Simmons et al. 2007). It is possible that this occurs because of 
huntingtin’s putative role as a regulator of the levels of iron in the cell as a type of iron 
response protein and its’ mutation leading to dysregulation and the subsequent 
accumulation (Hilditch-Maguire et al. 2000; Lumsden et al. 2007). As it has been 
previously discussed, accumulation of iron in microglia can trigger a more activated state 
without any exogenous stimulation. Therefore iron-fed microglia could be used in the 
study of HD in order to unravel the role of these cells in the pathology of the disease. The 
conditioned medium from iron-fed microglia could be applied to neurons expressing 
mutant huntingtin and their viability assessed. If that is affected, the possible involvement 
of microglial secreted factors in the assembly of toxic species of huntingtin and 
subsequent impairment of the proteostasis of neurons could be assessed by measuring 





The aged microglia model presented in this thesis is novel and investigates iron 
accumulation – a common but generally un-investigated phenomenon in aging. They were 
found to replicate aging microglia in many ways and importantly, to replicate microglial 
behaviour in neurodegenerative disease.  
Even though the studies presented in this thesis show that iron-fed microglia are 
applicable to the study of neurodegeneration it is important to understand that the model 
is still in its infancy. A lot of future work is needed to refine the model, most importantly 
optimising the method for generating the iron-fed phenotype for different cell lines and 
microglia from other species. Furthermore, it is essential to measure changes in other 
senescence factors and to perform RNAseq on the different iron-fed microglia models. 
That would allow for the model to be optimised for different applications in the study of 
aging and neurodegenerative disease. 
Aged microglia have been implicated in many neurodegenerative conditions and the 
versatility of this model means that aged microglia have great potential to be incorporated 
into both in vitro and in vivo studies of these diseases and also aging itself. One of the 
biggest potential impacts this model could have is in pioneering reversal of the effects of 
aging in microglia. Successfully reversing the iron-fed phenotype could lead to not only 
greater understanding of the aging process but also in powerful brain anti-aging 
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Abstract: Iron is a trace element of considerable interest to both chemistry and biology. 
In a biological context its chemistry is vital to the roles it performs. However, that same 
chemistry can contribute to a more deleterious role in a variety of diseases. The brain is 
a very sensitive organ due to the irreplaceable nature of neurons. In this regard regulation of 
brain iron chemistry is essential to maintaining neuronal viability. During the course of 
normal aging, the brain changes the way it deals with iron and this can contribute to its 
susceptibility to disease. Additionally, many of the known neurodegenerative diseases have 
been shown to be influenced by changes in brain iron. This review examines the role of iron 
in the brain and neurodegenerative diseases and the potential role of changes in brain iron 
caused by aging. 
Keywords: synuclein; amyloid; prion; Alzheimer’s disease; Parkinson’s disease; 
transmissible spongiform encephalopathy; ferrireductase; microglia 
1. Introduction
While the atomic nature of matter might be an absolute given in the 21st century, the role of metal
atoms in biological systems remains a developing field. In particular, the difficulty of translating between 
chemical and biological systems remains central to advancing concepts that could actually lead to a 
better understanding of how our minds work. At the fundamental level, we also still need to understand 
how the movement of single electrons can have a significant impact on cellular mechanisms that 
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influence the way we age. In biological systems the movement of electrons is often dependent on metal 
ions and their role in enzyme activities or more fundamentally as co-factors in catalysis of various 
reactions. The regulation of such reactions can be both positive and negative as one results in maintaining 
cellular activity essential for life while the opposite can result in the generation of harmful reactive 
chemical species of oxygen or nitrogen. The production of reactive oxygen species (ROS) or nitrogen 
species (RNS) has been linked to changes in the brain associated with normal aging and also to diseases 
that can occur during aging such as the neurodegenerative diseases [1,2]. For many neurodegenerative 
diseases, especially the most common ones like Alzheimer’s disease and Parkinson’s disease, aging is a 
prerequisite for developing them [3,4]. While we can measure changes in various chemicals or reactions 
in the brain, the actual mechanism by which growing older makes us more susceptible to 
neurodegenerative diseases is a mystery. Yet, it has quite clearly emerged that changes in certain metals, 
especially iron, might be very important to both how the brain ages and to neurodegeneration. 
Iron is the second most abundant metal on earth and has multiple oxidation states [5]. This makes it 
a leading candidate as a co-factor for enzyme-catalyzed reactions that require electron transfer. Iron can 
exist as Fe2+ (highly water soluble) or Fe3+ (much less soluble) in biological systems. Higher oxidation 
states are generated by some reactions but are much less stable than Fe2+ and Fe3+. The redox potential 
of Fe2+/Fe3+ is highly variable in biological systems and depends largely on the way it is coordinated 
within the structure of the ligands it binds [6]. This means that its utility is very high. Iron binding 
proteins can have different iron centers with specific classes of co-ordination [7]. The main classes are 
heme proteins, iron-sulfur proteins, and a class that is neither. This latter group includes iron storage and 
iron transport proteins, proteins coordinating a single Fe atom to histidine, glutamate or aspartate, or two 
Fe atoms in an oxygen-bridged center. The latter family includes many oxygen-binding proteins as well 
as Fe-oxidizing proteins such as ferritins. 
Iron enters the body through the diet and is taken up via two main mechanisms [8]. The first (major) 
source of iron is through the metabolism of heme, which is absorbed at the intestinal apical membrane 
where the iron is released by heme oxygenase. Iron released in this way can directly enter the cellular 
free iron pool, where it can either enter storage in ferritin, or be transported outside the intestinal cell.  
The second uptake mechanism is at the brush border of the duodenum where it is first reduced to Fe2+
by the reductase Dcytb and then transported into the enterocytes by divalent metal transporter 1  
(DMT-1) [9]. Iron taken up by this route enters the same pathway as heme iron. Once iron reaches the 
blood it is largely transported by transferrin. The main uptake mechanism involves the interaction of 
transferrin with its receptor at the cell surface. Internalization is through clathrin-coated pits, which 
directs transferrin to endosomes. There, the transferrin undergoes a conformational change as a result of 
the low pH of the endosomes causing iron release. The iron is reduced and transported to the cytosol. 
Iron uptake can also occur through DMT-1, which also transports other divalent metals [10]. 
Within cells, iron is associated with a variety of proteins as a co-factor, but is also stored. The main 
storage protein is ferritin, but other storage proteins exist such as hemosiderin [11,12]. Additionally, 
cells possess a pool of free iron known as the labile iron pool [13]. This pool is considered transient but 
necessary as the source of iron for newly synthesized proteins that require iron as a co-factor. The need 
to tightly regulate this pool of Fe2+ is considerable given the potential of free iron to catalyze radical 
generating reactions such as the Haber-Weiss reaction [14]. The production of radicals in the form of 
ROS and RSN has the potential to result in unwanted protein modifications and lipid peroxidation. These 
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modifications of proteins can also lead to misfolding of the proteins. Aggregation of proteins in the brain 
can potentially give rise to neurodegenerative diseases. The necessity of iron for many biological 
activities and the potential of iron to cause damage to cells must obviously be balanced. These processes 
deteriorate as we age. The consequences for the brain are particularly severe in this regard. However, 
the exact role of iron in either aging or neurodegeneration is still under investigation and remains 
uncertain. The evidence for its role is explored in this review. 
2. Iron in the Brain 
The brain contains significant amounts of iron. However, the distribution is not uniform.  
Regions such as the substantia nigra and the globus pallidus have the highest levels, exceeding that of 
the liver, the main site of iron storage in the body [15–17]. According to cell type, oligodendrocytes 
have the highest iron content and astrocytes have very low cellular iron [18]. The main storage protein 
for iron is ferritin, which is composed of a mixture of H- or L-ferritin monomers (heavy or light chain), 
and varies between cell types as to which is expressed predominantly. Neurons express predominantly  
H-ferritin while microglia express L-ferritin [19,20]. Some neurons, such as those of the  
substantia nigra, express neuromelanin. Neuromelanin is synthesized from L-Dopa in dopaminergic cells 
and forms stable complexes with Fe(III). Thus cells expressing neuromelanin are likely to have increased 
iron storage [21,22]. 
Iron storage increases with age in the brain [23]. Again, this is not uniform and some regions show 
greater increases than others. Studies of ferritin levels have indicated high increases in the cortex, globus 
pallidus, and substantia nigra. In other regions such as the locus coeruleus the iron concentrations remain 
low throughout life [24]. The main cell types accumulating iron with age are microglia and astrocytes [23]. 
These changes are found in many brain regions including the cortex, cerebellum, hippocampus, and 
basal ganglia. In contrast, there is little change in iron in oligodendrocytes despite their higher 
concentrations of cellular iron. The origin of increased brain iron remains unclear. However, increased 
vascularization of the brain may increase the chance of iron exchange between the blood and tissues of 
the brain, thus increasing the concentration of iron [25,26]. Whatever the reason, an increase in a 
potentially oxidative metal in the brain increases the chances of deleterious reactions. It is probably no 
coincidence that the regions associated with changes in iron are also those associated with several 
neurodegenerative diseases. 
3. Neurodegenerative Diseases Linked to Iron 
This review is aimed at understanding the potential role of iron in aging and neurodegeneration. 
However, despite a potential involvement in more common diseases, there are instances of quite specific 
diseases directly linked to iron and its metabolism. Some of these diseases have successful treatments 
that involve the use of iron chelators. 
Friedreich’s Ataxia is the most common of the ataxias and affects adolescents [27]. The disease is 
caused by mutations in the gene for frataxin, a protein found in the mitochondria that is associated with 
the assembly of Fe-S clusters and may act as an iron chaperone [28]. Mitochondria are also considered 
to be the main site of iron accumulation in Friedreich’s Ataxia [29]. Recent research has suggested that 
frataxin acts as an allosteric mediator of Fe-S cluster assembly [30]. It is found in tissue with high 
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metabolism such as the heart and dorsal root ganglia parallel to the spinal cord [31]. The mutation in the 
gene involves trinucleotide repeat insertions (GAA) in the first intron. Severity of the disease appears to 
be linked to the number of insertions, which decrease the expression level of frataxin [28]. Patients have 
severe neurological problems that seem to be linked to problems with excess iron. Treatment of patients 
with the iron chelator deferiprone caused marked reduction in iron levels within the dentate nuclei and 
alleviated symptoms including manipulative dexterity, speech fluency, reduction in neuropathy, and 
ataxia gait [32]. 
Neuroferritinopathy is a rare, dominantly inherited disease associated with mutations in the gene for 
ferritin [33]. The disease has early and late onset forms and is associated with motor symptoms, spasticity 
and cognitive deficits [34]. The cause is usually a frameshift mutation in exon 4 for the  
L-ferritin gene, which causes a conformational change in the C-terminus of the molecule and alters its 
ability to store iron [35,36]. The mutation results in iron/ferritin-rich aggregates forming in cells [37]. 
Mouse transgenic models show a strong relation between functional changes and abnormal iron 
metabolism [38]. However, attempts to treat the disease with chelation therapy have so far been 
unsuccessful [39]. 
Many of the iron-storage diseases are inherited and pantothenate kinase-associated neurodegeneration 
(PKAN, formerly known as Hallervorden-Spatz syndrome) is another such disease [40]. It is 
characterized by Parkinson’s-like symptoms as well as significant mental abnormalities. It develops in 
childhood and is usually fatal. It is associated with mutations in the gene encoding  
pantothenate kinase 2 (PANK2) [41]. For this reason the name was changed from Hallervorden-Spatz 
syndrome. PKAN, now the more common term for the disease, is considered one of a family of diseases 
called NBIA (neurodegeneration with brain iron accumulation) [42,43]. PKAN brains show specific 
areas with high levels of iron accumulation, including the globus pallidus and the  
substantia nigra [44]. The exact relation of iron accumulation to disease progress is unclear. It has been 
suggested that the disease results in coenzyme A deficiency and subsequently increased cysteine, which 
is then able to chelate the iron [45]. However, treatment of patients with iron chelation therapy caused 
reduced iron accumulation but no change in symptoms. Therefore, the role of iron in the disease is 
unclear and may just be a symptom rather than a cause [46]. 
NBIA diseases also include neuroferritinopathy, aceruloplasminemia, beta-propeller  
protein-associated neurodegeneration, and a number of inherited diseases [43,47,48]. The incidence of 
NBIA disease continues to increase and clearly shows the importance of understanding iron metabolism 
and its potential link to neuronal loss. Many NBIA diseases are childhood diseases and are clearly not 
linked to aging. However, they are illustrative of the potential impact that accumulation of iron in the 
brain due to natural aging processes has on the vulnerability of neurons to iron-associated cell death. 
4. Iron in Alzheimer’s Disease
Alzheimer’s disease (AD) is both the most common dementia and also the most common 
neurodegenerative disease. The greatest risk factor for the disease remains aging. The risk of developing 
the disease accelerates as we grow older, with those over 85 having almost a 1 in 2 change of developing 
it. AD is progressive and irreversible and results in memory loss, cognitive decline, a variety of 
psychological changes including anxiety, depression, and aggression, and eventual loss of physiological 
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functions due to dementia [49]. Several brain areas are affected including the hippocampus, temporal 
lobe, and frontal cortex. Particularly, the cholinergic innervation is severely disrupted [50]. The exact 
cause of the disease remains contentious. There are inherited and sporadic forms of the disease. The 
inherited forms, although much rarer, point towards the proteins most likely to be at the heart of the 
disease [51]. The lead hypothesis of the cause of AD is the amyloid cascade hypothesis [52]. The 
formation of aggregated forms of ?-amyloid (A?) is a common hallmark of the disease. A? is formed 
from a large precursor called APP (amyloid precursor protein). Inherited mutations linked to AD are 
found in the APP gene or in the genes of proteins associated with processing APP to form A?. The 
formation of A? aggregates in the brain is likely to play a significant role in the disease and may be 
associated with the neuronal loss observed [52]. The other significant protein in AD is tau, a  
microtubule-associated protein [53]. In AD tau becomes hyper-phosphorylated and forms paired-helical 
filaments (PHF), also known as tangles. There are suggestions that PHF are the true cause of AD. 
However, it could also be that some interplay between A? and tau may be important [54]. 
APP is a transmembrane protein and as the parent protein for A? there is significant debate over its 
role in the cell and whether altering its metabolism could be the significant causal effect that initiates  
AD [55]. A significant consideration in this debate is that APP binds metals [56]. APP contains a classical 
type II copper-binding domain in its N-terminus. The residues His147, His151, and Tyr168 were 
identified as the copper coordination sphere of the binding region within the E1 region of the  
protein [57]. The His-X-His motif is similar to that seen in Cu/Zn superoxide dismutase. APP has the 
potential to reduce Cu2+ to Cu+. The E2 domain of APP has also been suggested to have two metal binding 
sites [58]. Of these, Zn2+ is thought to be coordinated between His382, His432, and His436. Copper can 
also bind this site with the addition of His313 to the three His of the Zn site. A second, low-affinity site 
is coordinated by Glu387, Asp429, and His458. There has also been a report that the E2 site interacts 
with iron. A suggested site for iron binding around Glu337 and Glu340 is still debated [59]. The idea 
that APP could function as a ferroxidase [60] has been dismissed in favor of the suggestion that APP 
can regulate iron export from the cell (Figure 1) [59,61]. 
As well as physical interactions between metals and APP, there has been considerable research on 
the cellular implications of those possible interactions. Of considerable interest are those that might alter 
or initiate the disease (Figure 2). 
Interaction of APP with copper is thought to alter both its dimerization and the rate of cleavage to 
form A? [62,63]. However, the aggregation of A? is also thought to be influenced by its interaction with 
copper and zinc [64–66]. Cu, in particular, is considered to accelerate aggregation. This led the research 
group of Ashley Bush to investigate whether copper chelators such as clioquinol could inhibit A? 
aggregate accumulation and possibly be a treatment for AD itself. While clioquinol proved effective in 
depletion of A? in transgenic mice [67], it unfortunately did not progress in clinical trials [68]. 
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Figure 1. Several of the key proteins associated with neurodegeneration have been suggested 
to have roles associated with iron. This figure summaries these suggestions. ?-synuclein is 
associated with PD and has been shown to bind iron and reduce it, thus converting Fe3+ to 
Fe2+ which is utilized for many cellular activities. ?-synuclein, like most ferrireductases, is 
associated with the inner face of the cell membrane. There have also been reports that the 
prion protein, associated with diseases like CJD, can also act to reduce iron as a 
ferrireductase. Lastly, the amyloid precursor protein (APP) the precursor to beta-amyloid 
known from AD, has been shown to enhance iron export out of cells. This process requires 
the presence of ferroportin, which mediates the iron export process. 
While the relation of copper and zinc to AD and the APP protein has proven quite solid, evidence 
supporting a link between iron and AD has taken much longer to emerge [69]. Elevated brain iron has 
been reported in patients with AD [70,71]. However, as is clear from this review, this is not unique to 
AD. Iron accumulation in AD occurs without a parallel increase in ferritin [72]. IRP proteins normally 
respond to increased levels of iron by interacting with genes containing the IRE element and causing 
regulation of a number of proteins in a coordinated fashion. This usually ensures that the transferrin 
receptor and ferritin are regulated together. In AD it appears there is a dysfunction of this system that 
leads to increased free iron that would otherwise be stored in proteins such as ferritin [73]. In a recent 
clinical study of cerebral spinal fluid (CSF) from AD patients, it was found that ferritin levels were 
predictive of cognitive status [74]. While not being distinctly elevated in all cases of AD, declining 
cognitive status from mild cognitive impairment (MCI) to AD was associated with altered ferritin levels 
and was also greater with younger onset of AD. This would suggest a relationship between high iron 
burden in the brain and an early age for AD onset. Additionally, it was found that ferritin levels were 
higher in individuals with the APOE protein allele ?4 [74]. This allele is an epigenetic marker for greater 
risk of AD. However, the link between APOE and iron metabolism cannot currently be explained. 
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Figure 2. While numerous proteins associated with neurodegeneration may have a role in 
iron metabolism in the healthy cell, under certain conditions these processes might be 
disturbed. This diagram represents a summary of the potential changes that can occur during 
aging which might disturb the way iron is either utilized or its interactions with other 
proteins. Changes in the protein might result in changes in levels of iron, particularly Fe2+.
The protein may become overexpressed, resulting in the formation of excess Fe2+, or some 
kind of damage to the protein might result in lost activity and reduced Fe2+. Additionally, 
aging effects might result in the misfolding of the protein, either as a result of an increase or 
a loss of interaction with iron or simply through another process. Misfolded protein could 
then aggregate and cause toxic damage to cells. In the case of excess generation of Fe2+,
there could be abnormal interaction with other proteins such as neuromelanin or the Fe2+
could result in oxidative stress. In both cases the end result could be the generation of toxic 
species that lead to cell death. Lastly, in some cases the lack of Fe2+ might result in a 
breakdown of essential cellular process necessary for cell survival.
As mentioned above, A? binds metals. While there has been a focus on copper, there is also evidence 
for an interaction with iron [72]. While this could mediate toxicity or oxidation events, there has also 
been a suggestion that the interaction could be protective. In this case the A? would sequester the iron 
and prevent it mediating toxic damage. While this may seem paradoxical given the “bad” reputation of 
A?, it is actually true that free iron is highly toxic and A? can accumulate without any apparent cell 
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loss [75,76]. This observation, although suggesting a positive role for A? in AD, does not then explain 
how iron might be toxic. 
Mitochondria are the organelles most likely to show damage in AD [77]. As the site of heme synthesis 
in the cell, mitochondria are a major site for iron handling. Mitochondria are the major source of oxygen 
radical generation in cells. Damage to mitochondrial-specific proteins, which can increase free iron, has 
been shown [78]. Studies of mitochondrial DNA suggest that there is a greater turnover of the organelle 
in AD [79]. This supports the fact that there is mitochondrial abnormality in AD [80]. There is no direct 
evidence that this dysfunction is causal rather than a result of the damage that leads to cell death in AD 
or that there is a direct link between mitochondria and iron. Further research may bring into focus the 
causal links between these different factors. However, it is clear that iron disturbance is one important 
part of trying to decipher the mystery behind AD.
5. Synucleinopathies and Iron Reduction 
Synucleinopathies are a family of diseases associated with the deposition of the protein ?-synuclein 
in an aggregated form in CNS tissue [81]. These diseases include Parkinson’s disease (PD), Multiple 
System Atrophy, and Dementia with Lewy Bodies (DLB) [82,83]. Parkinson’s is very well known, being 
the most common of the non-dementing neurodegenerative diseases. It is associated with loss of 
dopaminergic neurons from the substantia nigra, which results in a movement disorder [84]. PD has  
a long association with disturbances to iron metabolism [85]. However, any mechanistic relation 
between the disease and iron metabolism has yet to be firmly established. PD, like AD has sporadic and 
inherited forms. The inherited forms are related to mutations in the genes of a long list of proteins which 
include ?-synuclein, parkin, leucine-rich repeat kinase (LRRK), PINK-1, and DJ-1 [86]. The inherited 
forms can be either early or late onset (depending on the mutation). The clinical symptoms of PD include 
resting tremors, muscle rigidity, and bradykinesia [87]. Treatments are generally focused on restoring 
some amount of dopamine to the patient as the loss of dopaminergic neurons is the principal change that 
results in the majority of symptoms. These treatments range from supplying the dopamine precursor  
(L-Dopa) to altering dopamine transport and breakdown [88]. 
Changes in PD patient brains include increased levels of Fe(III) and reduced levels of the  
Fe(III)-binding protein ferritin [89]. Increased iron deposits in the substantia nigra are associated with 
?-synuclein-positive Lewy bodies in PD and neurodegeneration with brain iron accumulation [90,91]. 
However, there are also changes in other metals in PD such as zinc in the substantia nigra and high levels 
of copper in the cerebrospinal fluid [92]. There is also evidence from epidemiological studies that 
increased incidence of PD is associated with environmental metal exposure. Individuals with chronic 
industrial exposure to copper, manganese, or iron have an increased rate of PD [93]. In experimental 
models, alterations in metal homeostasis were observed with toxin-induced animal models of PD. An 
accumulation of iron was observed in the substantia nigra of MPTP-treated mice, which is likely a result 
of the observed upregulation of transferrin receptor expression and iron uptake [94,95]. Although these 
observations may be consequences of the disease progression, experimental studies using FeCl3 injected 
directly into the substantia nigra of rats resulted in a 95% reduction in striatal dopamine and altered 
behavior, supporting the idea that iron initiates dopaminergic degeneration in PD [96]. 
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While observation of changes in metal levels in a disease might be interesting, without a mechanistic 
link the findings remain at best a marker of change. The increased cellular iron is likely to come about 
through changes either as a result of intake or release. However, with regards to the death of 
dopaminergic neurons, there is also the possibility that it is not the absolute amounts that are important 
but the ratio of Fe(II) to Fe(III). Similarly, alteration in the interactions of iron with various proteins may 
also be critical. For example, the substantia nigra is characterized by high levels of neuromelanin, the 
dark pigmented protein that gives the substantia nigra its name. Studies of PD patients have shown high 
levels of iron associated with neuromelanin granules [97]. This could suggest that neuromelanin traps 
redox-active Fe2+, which is then able to initiate the oxidative process [98,99].  However, another study 
suggests that the iron leaves the neuromelanin and migrates to the cytosol in PD [100]. 
Cellular responses to fluctuating iron levels are regulated by iron regulatory proteins (IRPs) that bind 
to iron response elements (IRE) in RNA [101]. However, they also respond to increased levels of 
oxidative stress and can then alter cellular protein expression to cause an increase in the free iron  
pool [102]. The implication is that oxidative stress can cause a dysregulation of iron metabolism. The 
read-out for such a change would be increased iron levels without a corresponding change in  
iron-binding proteins such as ferritin. This has been observed in PD [103]. As well as potential 
interactions of iron with other proteins, iron could also alter dopamine specifically, causing the 
generation of toxic dopamine byproducts that then kill dopaminergic cells specifically. One of the 
metabolic products of dopamine 3,4-dihydroxyphenylacetaldehyde (DOPAL) can induce aggregation of 
?-synuclein in the presence of iron [104]. DOPAL can also generate reactive oxygen species in the 
presence of iron [105]. 
Synucleins have been linked to metals. Firstly, all three synucleins bind copper [106,107].  
?-synuclein also binds other metals including iron [108,109]. Exposure of ?-synuclein to metals during 
extensive shaking can also accelerate its aggregation [110]. This creates a dichotomy with regards to  
?-synuclein in terms of both its potential normal cellular activity and its aggregation, which is associated 
with pathological states such as in PD. ?-synuclein toxicity is mostly associated with  
copper [111,112]. During the aggregation process, copper induces the formation of a unique stellate 
oligomer that is highly toxic to neuronal cells in culture [111]. Exposure to iron does not have this effect, 
although some studies have shown that iron can accelerate aggregation of ?-synuclein [113]. The 
aggregation of ?-synuclein in cells is associated with the increased expression levels of the protein. 
However, increased expression of ?-synuclein has also been shown to increase cellular iron 
concentrations [114]. 
Recent studies have shown that ?-synuclein can bind both copper and iron simultaneously [109]. 
When ?-synuclein binds copper it is able to undergo redox cycling, as shown by cyclic  
voltammetry [106]. The implication is that ?-synuclein can use copper to move electrons. Further studies 
have shown that ?-synuclein can cause the reduction of iron (Figure 1) [109]. Kinetic analysis with 
purified recombinant protein has shown that this activity is enzymatic, potentially making  
?-synuclein a ferrireductase. The implication is that the potential of ?-synuclein to generate Fe2+ in cells 
may be its normal cellular role. What this means for the pathology of the synucleinopathies currently 
remains unclear. However, there are two distinct possibilities. First, increased expression of ?-synuclein 
could result in excess production of Fe2+, which could then initiate catastrophic oxidative processes in 
the cell, interact with other proteins such as neuromelanin, or simply be neurotoxic (Figure 2). The 
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alternative is that when ?-synuclein is highly expressed in cells and begins to aggregate the protein 
becomes functionally inactive but may still bind Fe3+, thus sequestering iron that is needed for normal 
cellular activities such as the synthesis of dopamine. Give the potential role of Fe2+ in numerous aberrant 
processes, the former possibility is more likely. However, as with the general role of iron in PD, the role of 
iron reduction in PD is still unclear and further research is needed to understand what causative role there is, 
if any. 
6. Prion Diseases 
Also known as transmissible spongriform encephalopathies, prion diseases are rare [115]. They are 
more widely known because of the concurrent outbreaks of both bovine spongiform encephalopathy 
(BSE) in cattle and variant Creutzfeldt-Jakob disease (vCJD) in humans [116,117]. The potential 
transmissibility of prion diseases remains an ever-present concern. However, the major form of human 
prion disease (sporadic form of Creutzfeldt-Jakob disease) is still very rare and is not naturally 
transmissible [118]. Prion diseases can either be inherited (through mutations in the Prnp gene), sporadic 
(with no known cause) or transmissible. The transmissibility has largely been demonstrated experimentally, 
but may be a result of misadventure such as with vCJD or Kuru (a disease spread by ritual cannibalism). 
The disease transmissibility is associated with an abnormal isoform of the prion protein [119]. The prion 
protein (PrPc) is a cellular copper-binding glycoprotein expressed at the cell surface [120,121]. The 
function of PrPc remains controversial, but the strongest evidence supports its role as an antioxidant 
protein associated with increased cell viability [122–124]. The protease-resistant isoform of PrPc often 
accumulates at high levels in the central nervous tissue of patients and animals with prion diseases. 
Therefore, this abnormal isoform (PrPSc) is a hallmark of the disease. It is tightly associated with the 
infectious agent and may be a direct cause of the neurodegeneration seen in the disease [125]. 
Following the discovery of the copper binding capability of PrPc, extensive studies were carried out 
to assess the relation of PrPc and prion diseases to metal homeostasis. The strongest associations were 
found between prion diseases and copper metabolism but also manganese metabolism [126]. The latter 
was somewhat unexpected and remains controversial. While copper has been associated with normal 
PrPc activities, the data suggest that manganese binds to PrPc in disease and can cause its conformational 
change [127,128]. Manganese binding to PrP also increases its survival in the environment and increases 
its ability to cause prion infection in cells [129]. 
Studies looking at the levels of trace elements in the brains of animals with BSE, sheep scrapie, patients 
with CJD or vCJD, and rodents experimentally infected with scrapie all show a similar  
trend [130–132]. They indicate reduced levels of copper and increased levels of manganese. Similar 
changes have also been observed in the blood. A recent study has shown increased manganese in prion 
plaques in experimental hamsters [133]. Other trace elements were also studied and very little difference 
was observed for any other metal. These studies included Fe, which showed no changes in any of the 
tissues or diseases analyzed. 
Despite these studies showing no changes in iron, there are others that suggest a strong role for PrP 
in iron metabolism [134]. An initial study suggested increases in both ferritin and iron response proteins 
in astrocytes in rodent scrapie models [135]. The research group of Nina Singh has extensively studied 
the links between Fe and prion disease. Their findings initially suggested that PrP could influence iron 
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uptake [136]. Cells overexpressing PrP showed increased levels of intracellular iron. Further studies 
suggested that CJD patients have increased levels of iron, while PrP knockout mice have decreased iron 
levels [137,138]. A number of studies have shown that the divalent metal transporter-1 (DMT-1) is 
altered in both PrP-knockout and prion disease [139]. This protein is linked to the transport of multiple 
divalent metals and not just iron. However, changes in this protein could explain changes in intracellular 
iron. Despite the changes in uptake and storage of iron suggested by these studies, it has also been 
suggested that PrPc itself is a ferrireductase (Figure 1) [140]. The implication is that PrPc causes 
conversion of Fe3+ to Fe2+, which is then more likely to be transported into the cell, thus resulting in 
increased cellular iron. However, unlike alpha-synuclein, for which kinetic studies on purified protein 
suggested iron reduction is a result of true enzymatic catalysis109], studies on the ferrireductase activity 
of PrPc have only been performed on cell extracts [140]. As PrPc has already been suggested to be 
associated with redox balance in cells [123], this observation may only be reporting a secondary effect 
rather than a direct function of PrPc in iron reduction. 
Unlike other diseases where the association with iron metabolism has been robustly established,  
the link between iron and prion diseases remains unclear. The majority of the data do not support this 
link. Iron binding to PrP is weak and highly pH dependent, implying there is not likely to be a 
physiological interaction of PrPc and iron. However, it will be interesting to see if further data confirm a 
role of PrPc in iron metabolism. 
7. Microglia and Aging 
While iron metabolism is of interest to specific diseases, general aging can cause other changes  
upstream that also impact on the same diseases. Here again, changes in the way iron is handled by the 
brain impact on the cellular environment. An example of the changing environment in the aging brain is 
a change in the supporting cells in the brain, including microglia [141]. Microglia are the resident 
macrophages of the brain and are its first and main form of active immune defense. Healthy microglia 
are very sensitive to their environment, constantly surveying for and phagocytosing any foreign material 
or cellular debris that they encounter. Additionally, they are capable of releasing cytotoxic substances 
that can kill neurons that are damaged or infected. Such substances include H2O2, nitric oxide, inflammatory 
cytokines, proteases, and neurotransmitters. Activated microglia can act as antigen-presenting cells and 
activate T-cells. After an infection has been dealt with, microglia can recruit cells involved in neuronal 
repair and secrete anti-inflammatory cytokines [142]. The idea of aging microglia stems from 
histological observations of healthy aged brains where the cells often develop dystrophic phenotypic 
characteristics [143]. Resting microglia have a ramified morphology with many fine processes extending 
from the cell body. Dystrophic microglia found in aging brains lose this fine process of ramification  
(Figure 3). Dystrophic microglia often develop abnormally shaped processes with spheroidal swellings 
and cytoplasmic fragmentation (cytorrhexis) [143]. Dystrophic microglia have also been associated with 
increased release of toxic ROS and inflammatory cytokines and impaired phagocytic ability [144,145]. 
Cytokines are small proteins involved in intercellular signaling. They are released by a multitude of cell 
types including immune cells like microglia and bind to cell surface receptors on other cells where, 
through signaling cascades, they alter the transcriptional profile of the target cells. The proinflammatory 
cytokines found to be released by dystrophic microglia include IL-6, TNF-?, and IL-1? [145]. 
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Figure 3. Age-related changes in microglia. When microglia age they lose some of their 
processes and develop abnormalities in others. Additionally, they often exhibit cytoplasmic 
fragmentation. They also store more iron. Their increased release of neurotoxic substances 
and reduced ability to phagocytose debris and toxic protein aggregates leaves  
neurons vulnerable. 
Ferritin, the main iron storage protein in the brain, is highly expressed in microglia [19]. Microglia 
are the main cells in the brain that store iron. One way to identify dystrophic microglia, apart from their 
morphology, is their higher levels of iron storage, demonstrated by the expression of the iron storage 
protein ferritin. Additionally, an outward rectifier K+ channel called Kv1.3 has been found to increase 
expression in dystrophic microglia in aged mouse brains [146]. Dystrophic microglia become more 
prevalent with human aging and have been found to increase in a variety of diseases including AD [147] 
and Huntington’s disease [148]. There is also evidence that the chronic inflammation that accompanies 
neurodegeneration leads to local increases in microglia with high iron and ferritin content, possibly due 
to iron scavenging [149]. The association between increased iron storage and an altered microglia 
phenotype, particularly a dystrophic one, suggests a possible causative role for iron. As iron can damage 
cells, dystrophic microglia possibly develop as a direct result of increased iron storage. 
8. Microglia and Neurodegenerative Diseases
The presence of healthy glial cells is critically important to neuronal wellbeing. Microglia maintain 
homeostasis in the healthy brain and fight infection when it is present through a complicated system of 
signaling molecules. The importance of microglia to neurons is supported by a higher incidence of 
dystrophic microglia and microglial apoptosis in AD [150]. The inflammation of the nervous system in 
neurodegenerative disease was thought to be due to activated microglia. However, dystrophic microglia 
also have impaired neuroprotective ability and generate the low but sustained release of inflammatory 
factors seen during neurodegeneration. 
The effect of dystrophic microglia on the pathogenic changes occurring in Alzheimer’s disease is not 
well understood. Over the progression of the disease, microglia seem to change from exerting  
a neuroprotective function to being closer to a classically activated state. This change in phenotype may 
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result in microglial neurotoxicity or alternatively in dysfunction that prevents the cells from fulfilling 
their protective role [150]. Dystrophic microglia have been co-localized with neurofibrillary tangles in 
AD brains [151]. Microglia with impaired phagocytic and motility functions have been  
co-localized with A? deposits in mouse models of Alzheimer’s disease [152]. Healthy microglia have 
been shown to take up A? and also to release enzymes that degrade it [153]. However, dystrophic 
microglia have impaired A? phagocytic ability [144]. If healthy microglia are activated with LPS, they 
help reduce the A? burden in the brains of mice [154]. Pathologically activated microglia release  
pro-inflammatory cytokines and reactive oxygen species that can make neurons more sensitive to A?
toxicity [155]. Dystrophic microglia have been found to be hyper-responsive to stimulation [145]. 
Inflammatory cytokines have been shown to increase the expression of APP in neurons, which can result 
in increased production of A? through also favoring the amyloidogenic APP processing  
pathway [156–158]. The microglial p40 subunit of IL-12 and IL-23 has been found to be elevated in AD 
brains and to correlate with a worse A? pathology [159]. 
9. Conclusions 
Iron is a two-edged sword for biological systems—essential for many cellular activities, but also able 
to cause damage to macromolecules or disrupt sensitive processes. In the brain this balance is even more 
delicate given the irreplaceable nature of neurons. Research into the role of iron in both disease and 
normal activities in the brain will continue. However, the changes and impact of iron during aging and 
within neurodegenerative diseases is now well established. 
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